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1. What is cardiovascular disease
prevention?
1.1 Introduction
Atherosclerotic cardiovascular disease (CVD) is a chronic disorder
developing insidiously throughout life and usually progressing to an
advanced stage by the time symptoms occur. It remains the major
cause of premature death in Europe, even though CVD mortality
has fallen considerably over recent decades in many European
countries. It is estimated that .80% of all CVD mortality now
occurs in developing countries.
CVD causes mass disability: within the coming decades the
disability-adjusted life years (DALYs) estimate is expected to rise
from a loss of 85 million DALYs in 1990 to a loss of 150
million DALYs globally in 2020, thereby remaining the leading
somatic cause of loss of productivity.1
Joint ESC Guidelines1638







CVD is strongly connected to lifestyle, especially the use of
tobacco, unhealthy diet habits, physical inactivity, and psychosocial
stress.2 The World Health Organization (WHO) has stated that
over three-quarters of all CVD mortality may be prevented with
adequate changes in lifestyle. CVD prevention, remaining a major
challenge for the general population, politicians, and healthcare
workers alike, is defined as a co-ordinated set of actions, at
public and individual level, aimed at eradicating, eliminating, or min-
imizing the impact of CVDs and their related disability. The bases
of prevention are rooted in cardiovascular epidemiology and
evidence-based medicine.3
The aim of the 2012 guidelines from the Fifth Joint Task Force
(JTF) of the European Societies on Cardiovascular Disease Preven-
tion in Clinical Practice is to give an update of the present knowl-
edge in preventive cardiology for physicians and other health
workers. The document differs from 2007 guidelines in several
ways: there is a greater focus on new scientific knowledge. The
use of grading systems [European Society of Cardiology (ESC)
and Grading of Recommendations Assessment, Development,
and Evaluation (GRADE)] allows more evidence-based recommen-
dations to be adapted to the needs of clinical practice.
The reader will find answers to the key questions of CVD pre-
vention in the five sections: what is CVD prevention, why is it
needed, who should benefit from it, how can CVD prevention
be applied, and when is the right moment to act, and finally
where prevention programmes should be provided.
A literature search of clinical guidelines aimed at cardiovascular
risk assessment in clinical practice identified .1900 publications.4
When these were evaluated using the Appraisal of Guidelines Re-
search and Evaluation (AGREE) instrument, only seven achieved
the level considered ‘considerable rigour’. Too much guidance
and too little impact? The gap between state-of-the-art knowledge
and its implementation in clinical practice remains wide, as shown
in recent surveys such as EUROASPIRE III.5 Family doctors may be
flooded with recommendations in the wide field of family medi-
cine. Finding time to read and implement the many guidelines
can be an overwhelming task in a busy primary care centre or a
regional hospital clinic.
The Task Force behind the 2012 recommendations has chosen
to limit the size to the level of the executive summary of previous
JTF publications. All relevant reference material is available on the
dedicated CVD Prevention Guidelines page of the ESC Website
(www.escardio.org/guidelines). A one-page summary of all strong
recommendations according to the GRADE system will be pro-
vided, which may stimulate implementation; and a pocket version
will be available for daily clinical use.
1.2 Development of guidelines
The first joint recommendations (1994) reflected the need for a
consensus statement from the ESC, the European Atherosclerosis
Society, and the European Society of Hypertension, and advocated
the principle of total risk assessment for primary prevention. A re-
vision was published in 1998 by the second JTF involving these
three societies joined by the European Society of General Prac-
tice/Family Medicine, the European Heart Network (EHN), and
the International Society of Behavioural Medicine.
Appreciating that an even broader field of expertise was
required, the third JTF was extended to include eight societies:
the European Association for the Study of Diabetes and the Inter-
national Diabetes Federation Europe joined. The third JTF widened
the guidance from coronary heart disease (CHD) to CVD and
introduced the concept of total CVD risk assessment using the
database of the Systematic Coronary Risk Evaluation Project
(SCORE).
Special risk charts based on SCORE were produced for both
low- and high-risk countries and gained wide acceptance through-
out Europe. The concept of primary and secondary prevention was
replaced by the recognition that atherosclerosis was a continuous
process. Priorities were proposed at four levels: patients with
established disease, asymptomatic individuals at high risk of CVD
mortality, first-degree relatives of patients with premature CVD,
and other individuals encountered in routine clinical practice.
In the 2007 update, the fourth JTF reflected consensus from nine
scientific bodies as the European Stroke Initiative joined the group.
From the ESC, the European Association for Cardiovascular Pre-
vention & Rehabilitation contributed with scientists from the
fields of epidemiology, prevention, and rehabilitation. Novelties
were an increased input from general practice and cardiovascular
nursing, being key players in the implementation of prevention.
Lifestyle counselling was given greater importance and there was
a revised approach to CVD risk in the young, using a SCORE-based
relative risk chart.
The present update from the fifth JTF reflects the consensus on
the broader aspects of CVD prevention from the nine participating
organizations. For more detailed guidance, reference is made to
the specific guidelines from the participating societies, which are
in full congruence with this publication.
The partner societies co-operate in the Joint Societies Imple-
mentation Committee, which aims to stimulate dissemination of
the guidelines, acceptance at national levels, and the formation of
national alliances to translate the recommendations into clinical
practice. The programme ‘Call for Action’ was one of the efforts
of this committee.6
Implementation has been well accepted at the European Union
(EU) political level after the launch of the European Heart Health
Charter in the European Parliament in June 2007.6 This public
health statement has been endorsed by a majority of the EU
member states, defining the characteristics of people who tend
to stay healthy as:
† No use of tobacco.
† Adequate physical activity: at least 30 min five times a week.
† Healthy eating habits.
† No overweight.
† Blood pressure below 140/90 mmHg.
† Blood cholesterol below 5 mmol/L (190 mg/dL).
† Normal glucose metabolism.
† Avoidance of excessive stress.
1.3 Evaluation methods
Good guidelines are a major mechanism for improving the delivery
of healthcare and improving patient outcomes.7 Guidelines based
on credible evidence are more likely to be implemented in clinical
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practice.8 The present guidelines follow the quality criteria for de-
velopment of guidelines, which can be found at www.escardio.org/
knowledge/guidelines/rules.
In short, experts from the nine organizations performed a com-
prehensive review and a critical evaluation of diagnostic and thera-
peutic procedures, including assessment of the risk–benefit ratio.
The level of evidence and the strength of recommendation of par-
ticular treatment options were weighed and graded according to
the ESC recommendations (Tables 1 and 2).
Statements from the writing panel disclosing conflicts of interest
are available on the ESC website. Changes in conflicts of interest
that arose during the writing period were notified.
The preparation and publication of the fifth JTF report was
supported financially by the ESC without any involvement of
the pharmaceutical industry. Once the document had been fina-
lized by the fifth JTF experts it was submitted for extensive inde-
pendent external review. Following this revision and after
acceptance by the ESC Committee for Practice Guidelines and
the co-operating organizations in the fifth JTF, the document
was published.
1.4 Combining evaluation methods
An important novelty in reviewing quality of evidence and making
recommendations is the use of both the ESC-recommended
method of evaluation and the GRADE rating system.9 In contrast
to the 2007 guidelines, the JTF has chosen to provide guidance
with both systems so that readers acquainted with the former
method and those preferring GRADE will find their individually
adapted but still congruent guidance in the combined recommen-
dation tables.
The JTF introduced GRADE as it uses a transparent and rigorous
process to assess the quality of evidence in terms of whether further
research would or would not change confidence in the estimate of
intervention effects or diagnostic accuracy.10 Specific quality indica-
tors are: study limitations; inconsistency of findings; indirectness of
evidence; imprecision; and publication bias (Table 3). These are
Table 1 Classes of recommendations
Classes of 
recommendations
Definition Suggested wording to use
Class I Evidence and/or general agreement 
that a given treatment or procedure 
is beneficial, useful, effective. 
Is recommended/is 
indicated
Class II Conflicting evidence and/or a 
divergence of opinion about the 
usefulness/efficacy of the given 
treatment or procedure. 
    Class IIa Weight of evidence/opinion is in 
favour of usefulness/efficacy. 
Should be considered
    Class IIb Usefulness/efficacy is less well 
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement that 
the given treatment or procedure 
is not useful/effective, and in some 
cases may be harmful. 
Is not recommended
Table 2 Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
Table 3 Quality of evidence used in GRADE9
Study limitations Non-concealment of allocation; non-blinding of 




Variability due to differences in patients 
studied, intervention, outcomes assessed.
Indirectness of 
evidence 
Head-to-head comparisons are direct; 
intervention A vs. control and B vs. control is 
indirect in assessing A vs. B.
Imprecision Small patient numbers resulting in wide 
confidence intervals.
Publication bias Typically trials showing no effect of 
intervention are not published or are 
published in local non-indexed journals.
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applied to each outcome of critical importance for decision-making in
the judgement of the guideline group (e.g. reduction in clinical events
is usually critical; changes in biochemical values are not usually critic-
al). Judgements are then made on these indicators to rate evidence
quality from high (i.e. further research is unlikely to change confidence
in the estimate of effect), to moderate, low, and very low (i.e. any es-
timate of effect is very uncertain). This judgement is made on quality
of evidence for the critical outcomes and not those that are not crit-
ical for decision-making.
The value of this new approach is that systematic review or ran-
domized control trial (RCT) evidence that is biased, inconsistent,
or imprecise may be downgraded from high- to moderate- or low-
quality evidence. Similarly, observational data from cohort or
case–control studies may be upgraded from moderate or low
(as is typical in the old levels-of-evidence approach) to high if
bias is unlikely, and findings are consistent and precise. This is
very helpful in assessing evidence for CVD prevention where
RCTs of health behaviours are difficult to conduct and may be
misleading.
GRADE also distinguishes quality of evidence and strength of
recommendation.9 Strong evidence does not automatically lead
to a strong recommendation. Recommendations are based on
the quality of the evidence, the degree of uncertainty about the
balance of benefits and harms of the intervention, uncertainty
about the values and preferences of patients, and uncertainty
about whether the intervention is a wise use of resources.
Rather than have a range of classes of recommendation (e.g.
Class I–Class III), GRADE only uses two categories—strong or
weak (i.e. discretionary, conditional). The implications of a strong
recommendation are: most informed patients would choose the
recommended intervention (and request discussion if not
offered); clinicians would ensure that most patients should
receive the intervention; and the recommendation would be
adopted as policy in organized healthcare systems. In contrast,
for weak recommendations, some patients would want the inter-
vention but many would not; clinicians would help patients make
choices dependent on their values and preferences; policy
makers would require debate among various stakeholders to
decide on the role of the intervention.
The GRADE approach can be applied to diagnostic strategies
in the same way with a few minor changes to the quality
criteria used,9 and may also be used in conjunction with appraisals
of resource use and cost-effectiveness.10 However, as resources
are valued differently across Europe, it is not feasible in these
guidelines to make judgements about the appropriateness of
resource use for the interventions and diagnostic strategies consid-
ered here.
2. Why is prevention of
cardiovascular disease needed?
Key messages
† Atherosclerotic CVD, especially CHD, remains the leading
cause of premature death worldwide.
† CVD affects both men and women; of all deaths that occur
before the age of 75 years in Europe, 42% are due to CVD in
women and 38% in men.
† CVD mortality is changing, with declining age-standardized rates
in most European countries, which remain high in Eastern
Europe.
† Prevention works: .50% of the reductions seen in CHD mor-
tality relate to changes in risk factors, and 40% to improved
treatments.
† Preventive efforts should be lifelong, from birth (if not before)
to old age.
† Population and high-risk preventive strategies should be com-
plementary; an approach limited to high-risk persons will be
less effective; population education programmes are still
needed.
† Despite gaps in our understanding, there is ample evidence to
justify intensive public health and individual preventive efforts.
† There is still substantial room for improvement in risk factor
control, even in individuals at very high risk.
2.1 Scope of the problem
‘Coronary heart disease (CHD) is now the leading cause of death
worldwide; it is on the rise and has become a true pandemic that
respects no borders’. This statement from 2009 on the website of
the WHO11 does not differ much from the warning issued in 1969
by its Executive Board: ‘Mankind’s greatest epidemic: CHD has
reached enormous proportions striking more and more at
younger subjects. It will result in coming years in the greatest epi-
demic mankind has faced unless we are able to reverse the trend
by concentrated research into its cause and prevention’.12 The
second major CVD—stroke—is another substantial cause of
death and disability. For these reasons, the fifth JTF guidelines
refer to the total burden of atherosclerotic CVD.
The choice of total burden of atherosclerotic CVD may give the
impression that nothing has changed over the past 40 years, but
this is not true. On the contrary, the epidemic has been and still
is extremely dynamic and is influenced by both changes in cardio-
vascular risk factors and in increased opportunities for targeted
interventions to prevent and treat CVD. This results in ups and
downs of cardiovascular morbidity and mortality over relatively
short periods with wide variability across the globe, including
developing countries where the major proportion of all events
occurs nowadays. In different parts of the world, the dynamics of
the epidemic vary greatly in pattern, magnitude, and timing.13 In
Europe, the burden remains high: CVD remains a major cause of
premature deaths and loss of DALYs—a composite of premature
death and living with the disease. It is not widely appreciated that
CVD is the main cause of premature death in women: CVD was
responsible for 42% of all deaths below 75 years of age in Euro-
pean women and for 38% of all deaths at ,75 years in men.14
However, a decline in age-standardized CHD and CVD mortality
has been observed in many European countries between the
1970s and 1990s, with the earliest and most prominent decrease
in the more affluent countries, illustrating the potential for preven-
tion of premature deaths and for prolonging healthy life
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expectancy. In several eastern European countries, however, CVD
and CHD mortality remains high.15
Policy makers need to know whether major contributors to
morbidity and mortality such as CVD are tracking up or down.
A valid and actual description of the epidemic by place, time, and
personal characteristics is continuously needed to guide and
support health policies.
At present there is no standardized source of Europe-wide CVD
morbidity data. Results from the Multinational MONItoring of
trends and determinants in CArdiovascular disease (MONICA)
project indicated a heterogeneous trend in CHD incidence in
the 1980s to 1990s in Europe.16 This pattern may have changed,
and results from recent reports do suggest that mortality and mor-
bidity from CHD is levelling, especially in younger adults.17,18 One
should also realize that because of an ageing population and a
reduced case fatality of acute coronary events, the total number
of people living with CHD increases. The majority of these patients
develop the disease at an advanced age, leading to a compression
of morbidity in the very old of the community and to a prolonged
life expectancy in good health. The Global Health Observatory
database of the WHO (http://apps.who.int/ghodata/?vid=2510)
provides data on present mortality rates from CVD in the world.
2.2 Prevention of cardiovascular disease:
a lifelong approach
Prevention of CVD ideally starts during pregnancy and lasts until
the end of life. In daily practice, prevention efforts are typically tar-
geted at middle-aged or older men and women with established
CVD (i.e. secondary prevention) or those at high risk of developing
a first cardiovascular event [e.g. men and women with combina-
tions of smoking, elevated blood pressure (BP), diabetes or dyslipi-
daemia (i.e. primary prevention)]; CVD prevention in the young,
the very old, or those with just a moderate or mild risk is still
limited, but can result in substantial benefit. Prevention is typically
categorized as primary or secondary prevention, although in CVD
the distinction between the two is arbitrary in view of the under-
lying, gradually developing atherosclerotic process. Since the in-
struction by Geoffrey Rose decades ago, two approaches
towards prevention of CVD are considered: the population strat-
egy and the high-risk strategy.19
The population strategy aims at reducing the CVD incidence at
the population level through lifestyle and environmental changes
targeted at the population at large. This strategy is primarily
achieved by establishing ad-hoc policies and community interven-
tions. Examples include measures to ban smoking and reduce the
salt content of food. The advantage is that it may bring large ben-
efits to the population although it may offer little to the individual.
The impact of such an approach on the total number of cardiovas-
cular events in the population may be large, because all subjects
are targeted and a majority of events occur in the substantial
group of people at only modest risk.
In the high-risk approach, preventive measures are aimed at
reducing risk factor levels in those at the highest risk, either indivi-
duals without CVD at the upper part of the total cardiovascular
risk distribution or those with established CVD. Although indivi-
duals targeted in this strategy are more likely to benefit from the
preventive interventions, the impact on the population level is
limited, because people at such high risk are few. For a long time
the population strategy has been considered to be more cost-
effective than the high-risk approach but since the introduction
of highly effective lipid lowering drugs, improvement in smoking
cessation programmes and lower costs of antihypertensive drugs,
the effectiveness of the high risk approach has increased.20
There is consensus that the largest preventive effect is achieved
when these are combined.
Importantly, evidence that increased cardiovascular risk starts
developing at a (very) young age has accumulated over past
decades. Even exposure to risk factors before birth may influence
the lifetime risk of CVD,21 as has been illustrated from studies in
the offspring of women who were pregnant during the Dutch
famine in the Second World War.22 Although children are at
very low absolute risk of developing CVD, those at a relatively
high risk compared with their peers remain at increased risk of ex-
periencing a cardiovascular event later in life because of ‘tracking’
of risk factors (i.e. those at the high end of the distribution of a
risk factor in early life tend to stay in the upper part of the distri-
bution).23 Thus a healthy lifestyle in the young is crucial, although
ethical and other reasons prohibit the provision of strong levels of
evidence based on randomized trials for the benefits in terms of
reduced incidence of CVD from, for example, school programmes
on health education or smoking cessation actions. Also, the limited
attention on CVD prevention in the elderly has proven unjustified.
Studies have shown that preventive measures (i.e. BP lowering and
smoking cessation) are beneficial up to advanced age.24,25 These
facts exemplify that prevention of CVD should be a lifelong
effort, albeit that the beneficial effects in terms of, for example, a
lower incidence of fatal or non-fatal cardiovascular events or
improvement in quality of life, should always be weighed against
the potential harm that specific measures may cause (including
side effects of drugs and psychological effects of labelling healthy
subjects as patients) and against related costs.
2.3 Prevention of cardiovascular disease
pays off
In order to interpret the dynamics of the CVD epidemic, it is
important to differentiate the effect of a reduced case fatality
and changes related to preventing clinical events. Some authors
credit the greater use of evidence-based medical therapies such
as thrombolysis, aspirin, angiotensin-converting enzyme (ACE)
inhibitors, percutaneous coronary intervention (PCI), and coron-
ary artery bypass graft (CABG) surgery,26,27 while others credit
improved management of major risk factors such as smoking,
hypertension, and dyslipidaemia.28
The MONICA project, performed during the 1980s and 1990s,
showed that only part of the variation in the time trends of coron-
ary event rates could be predicted by trends in risk factors.16 The
relationship between changes in risk factor scores and changes in
event rates was substantial. and the changes in risk factors
explained almost half the variation in event rates in men but less
in women.
Moreover, there was a significant association between treatment
change and case fatality. Thus it was concluded that both primary
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prevention and treatment of cardiovascular events influence mor-
tality. In many MONICA centres there were quite substantial
changes, up or down, in CVD events within time periods as
small as 10 years. The only reasonable explanation is that both
environmental changes, especially related to lifestyle, and improved
management are important.
Another approach to understanding the changes in CVD mortal-
ity and incidence rates is by applying models such as the IMPACT
mortality model.29 Based on information on changes in coronary
risk factors and in treatment as obtained from the results of
RCTs regarding the effectiveness of different treatment modalities,
it estimates the expected influence on CHD mortality by age and
gender. This model has been applied in different countries; the
results from these studies are rather consistent and similar to
what has been observed in other studies of the same subject, as
summarized in Figure 1. Beneficial reductions in major risk
factors—in particular smoking, BP, and cholesterol—accounted
for more than half of the decrease in CHD deaths, although they
were counteracted by an increase in the prevalence of obesity
and type 2 diabetes; 40% of the decline in CHD death rates is
attributed to better treatments of acute myocardial infarction,
heart failure, and other cardiac conditions. Results from clinical
trials and natural experiments also show that a decline in CHD
mortality can happen rapidly after individual or population-wide
changes in diet or smoking.30
The potential for prevention based on healthy lifestyles, appro-
priate management of classical risk factors, and selective use of
cardioprotective drugs is obvious. The human and economic argu-
ments in favour of CVD prevention were recently estimated by the
National Institute for Health and Clinical Excellence (NICE)32 as
overwhelmingly positive, and many committees from other
countries have almost the same views.33 According to the report
of NICE, implementation of the population approach may bring
numerous benefits and savings:
† Narrowing the gap in health inequalities.
† Cost savings from the number of CVD events avoided.
† Preventing other conditions such as cancer, pulmonary diseases,
and type 2 diabetes.
† Cost savings associated with CVD such as medications, primary
care visits, and outpatient attendances.
† Cost savings to the wider economy as a result of reduced loss of
production due of illness in those of working age, reduced
benefit payments, and reduced pension costs from people
retiring early from ill health.
† Improving the quality and length of people’s lives.
2.4 Ample room for improvement
Within the scope of the comprehensive programme on CVD pre-
vention of the ESC, surveys are carried out to document how well
the guidelines are implemented in clinical practice. These surveys
are called EUROASPIRE; the results from the hospital arm of
EUROASPIRE III33 (2006–2007) in 8966 patients with established
CHD from 22 European countries show that large proportions of
patients still do not achieve the lifestyles, risk factor levels, and
therapeutic targets set in 2003 by the third JTF. The proportions
of patients who were at goal for the different recommendations
and for risk factor management are given in Table 4; ideally,
100% of patients should reach the goals, but in practice fewer
than half tend to reach the targets.
Moreover, the changes between EUROASPIRE I (1996) and
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Figure 1 Percentage of the decrease in deaths from coronary heart disease attributed to treatments and risk factor changes in different popu-
lations (adapted from Di Chiara et al.31)
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change and BP control has not improved despite increased use of
antihypertensive drugs, while the number of patients with (central)
obesity continues to increase. On the other hand, lipid control has
improved significantly.5 In EUROASPIRE III, asymptomatic high-risk
subjects have been included in the primary prevention arm; the ad-
herence to the recommended lifestyles and the proportions at goal
for blood pressure, lipids, and blood glucose are even worse.34
These findings call for comprehensive and multidisciplinary pro-
grammes involving both patients and their families. The efficacy and
safety of such programmes have been demonstrated in the EURO-
ACTION project—an ESC demonstration project showing that
the recommended lifestyle changes and the targeted management
of cardiovascular risk factors are achievable and sustainable in daily
clinical practice, in both primary and secondary care.35
Remaining gaps in the evidence
† Our understanding of the reasons for changes in the behaviour
of both populations and individuals remains incomplete.
† The mechanisms whereby such changes in behaviour translate
into changes in disease patterns are also incompletely
understood.
† Auditing and studying the most effective preventive measures is
therefore challenging.
† More research into prevention of CVD is needed, starting early
in life or even during fetal development.
† It is uncertain whether CVD is merely deferred by preventive
efforts or if it of can be avoided completely.
† There is an ongoing need for a valid and accurate description of
CVD morbidity and mortality throughout the world.
3. Who should benefit from it?
3.1 Strategies and risk estimation
Key messages*
*The detailed SCORE charts with integrated HDL-cholesterol values
can be found on http://www.escardio.org/guidelines-surveys/esc-
guidelines/Pages/cvd-prevention.aspx in the related materials section.
† In apparently healthy persons, CVD risk is most frequently the
result of multiple interacting risk factors.
† A risk estimation system such as SCORE can assist in making
logical management decisions, and may help to avoid both
under- and overtreatment.
† Certain individuals are at high CVD risk without needing risk
scoring and require immediate intervention for all risk factors.
† In younger persons, a low absolute risk may conceal a very high
relative risk, and use of the relative risk chart or calculation of
their ‘risk age’ may help in advising them of the need for inten-
sive lifestyle efforts.
† While women appear to be at lower CVD risk than men, this is
misleading as risk is deferred by 10 years rather than avoided.
† All risk estimation systems are relatively crude and require at-
tention to qualifying statements.
† Additional factors affecting risk can be accommodated in
electronic risk estimation systems such as HeartScore
(www.heartscore.org).
† The total risk approach allows flexibility: if perfection cannot be
achieved with one risk factor, risk can still be reduced by trying
harder with others.
3.1.1 Introduction
The encouragement of the use of total risk estimation as a crucial
tool to guide patient management has been a cornerstone of the
guidelines since the first edition.38 This is because clinicians treat
Recommendations regarding risk estimation
Recommendations Classa Levelb GRADE RefC
Total risk estimation using 
multiple risk factors (such as 
SCORE) is recommended for 
asymptomatic adults without 
evidence of CVD.
I C Strong 36
High-risk individuals can be 
detected on the basis of 
established CVD, diabetes
mellitus, moderate to
severe renal disease, very
high levels of individual risk
factors, or a high SCORE risk,
and are a high priority for
intensive advice about all risk
factors.        
I C Strong 36,37




Table 4 Guideline recommendations vs.
achievements in patients with established coronary
heart disease in EUROASPIRE III
Guideline recommendations Proportions at goal
Smoking cessation among smokers 48
Regular physical activity 34
BMI <25 kg/m2 18
Waist circumference
 <94 cm (men)
 <80 cm (women)
25
12
Blood pressure <140/90 mmHg 50
Total cholesterol <4.5 mmol/L (175 mg/dL) 49
LDL cholesterol <2.5 mmol/L (100 mg/dL) 55
Among patients with type 2 diabetes:




BMI ¼ body mass index; HbA1c ¼ glycated haemoglobin; LDL ¼ low-density
lipoprotein.
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whole people (and not individual risk factors), whose cardiovascu-
lar risk usually reflects the combined effects of several risk factors
that may interact, sometimes multiplicatively. Having said that, the
implication that total risk assessment, while logical, is associated
with improved clinical outcomes when compared with other strat-
egies has not been adequately tested.
Although clinicians often ask for threshold values at which to
trigger an intervention, this is problematic since risk is a continuum
and there is no exact point above which, for example, a drug is
automatically indicated, nor below which lifestyle advice may not
usefully be offered. This issue is dealt with in more detail in
these guidelines, as is the issue of how to advise younger
persons at low absolute but high relative risk, and the fact that
all elderly people will eventually be at high risk of death and may
be overexposed to drug treatments.
The priorities suggested in this section are to assist the physician
in dealing with individual people and patients. As such, they ac-
knowledge that individuals at the highest levels of risk gain most
from risk factor management. However, as noted elsewhere, the
majority of deaths in a community come from those at lower
levels of risk, simply because they are more numerous.19
3.1.2 Strategies
Cardiovascular risk in the context of these guidelines means the
likelihood of a person developing an atherosclerotic cardiovascular
event over a defined time period.
‘Total risk’ implies an estimate of risk made by considering the
effect of the major factors: age, gender, smoking, BP, and lipid
levels. The term has become widely used; however, ‘total risk’ is
not comprehensive because the effects of other risk factors are
not considered except as qualifying statements.
The importance of total risk estimation before management
decisions are made is illustrated in Table 5 and Figure 2. The
figure shows that the effect of the lipid levels on risk is modest
in women who are at otherwise low risk, and that the risk
advantage of being female is lost by the combination of smoking
and mild hypertension. Table 5 shows that a person with a choles-
terol concentration of 8 mmol/L (310 mg/dL) can be at 10 times
lower risk than someone with a cholesterol concentration of
5 mmol/L (190 mg/dL) if the latter is a male hypertensive
smoker. RCTs of single risk factors do not give sufficient data to
address these issues fully. While audits such as EUROASPIRE5,38,39
suggest inadequate risk factor management in very-high-risk sub-
jects, it is also likely that, in the context of low-risk subjects who
have not had a vascular event, there is the potential for substantial
overuse of drugs by inappropriate extrapolation of the results of
trials conducted mostly in high-risk men to low-risk individuals.
In general, women and old and young subjects have been under-
represented in the classic drug trials that have informed guidelines
to date.
It is essential for clinicians to be able to assess risk rapidly and
with sufficient accuracy to allow logical management decisions.
Table 5 Impact of combinations of risk factors on








F 60 8 120 No 2
F 60 7 140 Yes 5
M 60 6 160 No 8
M 60 5 180 Yes 21
CHOL ¼ cholesterol; SBP ¼ systolic blood pressure.
aSCORE risk at 10 years; 5 mmol/L ¼ 190 mg/dL, 6 mmol/L ¼ 230 mg/dL,




SBP = 160 mmHg
Men, non-smoking,
SBP = 120 mmHg
Women, smoking,
SBP = 160 mmHg
Women, non-smoking,
























CVD = cardiovascular disease; 
HDL = high-density lipoprotein; 
SBP = systolic blood pressure; 
TC = total cholesterol.
Figure 2 Relationship between total cholesterol/HDL cholesterol ratio and 10-year fatal CVD events in men and women aged 60 years with
and without risk factors, based on a risk function derived from the SCORE project.
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This realization led to the development of the risk chart used in the
1994 and 1998 guidelines.38,40 This chart, developed from a
concept pioneered by Anderson et al.,41 used age, sex, smoking
status, total cholesterol, and systolic blood pressure (SBP) to esti-
mate the 10-year risk of a first fatal or non-fatal CHD event. There
were several problems with this chart, outlined in the fourth JTF
guidelines on prevention,37 which led to the presently recom-
mended risk estimation system, SCORE.
3.1.3 Risk estimation
When do I assess total risk?
As noted in the ‘priorities’ section, persons with established
CVD are already at very high risk of further events and need
prompt intervention on all risk factors, while in apparently
healthy persons total risk should be assessed by using the
SCORE system.
While the ideal scenario would be for all adults to have their
risk of CVD assessed, this may not be practicable for many
societies. This decision must be made by individual countries and
will be resource dependent. It is recommended that risk factor
screening including the lipid profile may be considered in adult
men .40 years old and in women .50 years of age or
post-menopausal.42
Most people will visit their family doctor at least once over a
2-year period giving an opportunity for risk assessment. General
practice databases may be useful to store risk factor data, and to
flag high-risk persons. It is suggested that total risk assessment
be offered during a consultation if:
† The person asks for it.
† One or more risk factors such as smoking, overweight, or
hyperlipidaemia are known.
† There is a family history of premature CVD or of major risk
factors such as hyperlipidaemia.
† There are symptoms suggestive of CVD.
Special efforts should be made to assess risk in the socially
deprived who are more likely to carry a heavy burden of risk
factors.43
The 2003 guidelines44 used the SCORE chart for risk estima-
tion,45 which was based on data from 12 European cohort
studies; it included 205 178 subjects examined at baseline
between 1970 and 1988 with 2.7 million years of follow-up and
7934 cardiovascular deaths. The SCORE risk function has been ex-
ternally validated.46
Risk charts such as SCORE are intended to facilitate risk estima-
tion in apparently healthy persons. Patients who have had a clinical
event such as an acute coronary syndrome (ACS) or stroke auto-
matically qualify for intensive risk factor evaluation and
management.
SCORE differs from earlier risk estimation systems in several im-
portant ways, and has been modified somewhat for the present
guidelines. Details of these modifications follow.
The SCORE system estimates the 10-year risk of a first fatal ath-
erosclerotic event, whether heart attack, stroke, aneurysm of the
aorta, or other. All ICD (International Classification of Diseases)
codes that could reasonably be assumed to be atherosclerotic
are included. Most other systems estimate CHD risk only.
The choice of CVD mortality rather than total (fatal + non-
fatal) events was deliberate although not universally popular. Non-
fatal event rates are critically dependent upon definitions and the
methods used in their ascertainment. Striking changes in both diag-
nostic tests and therapies have occurred since the SCORE cohorts
were assembled. Critically, the use of mortality permits
re-calibration to allow for time trends in CVD mortality. Any
risk estimation system will overpredict in countries in which mor-
tality has fallen and underpredict in those in which it has risen.
Re-calibration to allow for secular changes can be undertaken if
good quality, up-to-date mortality and risk factor prevalence data
are available. Data quality does not permit this for non-fatal
events. For these reasons, the CVD mortality charts were pro-
duced, and have been re-calibrated for a number of European
countries. Calibrated country-specific versions for Cyprus, Czech
Republic, Germany, Greece, Poland, Slovakia, Spain, and Sweden,
and country-specific versions for Bosnia and Herzegovina,
Croatia, Estonia, France, Romania, Russian Federation, and
Turkey can be found at www.heartscore.org. Nevertheless it is es-
sential to address the issue of total risk.
In the 2003 guidelines,44 a 10-year risk of CVD death of ≥5%
was arbitrarily considered high risk. Yet this implies a 95%
chance of not dying from CVD within 10 years, less than impres-
sive when counselling patients. The new nomenclature in the
2007 guideline was that everyone with a 10-year risk of cardiovas-
cular death ≥5% has an increased risk. Clearly the risk of total fatal
and non-fatal events is higher, and clinicians naturally wish for this
to be quantified. The biggest contributor to the high-risk SCORE
charts is the Finnish contribution to MONICA, FINRISK, which
has data on non-fatal events defined according to the MONICA
project.47 Calculating total event rates from FINRISK suggests
that, at the level (5%) at which risk management advice is likely
to be intensified, total event risk is 15%. This three-fold multi-
plier is somewhat smaller in older persons in whom a first event
is more likely to be fatal. An examination of the Framingham esti-
mates of risk of total CVD events results in similar conclusions: a
5% SCORE risk of CVD death equates to a 10–25% Framingham
risk of total CVD, depending upon which of the several Framing-
ham functions is chosen. Again the lower end of the range
applies to older persons.
In summary, the reasons for retaining a system that estimates
fatal as opposed to fatal + non-fatal CVD are:
† Death is a hard and reproducible endpoint; a non-fatal event is
variable and depends upon definitions, diagnostic criteria, and
diagnostic tests, all of which may vary over time. Thus, the
‘20% total CVD (or CHD)’ risk used to denote high risk in
many guidelines is likely to be variable, unstable over time,
and hard to validate.
† A high risk of CVD death automatically indicates a higher risk of
total events.
† The multiplier to convert fatal to total CVD is similarly unstable
and is often less than clinicians expect, since follow-up is termi-
nated in all current systems with the first event, and subsequent
fatal or non-fatal events are not counted.
† The use of fatal CVD as the endpoint allows accurate
re-calibration to other countries and cultures to adjust for
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time trends in mortality and in risk factor prevalence, an import-
ant consideration given the cultural diversity within Europe.
As noted in the introduction, thresholds to trigger certain inter-
ventions are problematic since risk is a continuum and there is
no threshold at which, for example, a drug is automatically indi-
cated. A particular problem relates to young people with high
levels of risk factors: a low absolute risk may conceal a high relative
risk requiring advice for intensive lifestyle measures. In the 2003
guidelines,44 it was suggested to extrapolate risk to age 60 to
stress that a high absolute risk would occur if preventive action
was not taken. This part of the text has been rephrased, and a rela-
tive risk chart added to the absolute risk charts to illustrate that,
particularly in younger persons, lifestyle changes can reduce risk
substantially as well as reducing the increase in risk that will
occur with ageing. A new approach to this problem in these guide-
lines is cardiovascular risk age, which is explored later in this
section.
Another problem relates to old people. In some age categories
the majority, especially of men, will have estimated cardiovascular
death risks exceeding the 5–10% level, based on age (and gender)
only, even when other cardiovascular risk factor levels are relative-
ly low. This could lead to excessive use of drugs in the elderly. This
issue is dealt with later in this section.
The role of high-density lipoprotein (HDL) cholesterol in risk
estimation has been systematically re-examined using the SCORE
database.48,49 This work has shown that HDL cholesterol can con-
tribute substantially to risk estimation if entered as an independent
variable. For example, HDL cholesterol modifies risk at all levels of
risk as estimated from the SCORE cholesterol charts.50 Further-
more, this effect is seen in both sexes and in all age groups, includ-
ing older women.51 This is particularly important at levels of risk
just below the threshold for intensive risk modification of 5%.
Many of these subjects will qualify for intensive advice if their
HDL cholesterol is low.50 The electronic, interactive version
of SCORE—HeartScore (available through www.heartscore.org)
is currently being adapted to allow adjustment for the impact of
HDL cholesterol on total risk.
The role of raised plasma triglycerides as a predictor of CVD has
been debated for many years. Fasting triglycerides relate to risk in
univariate analyses, but the effect is attenuated by adjustment for
other factors, especially HDL cholesterol. After adjustment for
HDL cholesterol, there is no significant association between
triglycerides and CVD.52 More recently, attention has focused on
non-fasting triglycerides, which may be more strongly related to
risk independently of the effects of HDL cholesterol.53 –55
Heart rate has been shown to be an independent risk factor for
CVD in the general population.56,57 Sudden cardiac death was par-
ticularly associated with elevated resting heart rate.57 Measure-
ment of resting heart rate should be done in the sitting position
after 5 min rest and should form part of the routine physical exam-
ination when assessing cardiovascular risk.
Two large observational studies have demonstrated increased
risk of cardiac events in individuals whose resting heart rate
increased over time.58,59 However, the reverse has only been
demonstrated in one of these studies; that individuals whose
heart rate decreased over time had a lower risk of CVD.58
No trial of heart rate lowering for CVD prevention in a healthy
population has been conducted to date; therefore, pharmacologic-
al lowering of heart rate in primary prevention cannot be
recommended.
Elevated heart rate has been shown to be associated with
increased risk of further cardiac events in those with established
CVD.60,61 In those post-myocardial infarction and in heart
failure patients, use of beta-blockade in carefully titrated doses
is associated with improved outcomes.62,63 More recently, in
patients with resting heart rates ≥70 b.p.m. and reduced left ven-
tricular function (either coronary artery disease or heart failure),
trials of pure heart rate reduction have shown benefit.64,65 There
is not enough evidence, at present, to recommend a target heart
rate.
Dealing with the impact of additional risk factors such as HDL
cholesterol, body weight, family history, and newer risk markers
is difficult within the constraint of a paper chart. The electronic
version of SCORE—HeartScore—is less constrained. It presently
replicates SCORE in an electronic format but will be used to
accommodate the results of new SCORE analyses, such as those
relating to HDL cholesterol, as these are checked and validated.
It should be stressed, however, that although many risk factors
other than the few included in the available risk functions have
been identified [such as C-reactive protein (CRP) and homocyst-
eine levels], their contribution to absolute cardiovascular risk esti-
mations of individual patients (in addition to traditional risk factors)
is generally modest.66
The impact of self-reported diabetes has been re-examined.
While there is heterogeneity between cohorts, overall, the
impact of diabetes on risk appears greater than in risk estimation
systems based on the Framingham cohort, with relative risks of
5 in women and 3 in men.
Some of the advantages of using the risk charts may be
summarized:
Advantages of using the risk chart
• Intuitive, easy-to-use tool.
• Takes account of the multifactorial nature of cardiovascular disease.
• Allows flexibility in management if an ideal risk factor level cannot be 
achieved; total risk can still be reduced by reducing other risk 
factors.
• Allows a more objective assessment of risk over time.
• Establishes a common language of risk for clinicians.
• Shows how risk increases with age.
• The new relative risk chart helps to illustrate how a young person 
with a low absolute risk may be at a substantially high and reducible 
relative risk.
• Calculation of an individual’s ‘risk age’ may also be of use in this 
situation.
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The SCORE risk charts are shown in Figures 3–5, including a
chart of relative risks. Instructions on their use and qualifiers
follow.
Please note that the chart in Figure 5 shows relative and not
absolute risk. Thus a person in the top right-hand box has a
risk that is 12 times higher than a person in the bottom
left. This may be helpful when advising a young person with
a low absolute but high relative risk of the need for lifestyle
change.
Cardiovascular risk age
The risk age of a person with several cardiovascular risk factors is
the age of a person with the same level of risk but with ideal levels






















High CVD risk countries are all those not listed under the low risk chart (Figure 4). Of these, some are at very high risk, and the high-risk
chart may underestimate risk in these. These countries are Armenia, Azerbaijan, Belarus, Bulgaria, Georgia, Kazakhstan, Kyrgyzstan, Latvia,
Lithuania, Macedonia FYR, Moldova, Russia, Ukraine, and Uzbekistan.
Figure 3 SCORE chart: 10-year risk of fatal cardiovascular disease (CVD) in countries at high CVD risk based on the following risk factors:
age, sex, smoking, systolic blood pressure, and total cholesterol.
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≥60 years. Risk age is an intuitive and easily understood way of
illustrating the likely reduction in life expectancy that a young
person with a low absolute but high relative risk of cardiovascular
disease will be exposed to if preventive measures are not adopted.
Risk age can be estimated visually by looking at the SCORE chart
(as illustrated in Figure 6). In this table, the risk age is calculated
compared with someone with ideal risk factor levels, which have
been taken as non-smoking, total cholesterol of 4 mmol/L
(155 mg/dL), and blood pressure 120 mmHg.67 Risk age is also
automatically calculated as part of the latest revision of HeartScore
(www.HeartScore.org).
Risk age has been shown to be independent of the cardiovas-
cular endpoint used,67 which bypasses the dilemma of whether to
use a risk estimation system based on CVD mortality or on the
more attractive but less reliable endpoint of total CVD events.
Risk age can be used in any population regardless of baseline
risk and of secular changes in mortality, and therefore avoids






















Low CVD countries are Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy,
Luxembourg, Malta, Monaco, The Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland, United Kingdom.
Figure 4 SCORE chart: 10-year risk of fatal cardiovascular disease (CVD) in countries at low CVD risk based on the following risk factors:
age, sex, smoking, systolic blood pressure, and total cholesterol. Note that the risk of total (fatal + non-fatal) CVD events will be approximately
three times higher than the figures given.
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recommended for helping to communicate about risk, especially
to younger people with a low absolute risk but a high relative
risk. It is not currently recommended to base treatment decisions
on risk age.
What is a low-risk country? (countries in Figure 4)
The fact that CVD mortality has declined in many European coun-
tries means that more countries now fall into the low-risk cat-
egory. While any cut-off point is arbitrary and open to debate, in
these guidelines the cut-off points are based on 2008 CVD plus
diabetes mortality in those aged 45–74 years (220/100 000 in
men and 160/100 000 in women).69 This defines 21 countries
and marks a point at which there is an appreciable gap before
the 22nd country (Czech Republic).
This list is based on European countries that are ESC members.
However, several European countries are not ESC members
because they do not have a national cardiac society or because
of size. In addition, the JTF felt it sensible to look also at
Mediterranean countries that are ESC members while not strictly
‘European’ in WHO terminology.
Very-high-risk countries
Some European countries have levels of risk that are more than
double the CVD mortality of 220/100 000 in men used to define



















Figure 5 Relative risk chart for 10-year mortality. Conversion
of cholesterol mmol/L mg/dL: 8 ¼ 310, 7 ¼ 270, 6 ¼ 230,























Figure 6 Illustration of the risk–age concept.
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low-risk countries, suggesting a major problem for women. Even
the high-risk charts may underestimate risk in these countries.
Countries with a CVD mortality risk of .500/100 000 for men
and .250/100 000 for women are at very high risk and listed in
Figure 3. All remaining countries are high-risk countries.
How to use the risk estimation charts
† Use of the low-risk chart is recommended for the countries listed
in Figure 4. Use of the high-risk chart is recommended for all other
European and Mediterranean countries. Note that several coun-
tries have undertaken national re-calibrations to allow for time
trends in mortality and risk factor distributions. Such charts are
likely to better represent current risk levels.
† To estimate a person’s 10-year risk of CVD death, find the
correct table for their gender, smoking status, and age. Within
the table find the cell nearest to the person’s BP and total chol-
esterol or cholesterol:HDL cholesterol ratio. Risk estimates will
need to be adjusted upwards as the person approaches the next
age category.
† Low-risk persons should be offered advice to maintain their
low-risk status. While no threshold is universally applicable, the in-
tensity of advice should increase with increasing risk. In general,
those with a risk of CVD death of ≥5% qualify for intensive
advice, and may benefit from drug treatment. At risk levels
.10%, drug treatment is more frequently required. In persons
older than 60, these thresholds should be interpreted more lenient-
ly, because their age-specific risk is normally around these levels,
even when other cardiovascular risk factor levels are ‘normal’.
† The relative risk chart may be helpful in identifying and counsel-
ling in young persons, even if absolute risk levels are low
† The charts may be used to give some indication of the effects of re-
ducing risk factors, given that there will be a time lag before risk
reduces and the results of RCTs in general give better estimates
of benefits. Those who stop smoking in general halve their risk.
Qualifiers
† The charts can assist in risk assessment and management but
must be interpreted in the light of the clinician’s knowledge
and experience, especially with regard to local conditions.
† Risk will be overestimated in countries with a falling CVD mor-
tality, and underestimated in countries in which mortality is
increasing.
† At any given age, risk estimates are lower for women than for
men. Inspection of the charts indicates that risk is merely
deferred in women, with a 60-year-old woman resembling a
50-year-old man in terms of risk.
Risk may also be higher than indicated in the charts in:
† Sedentary subjects and those with central obesity; these charac-
teristics determine many of the other aspects of risk listed
below. The increased risk associated with overweight is
greater in younger subjects than in older subjects.
† Socially deprived individuals and those from ethnic minorities.
† Individuals with diabetes: SCORE charts should be used only in
those with type 1 diabetes without target organ damage. Risk
rises with increasing blood sugar concentration before overt
diabetes occurs.
† Individuals with low HDL cholesterol, increased triglycerides, fi-
brinogen, apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)]
levels, especially in combination with familial hypercholesterol-
aemia, and perhaps increased high-sensitivity CRP (hsCRP). In
particular, a low HDL level will indicate a higher level of risk
in both sexes, all age groups, and at all levels of risk.51
† Asymptomatic individuals with preclinical evidence of athero-
sclerosis, for example plaque on carotid ultrasonography.
† Those with moderate to severe chronic kidney disease [glom-
erular filtration rate (GFR) ,60 mL/min/1.73 m2].
† Positive family history of premature CVD.
Priorities
The higher the risk the greater the benefit from preventive efforts,
which guides the following priorities:
1. Very high risk
Subjects with any of the following:
† Documented CVD by invasive or non-invasive testing (such as
coronary angiography, nuclear imaging, stress echocardiography,
carotid plaque on ultrasound), previous myocardial infarction,
ACS, coronary revascularization (PCI, CABG), and other arterial
revascularization procedures, ischaemic stroke, peripheral
artery disease (PAD).
† Diabetes mellitus (type 1 or type 2) with one or more CV risk
factors and/or target organ damage (such as microalbuminuria:
30–300 mg/24 h).
† Severe chronic kidney disease (CKD) (GFR ,30 mL/min/
1.73 m2).
† A calculated SCORE ≥10%.
2. High risk
Subjects with any of the following:
† Markedly elevated single risk factors such as familial dyslipidae-
mias and severe hypertension.
† Diabetes mellitus (type 1 or type 2) but without CV risk factors
or target organ damage.
† Moderate chronic kidney disease (GFR 30–59 mL/min/1.73 m2).
† A calculated SCORE of ≥5% and ,10% for 10-year risk of fatal
CVD.
3. Moderate risk
Subjects are considered to be at moderate risk when their SCORE
is ≥1 and ,5% at 10 years. Many middle-aged subjects belong to
this category. This risk is further modulated by factors mentioned
above.
4. Low risk
The low-risk category applies to individuals with a SCORE ,1%
and free of qualifiers that would put them at moderate risk.
These risk categories are compatible with the joint European
Atherosclerosis Society/ESC lipid guidelines.70 The joint guidelines
offer further advice on lipid intervention based on these risk
categories.
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Estimation of total risk remains a crucial part of the present guidelines.
The SCORE system has been updated with an estimate of total CVD
risk as well as risk of CVD death. New information on diabetes is
included. Information on relative as well as absolute risk is added
to facilitate the counselling of younger persons whose low absolute
risk may conceal a substantial and modifiable age-related risk.
The priorities defined in this section are for clinical use and
reflect the fact that those at highest risk of a CVD event benefit
most from preventive measures. This approach should comple-
ment public actions to reduce community risk factor levels and
promote a healthy lifestyle.
The principles of risk estimation and the definition of priorities
reflect an attempt to make complex issues simple and accessible,
but they must be interpreted in the light of both the physician’s
detailed knowledge of their patient and local guidance and conditions.
Remaining gaps in the evidence
† Current systems of grading evidence give most weight to RCTs.
While this is appropriate, many lifestyle measures are less amen-
able to such assessment than are drug treatments, which will
therefore tend to receive a higher grade. While the GRADE
system attempts to address this issue, more debate is needed.
† There are no recent RCTs of a total risk approach to: (i) risk
assessment; or (ii) risk management.
† The young, women, older people, and ethnic minorities con-
tinue to be under-represented in clinical trials.
† A systematic comparison of current international guidelines is




† The importance of the familial prevalence of early-onset CVD is
not yet sufficiently understood in clinical practice.
Familial prevalence of atherosclerotic disease or of major risk
factors (high BP, diabetes mellitus, hyperlipidaemia) should be sys-
tematically sought in the first-degree relatives of any patient
affected before 55 years in men and 65 years in women.73 This rec-
ommendation is not sufficiently applied. In SCORE, accounting for
family history is probably very crude and is most certainly an
underestimate. Family history is a variable combination of genetics
and shared environment. There is evidence of strong heritability of
many cardiovascular risk factors.
A number of genetic polymorphisms (sequence variants that
occur at a frequency .1%) appear to be associated with statistic-
ally significant effects on risk at the population level. Because of the
polygenic and polyfactorial determinants of the most common
CVDs, the impact of any single polymorphism remains rather
modest. Genetic testing can identify variants associated with
increased risk to individual CVD risk factors, CHD, or stroke.
Commercial testing was recently made available to predict an indi-
vidual’s genetic risk, including direct-to-consumer testing. The clin-
ical benefits of commercial testing have not yet been
demonstrated.74
In some conditions the process of genetic counselling can be
optimized and extended with cascade screening, which identifies
patients at risk and enables timely treatment of affected relatives,
as is the case for familial hypercholesterolaemia.72,75
3.3 Age and gender
Key messages
† CVD is by far the biggest cause of death in women.
† The risk of CVD in women, as in men, can be reduced by not
smoking, by being active, avoiding overweight, and by having a
blood pressure and blood cholesterol check (and intervention,
if elevated).
Increasing age and male sex increase CVD risk and are
‘fixed’ characteristics used to stratify risk assessments.45
Using age 55+ years as the only risk factor in determining
need for pharmacological intervention with a combined
low-dose antihypertensive, statin, and aspirin pill has been
Recommendations for genetic testing
Recommendations Classa Levelb GRADE Ref C
DNA-based tests 
for common genetic 
polymorphisms do not 
presently add significantly 
to diagnosis, risk prediction, 
or patient management and 
cannot be recommended.
III B Strong 71
The added value of 
genotyping, as an alternative 
or in addition to phenotyping, 
for a better management 
of risk and early prevention 
in relatives, cannot be 
recommended.




Recommendation regarding age and gender
Recommendations Classa Levelb GRADE Ref C
Women and older people 
should be included in CVD 
risk assessments in the same 
way as other groups to 
determine need for specific 
treatments.
I B Strong 76, 77












advocated.78 However, exposure to common risk factors also
increases with age, and between one-third and one-half of the
age differences (between 25–49 vs. 50–59 and 60–64 years)
in CHD risk in Finnish people is explained by smoking,
HDL:total cholesterol ratio, SBP, body mass index (BMI), and
diabetes.76 Other risk factors such as physical inactivity and
low socio-economic status are also likely to contribute to
age differences in risk.
Age is a good marker of duration of exposure to known and
unknown CHD risk factors. Relatively young people are at low
absolute risk of a CVD event in the ensuing 10 years despite
having a full complement of risk factors. For example, a man
of 45 who smokes, has a SBP of 180 mmHg, and a blood choles-
terol of 8 mmol/L has a risk of fatal CVD of only 4% over 10
years (SCORE charts), suggesting no need for drug treatment.
However, the relative risk chart (Figure 5) indicates that his
risk is already 12-fold higher than that of a man with no risk
factors. Five years later, when he reaches 50 years, his risk
increases into the danger zone of 14% over 10 years and he
requires treatment. Similar considerations apply in women
who are at lower absolute risk at younger ages and may have
high levels of specific risk factors. In these circumstances, clinical
judgement is required—risk scores guide and do not dictate
treatment decisions. Investment in additional measurements
such as imaging with computed tomography to obtain coronary
calcium scores may be helpful,79 but adds considerably to the
cost and time involved in risk factor scoring, and its benefit
remains unproven.80
CVD is the major cause of death in women in all European
countries; below 75 years, 42% of women die from CVD com-
pared with 38% of men.14 The lower rates of CHD in women—
but not of stroke—may be interpreted as a protective effect of
endogenous oestrogens. However, exploration of trends over
time and between countries shows that the relationship
varies, making this an implausible explanation.81 Sex differences
in dietary fat intake (rather than excess smoking in men) may be
responsible.81 CVD mortality does not accelerate in women fol-
lowing the menopause, indicating that women are postponing
their risk rather than avoiding it altogether. The American
Heart Association (AHA) published an update of its guidelines
for the prevention of CVD in women,82 which emphasizes
that recommendations are the same for both men and
women, with few exceptions. Use of the Framingham score is
recommended but now includes a category of ‘ideal cardiovas-
cular health’ comprising absence of raised risk factors, BMI
,25 kg/m2, regular moderate-to-vigorous physical activity, and
a healthy diet. In the US Women’s Health Initiative, only 4%
of women fell into this ideal state and a further 13% had no
risk factors but failed to follow a healthy lifestyle.83 There was
a 18% difference in major CVD events in favour of the ideal life-
style vs. the no-risk factor groups: 2.2% and 2.6% per 10 years,
respectively.
Most important new information
† Asymptomatic women and older people benefit from risk
scoring to determine management.
Remaining gaps in the evidence
† Clinical investigation to aid treatment decisions in younger
people with high levels of risk factors requires further
evaluation.
3.4 Psychosocial risk factors
Key messages
† Low socio-economic status, lack of social support, stress at
work and in family life, depression, anxiety, hostility, and the
type D personality contribute both to the risk of developing
CVD and the worsening of clinical course and prognosis of
CVD.
† These factors act as barriers to treatment adherence and efforts
to improve lifestyle, as well as to promoting health and well-
being in patients and populations. In addition, distinct psychobio-
logical mechanisms have been identified, which are directly
involved in the pathogenesis of CVD.
3.4.1 Risk factors
Low socio-economic status
Multiple prospective studies have shown that men and women
with low socio-economic status, defined as low educational level,
low income, holding a low-status job, or living in a poor residential
area, have an increased all-cause as well as CVD mortality risk
[relative risk (RR) 1.3–2.0].87– 91
Social isolation and low social support
Recent systematic reviews confirm that people who are isolated or
disconnected from others are at increased risk of dying premature-
ly from CVD. Similarly lack of social support leads to decreased
survival and poorer prognosis among people with clinical manifes-
tations of CVD (RR 1.5–3.0).92,93
Stress at work and in family life
According to a recent review, there is moderate evidence that
work-related stress (e.g. high psychological demands, lack of
Recommendation regarding psychosocial factors
Recommendations Classa Levelb GRADE Ref C
Psychosocial risk factors
should be assessed by clinical
interview or standardized
questionnaires. Tailored
clinical management should be
considered in order to
enhance quality of life and
CHD prognosis.  
IIa B Strong 84–86
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social support, and job strain) are risk factors for incident CVD in
men [odds ratio (OR) 1.5].94,95 Studies involving women were too
few to draw firm conclusions.94 Conflicts, crises, and long-term
stressful conditions in family life have also been shown to increase
CHD risk [hazard ratio (HR) 2.7–4.0], especially in women (RR
2.9–4.0).96,97
Depression
Several systematic reviews and meta-analyses have shown that
clinical depression and depressive symptoms predict incident
CHD (RR 1.6 and 1.9),98– 100 and worsen its prognosis (OR 1.6
and 2.4).100 –102 Perceived social support seems to counteract
the adverse effect of depression,103 whereas lack of support was
found to reinforce its adverse effects.104
Anxiety
Large epidemiological studies indicate that panic attacks increase
the risk of incident cardiovascular events (HR 1.7 and 4.2, respect-
ively),105,106 and generalized, phobic anxiety, and panic attacks may
worsen the course of established CVD (OR 1.01 and 2.0, respect-
ively).107– 109 In contrast to these findings, a recent post-hoc ana-
lysis of a large prospective cohort study found a lower all-cause
mortality in anxious CVD patients (HR 0.7). A higher mortality
could only be observed in post-myocardial infarction patients
with reduced systolic left ventricular function (HR 1.3), suggesting
antipodal effects of anxiety in different subgroups of CVD
patients.110 However, two recent meta-analyses confirmed that
anxiety is an independent risk factor for incident CHD (HR
1.3)111 and for adverse events following myocardial infarction
(OR 1.5 and 1.7, respectively).112
Hostility and anger
Hostility is a personality trait, characterized by extensive experi-
ence of mistrust, rage, and anger, and the tendency to engage in
aggressive, maladaptive social relationships. A recent meta-analysis
has confirmed that anger and hostility are associated with an
increased risk for cardiovascular events in both healthy and CVD
populations (HR 1.2).113 Failure to express anger might be of par-
ticular importance, as patients with CVD who suppress their anger
have an increased risk of adverse cardiac events (OR 2.9).114
Type D personality
In contrast to isolated depressive and anxious symptoms, which
often occur in episodes, the type D (‘distressed’) personality
involves an enduring tendency to experience a broader spectrum
of negative emotions (negative affectivity) and to inhibit
self-expression in relation to others (social inhibition). The type
D personality has been shown to predict poor prognosis in
patients with CVD (OR 3.7), even after adjustment for depressive
symptoms, stress, and anger.115
3.4.2 Clustering of psychosocial risk factors
and bio-behavioural mechanisms
In most situations, psychosocial risk factors cluster in the same
individuals and groups. For example, both women and men of
lower socio-economic status and/or with chronic stress are
more likely to be depressed, hostile, and socially isolated.116,117
Mechanisms that link psychosocial factors to increased CVD risk
include unhealthy lifestyle (more frequent smoking, unhealthy food
choice, and less physical exercise), increased healthcare utilization,
and low adherence to behaviour-change recommendations or
cardiac medications.88,90,116 – 119 Financial barriers to healthcare
have also been shown to predict negative outcomes after myocar-
dial infarction.91
In addition, persons and patients with depression and/or chronic
stress show alterations in autonomic function (including reduced
heart rate variability) in the hypothalamic–pituitary axis and in
other endocrine markers, which affect haemostatic and inflamma-
tory processes, endothelial function, and myocardial perfu-
sion.117,118,120 Enhanced risk in patients with depression may also
be due in part to adverse effects of tricyclic antidepressants.121,122
3.4.3 Assessment of psychosocial risk factors
The assessment of psychosocial factors in patients and persons
with CVD risk factors is crucial as a means to stratify future pre-
ventive efforts according to the individual risk profile of the
patient. Standardized measurements for depression, anxiety, hostil-
ity, socio-economic status, social support, psychosocial stress, and
type D personality are available in many languages and coun-
tries.115,123 Alternatively, a preliminary assessment of psychosocial
factors can be made within the physicians’ clinical interview, as
detailed in Table 6.
Table 6 Core questions for the assessment of




What is your highest educational degree?




Do you lack control over how to meet the demands 
at work?
Is your reward inappropriate for your effort?
Do you have serious problems with your spouse?
Social 
isolation
Are you living alone?
Do you lack a close confidant?
Depression
Do you feel down, depressed, and hopeless?
Have you lost interest and pleasure in life?
Anxiety
Do you frequently feel nervous, anxious, or on edge?
Are you frequently unable to stop or control worrying?
Hostility
Do you frequently feel angry over little things?
Do you often feel annoyed about other people’s habits?
Type D 
personality
In general, do you often feel anxious, irritable, or 
depressed?
Do you avoid sharing your thoughts and feelings with 
other people?
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No more than mandatory education and/or a ‘yes’ for one or
more items indicates a higher risk than that assessed with the
SCORE tools or priority categories. Relevance of psychosocial
factors with respect to quality of life and medical outcome should
be discussed with the patient, and further tailored clinical manage-
ment should be considered (Section 4.5). Routine screening for
depression does not contribute to better cardiac prognosis in the
absence of changes in current models of cardiovascular care.124
Most important new information
† Recent meta-analyses have shown that symptoms of anxiety and
the type D personality increase risk for CVD and contribute to
worse clinical outcome.
Remaining gaps in the evidence
† There is limited evidence that routine screening for psychosocial
risk factors contributes to fewer future cardiac events, as screen-
ing has not yet translated into improved healthcare models.
3.5 Other biomarkers of risk
Key messages
† Novel biomarkers have only limited additional value when
added to CVD risk assessment with the SCORE algorithm.
† High-sensitive CRP and homocysteine may be used in persons at
moderate CVD risk.
Although the number of potential novel risk markers is ever
expanding yearly, this number scales down to a level close to
unity once the possible candidates have passed through the
grading of clinical evidence. Emerging biomarkers were selected
from published data, if tested as alternatives or on top of classical
risk factors, for their ability to predict or modify 10-year cardiovas-
cular morbidity or mortality. Only circulating biomarkers assessed
by standardized and validated methods (and identified as risk
factors worth translating into clinical practice) were considered
in these guidelines, in a context of cost-effectiveness for assess-
ment of individual risk in the general population.
After removing novel biomarkers relevant to glucose metabol-
ism, lipid metabolism, or organ-specific biomarkers, which are
included in the specific sections (see Section 4), two groups of sys-
temic biomarkers relevant to CVD risk assessment were identified:
† Inflammatory: hsCRP, fibrinogen.
† Thrombotic: homocysteine, lipoprotein-associated phospholip-
ase (LpPLA2).
3.5.1 Inflammatory: high-sensitivity C-reactive protein,
fibrinogen
High-sensitivity CRP has shown consistency across large prospect-
ive studies as a risk factor integrating multiple metabolic and low-
grade inflammatory factors underlying the development of unstable
atherosclerotic plaques, with a magnitude of effect matching that of
classical major risk factors. This marker was used in individuals
showing a moderate level of risk from clinical assessment of
major CVD risk factors.125,126 However, several weak points
exist when including this novel biomarker for risk assessment:
† Multiplicity of confounders: dependence on other classical
major risk factors.
† Lack of precision: narrow diagnostic window for hsCRP level
and risk of CVD.
Recommendations for inflammatory biomarkers
Recommendations Classa Levelb GRADE RefC
High-sensitivity CRP may be 
measured as part of refined 
risk assessment in patients 
with an unusual or moderate 
CVD risk profile.
IIb B Weak 125
High-sensitivity CRP 
should not be measured 
in asymptomatic low-risk 
individuals and high-risk 
patients to assess 10-year risk 
of CVD.
III B Strong 126
Fibrinogen may be measured 
as part of refined risk 
assessment in patients with 
an unusual or moderate CVD 
risk profile.
IIb B Weak 127
Fibrinogen should not be 
measured in asymptomatic 
low-risk individuals and
 high-risk patients to assess 
10-year risk of CVD.
III B Strong 127




Recommendations for thrombotic biomarkers
Recommendations Classa Levelb GRADE Ref C
Homocysteine may be 
measured as part of a refined 
risk assessment in patients 
with an unusual or moderate 
CVD risk profile.
IIb B Weak 128
Homocysteine should not be 
measured to monitor CVD 
risk prevention.
III B Strong 128
LpPLA2 may be measured 
as part of a refined risk 
assessment in patients at 
high risk of a recurrent acute 
atherothrombotic event.
IIb B Weak 129
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† Lack of specificity: similar level of risk for other non-
cardiovascular causes of morbidity and mortality (e.g. other low-
grade inflammatory diseases).
† Lack of dose–effect or causality relationship between changes in
hsCRP level and risk of CVD.
† Lack of specific therapeutic strategies or agents targeting circu-
lating CRP and showing reduction in CVD incidence.
† Higher cost of test compared with classical biological risk
factors (e.g. blood glucose and lipids).
† Similar statements are made for fibrinogen.127
3.5.2 Thrombotic
Homocysteine
Homocysteine has shown precision as an independent risk factor
for CVD. The magnitude of effect on risk is modest, and consist-
ency is often lacking, mainly due to nutritional, metabolic (e.g.
renal disease), and lifestyle confounders.128 In addition, interven-
tion studies using B vitamins to reduce plasma homocysteine
have proven inefficient in reducing risk of CVD.128 Together
with the cost of the test, homocysteine remains a ‘second-line’
marker for CVD risk estimation.
Lipoprotein-associated phospholipase 2
LpPLA2 has recently emerged as a marker with high consistency
and precision as an independent risk factor for plaque rupture
and atherothrombotic events. The magnitude of effect on risk
remains modest at the level of the general population; study limita-
tions or bias are present. Together with the cost of the test,
LpPLA2 remains a ‘second-line’ marker for CVD risk estimation.129
Most important new information
† Overall, emerging validated biomarkers may add value in a
context of specialized practice, to assess CVD risk more pre-
cisely in specific subgroups of patients at moderate, unusual,
or undefined levels of risk (e.g. asymptomatic patients without
multiple major classical risk factors, but affected with a rare
metabolic, inflammatory, endocrine, or social condition asso-
ciated with atherosclerosis or displaying signs of atherosclerosis
progression).
Remaining gaps in the evidence
† For both biomarkers that are already well-established and novel
biomarkers that arise in the future there is a need to redefine
specific subgroups (intermediate, undefined, or unusual CVD
risk) that would benefit most from the use of these biomarkers,
particularly in early primary prevention.
3.6 Imaging methods in cardiovascular
disease prevention
Key message
† Imaging methods can be relevant in CVD risk assessment in
individuals at moderate risk.
The consequences of coronary atherosclerosis can be objective-
ly assessed non-invasively using a variety of techniques such as
bicycle or treadmill exercise electrocardiogram (ECG) testing,
stress echocardiography, or radionuclide scintigraphy. Unfortu-
nately, sudden cardiac death is for many individuals the first mani-
festation of CVD. Detection of asymptomatic but diseased patients
is crucial for an adequate prevention programme.
At every level of risk factor exposure, there is substantial vari-
ation in the amount of atherosclerosis. This variation in disease
is probably due to genetic susceptibility, combinations of different
risk factors, and interactions between genetic and environmental
factors. Thus measurements of subclinical disease may be useful
for improving CVD risk prediction. Non-invasive tests such as
carotid artery scanning, electron-beam computed tomography,
multislice computed tomography, ankle–brachial BP ratios, and
magnetic resonance imaging (MRI) techniques offer the potential
for directly or indirectly measuring and monitoring atherosclerosis
Recommendations regarding imaging methods
Recommendations Classa Levelb GRADE Ref C
Measurement of carotid 
intima-media thickness and/or 
screening for atherosclerotic 
plaques by carotid artery 
scanning should be 
considered for cardiovascular 
risk assessment in 






brachial index should be 
considered for cardiovascular 
risk assessment in 





Computed tomography for 
coronary calcium should be 
considered for cardiovascular 
risk assessment in 






may be considered 
for cardiovascular risk 
assessment in moderate-
risk asymptomatic adults 
(including sedentary 
adults considering starting 
a vigorous exercise 
programme), particularly 
when attention is paid to 
non-electrocardiogram 

















in asymptomatic persons, but cost-effectiveness needs to be
documented.
3.6.1 Early detection by magnetic resonance imaging
of cardiovascular disease in asymptomatic subjects
Magnetic resonance imaging has been evaluated as a means of
assessing coronary artery stenosis. The value of this technique is
still in question.141,142 Currently, the sensitivity, specificity, and
robustness of this technique are not sufficiently high to perform
screening for coronary stenoses in asymptomatic people.
Recently, coronary wall MRI detected positive remodelling in
asymptomatic patients with subclinical atherosclerosis, opening
up a new research field in the prevention of CVD.143 In vitro,
MRI can differentiate the plaque components of carotid, aortic,
and coronary artery specimens obtained at autopsy.144 The
current fast technical improvement has led to three-dimensional
black blood vessel wall imaging, which permits in vivo distinction
of ‘normal’ and diseased vessel walls.145 At present, MRI is a prom-
ising research tool, but its routine use remains limited and it is not
yet appropriate for identifying patients at high risk for CVD.146
3.6.2 Coronary calcium score
Coronary calcifications indicate atherosclerosis of coronary arter-
ies.147 On the other hand, atherosclerotic diseased coronary arter-
ies do not necessarily always show calcifications. The extent of the
calcification correlates with the extent of the total coronary plaque
burden.147 Coronary calcification is an indicator neither of stability
nor of instability of an atherosclerotic plaque.148 In patients with an
ACS, the extent of coronary calcification is more pronounced than
in control groups without known CHD.149 Moreover, the inflam-
matory component has been emphasized for patients with an
ACS,150 underlining the concept of evaluation of the total coronary
plaque burden by quantification of coronary calcium burden.151
Most scientific data on the evaluation of the presence and extent
of coronary calcified atherosclerosis are related to the use of the
‘Agatston score’.152
Recently it has been suggested that the score is to be replaced
with volumetric variables, such as total calcium volume (mm3),
calcium mass (mg), or calcium density (mg/mm3). For clinical pur-
poses, however, it is not yet known if these new variables are su-
perior to the Agatston score.153 The value of the score can be
further increased if the age and gender distribution within percen-
tiles are also taken into account.153
The presence of coronary calcium is not in the least identical to
the presence of relevant coronary stenosis because its specificity
regarding the presence of ≥50% stenosis is only 50%. Misunder-
standings in recent years regarding coronary calcium and extrapo-
lation to CHD are due to a mix-up of definitions: while the
presence of coronary calcium proves a ‘coronary disease’ (coron-
ary atherosclerosis)—it does not necessarily reflect ‘CHD’ defined
as ≥50% narrowing.
In contrast, coronary calcium scanning shows a very high nega-
tive predictive value: the Agatston score of 0 has a negative pre-
dictive value of nearly 100% for ruling out a significant coronary
narrowing.154 However, recent studies have questioned the nega-
tive predictive value of the calcium score: the presence of signifi-
cant stenosis in the absence of coronary calcium is possible. It is
more likely in the setting of unstable angina or non-ST elevation
myocardial infarction (NSTEMI) than in stable chest pain, and
occurs more frequently in younger patients.155 Many prospective
studies have shown the prognostic relevance of the amount of cor-
onary calcium.156
The Agatston score is an independent risk marker regarding the
extent of CHD157 and prognostic impact.158 The Rotterdam calci-
fication study showed that the upper percentile range reflects a
12-fold increased risk of myocardial infarction—independent of
the classical risk factors—even in elderly people.159
Although calcium scanning is widely applied today, it is especially
suited for patients at moderate risk.137 The radiation exposure
with the properly selected techniques is 1 mSv. Recent studies
have also shown that multislice computed tomography coronary
angiography with decreased radiation levels is highly effective in
re-stratifying patients into either a low or high post-test risk
group.160
3.6.3 Carotid ultrasound
Population-based studies have shown a correlation between the
severity of atherosclerosis in one arterial territory and the involve-
ment of other arteries.130 Therefore, early detection of arterial
disease in apparently healthy individuals has focused on the periph-
eral arterial territory and on the carotid arteries. Risk assessment
using carotid ultrasound focuses on the measurement of the
intima-media thickness (IMT) and the presence of plaques and
their characteristics.
The IMT is a measurement not only of early atherosclerosis but
also of smooth muscle hypertrophy/hyperplasia, which may be
related even to genetic factors, hypertension, and age-related
sclerosis.132 Although there is a graded increase in cardiovascular
risk with rising IMT, a value .0.9 mm is considered abnormal.
Persons without known CVD with increased IMT are at increased
risk for cardiac events and stroke. Although the relative risk for
events is slightly lower after statistical correction for the presence
of traditional risk factors, the risk remains elevated at higher
IMT.130
When IMT is used to predict the incidence of subsequent
stroke, the risk is graded but non-linear, with hazards increasing
more rapidly at lower IMTs than at higher IMTs.130 The risk of
cardiac events over 4–7 years of follow-up in patients free of clin-
ical CVD at baseline is also non-linearly related to IMT.131
Plaque is defined as a focal structure of the inner vessel wall at
least ≥0.5 mm (or .50%) of the surrounding IMT, or any IMT
measurement ≥1.5 mm. Plaques may be characterized by their
number, size, irregularity, and echodensity (echolucent vs. calci-
fied). Plaques are related to both coronary obstructive disease
and the risk of cerebrovascular events. Echolucent plaques imply
an increased risk of cerebrovascular events as compared with cal-
cified plaques.
Plaque characteristics as assessed by carotid ultrasound were
found to be predictive of subsequent cerebral ischaemic
events.131 Patients with echolucent stenotic plaques had a much
higher risk of cerebrovascular events than subjects with other
plaque types. Ultrasound imaging of the carotids is a non-invasive
means of assessing subclinical atherosclerosis. The extent of
carotid IMT is an independent predictor of cerebral and coronary
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events, but seems to be more predictive in women than in men.
Consequently, carotid ultrasound can add information beyond as-
sessment of traditional risk factors that may help to make decisions
about the necessity to institute medical treatment for primary
prevention.
Arterial stiffness has been shown to provide added value in
stratification of patients. An increase in arterial stiffness is usually
related to damage in the arterial wall, as has been suggested in
hypertensive patients.161,162
3.6.4 Ankle–brachial index
The ankle–brachial BP index (ABI) is an easy-to-perform and re-
producible test to detect asymptomatic atherosclerotic disease.
An ABI ,0.9 indicates ≥50% stenosis between the aorta and
the distal leg arteries. Because of its acceptable sensitivity (79%)
and specificity, an ABI ,0.90 is considered to be a reliable
marker of PAD.133 An ABI value indicating significant PAD adds
additional value to medical history, because 50–89% of patients
with an ABI ,0.9 do not have typical claudication.134 In asymptom-
atic individuals over 55 years of age, an ABI ,0.9 may be found in
12–27%. Even in an elderly population (71–93 years), a low ABI
further identifies a higher risk CHD subgroup.
The ABI also predicts further development of angina, myocardial
infarction, congestive heart failure, CABG surgery, stroke, or
carotid surgery.135 ABI is inversely related to CVD risk.163
3.6.5 Ophthalmoscopy
It has been shown that the extent of retinal artery atherosclerosis
correlates with the extent of coronary artery atherosclerosis and
with serum levels of cholesterol, triglycerides, and apoB.164
However, its place in vascular disease risk assessment remains
uncertain.
Most important new information
† Vascular ultrasound screening is reasonable for risk assessment
in asymptomatic individuals at moderate risk.
† Measurement of coronary artery calcifications may be reason-
able for cardiovascular risk assessment in asymptomatic adults
at moderate risk.
Remaining gaps in the evidence
† The role of computed tomography scanning for screening in
asymptomatic patients needs further investigation.
† Prospective studies proving the value of coronary scanning
(level A evidence) do not as yet exist.
† Magnetic resonance imaging for detection of vascular plaque
may be of interest for cardiovascular risk assessment in asymp-
tomatic adults, but studies are still not convincing.
3.7 Other diseases with increased risk for
cardiovascular disease
Atherosclerosis is an inflammatory disease in which immune
mechanisms interact with metabolic risk factors to initiate, propa-
gate, and activate lesions in the arterial tree.170 Several diseases in
which infection or non-infectious inflammatory processes deter-
mine the clinical picture are associated with an increased cardio-
vascular event rate. The optimal concept of prevention in these
diseases is not established, and randomized studies evaluating
prognosis are not available. Management of all risk factors
appears advisable even in the absence of randomized studies.
3.7.1 Influenza
Influenza epidemics are associated with an increased rate of cardio-
vascular events. Influenza vaccination as a population-wide preven-
tion measure was associated with a very cost-effective reduction in
clinical events.171 Annual influenza vaccinations are recommended
for patients with established CVD.172
3.7.2 Chronic kidney disease
Hypertension, dyslipidaemia, and diabetes mellitus are common
among patients with CKD. They are major risk factors for the de-
velopment and progression of endothelial dysfunction and athero-
sclerosis, and contribute to the progression of renal failure—yet
these patients tend to be less intensely treated than patients
with normal renal function.165 Inflammatory mediators and promo-
ters of calcification are increased and inhibitors of calcification are
reduced in CKD, which favours vascular calcification and vascular
injury.136 Microalbuminuria increases cardiovascular risk two- to
four-fold. A decreasing GFR is an indicator of increased risk for
CVD and all-cause mortality. In a large cohort study, anaemia,
decreased GFR, and microalbuminuria were independently asso-
ciated with CVD and, when all were present, CVD was common
and survival was reduced.173
There is a quantitative association between decreased GFR and
cardiovascular risk: patients with moderately decreased renal
Recommendations regarding other diseases with
increased risk for cardiovascular disease
increased risk for cardiovascular disease
Recommendations Classa Levelb GRADE RefC
In patients with chronic 
kidney disease, risk factors 
have to be attended to in the 





All persons with obstructive 
sleep apnoea should undergo 
medical assessment, including 





All men with erectile 
dysfunction should undergo 
medical assessment, including 
risk stratification and risk 
management.












function (stage 3, GFR 30–59 mL/min/1.73 m2) have a two- to
four-fold increased risk in comparison with persons free of CKD.
The risk increases to four- to 10-fold in stage 4 (GFR 15–
29 mL/min/1.73 m2) and to 10- to 50-fold in stage 5 renal failure
(end-stage) (GFR ,15 mL/min/ 1.73 m2 or dialysis).136
Lipid lowering appears useful in a wide range of patients with
advanced CKD but with no known history of myocardial infarction
or coronary revascularization: a reduction of low-density lipopro-
tein (LDL) cholesterol by 0.85 mmol/L (33 mg/dL) with daily 20 mg
simvastatin plus 10 mg ezetimibe reduced the incidence of major
events: non-fatal myocardial infarction, coronary death, non-
haemorrhagic stroke, or any arterial revascularization
procedure.174
3.7.3 Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) is characterized by recurrent
partial or complete collapse of the upper airway during sleep. It
affects an estimated 9% of adult women and 24% of adult men.175
Repetitive bursts of sympathetic activity, surges of blood pres-
sure, and oxidative stress brought on by pain and episodic hypox-
aemia associated with increased levels of mediators of
inflammation are thought to promote endothelial dysfunction
and atherosclerosis.176 OSA has been associated with a 70% rela-
tive increased risk of cardiovascular morbidity and mortality.177
The risk correlates in men between 40 and 70 years with the
apnoea–hypopnea index.167 Screening for and treating OSA in
patients with chronic coronary artery disease178 and hypertension
may result in decreased cardiac events and cardiac death.168
3.7.4 Erectile dysfunction
Erectile dysfunction (ED), defined as the consistent inability to
reach and maintain an erection satisfactory for sexual activity,
afflicts to some degree 52% of male adults between the ages of
40 and 70 years. It may result from psychological, neurological,
hormonal, arterial, or cavernosal impairment or from a combin-
ation of these factors.179 –181 ED has a high prevalence in indivi-
duals with multiple cardiovascular risk factors and in individuals
with CVD. ED is a marker for CVD and a predictor of future
events in middle-aged and older men but not beyond that
offered by the Framingham risk score.182 – 184 Lifestyle modification
and pharmacotherapy for risk factors are effective in improving
sexual function in men with ED.169
3.7.5 Autoimmune diseases
3.7.5.1 Psoriasis
Psoriasis appears to be an independent risk factor for myocardial
infarction. The pathophysiology of psoriasis is characterized by
an increase in antigen presentation, T-cell activation, and
T-helper cell type 1 cytokines, resulting in thick scaly red plaques
and, in some patients, arthritis. Psoriasis is also associated with
markers of systemic inflammation, such as increased CRP levels.
The risk of myocardial infarction associated with psoriasis is great-
est in young patients with severe psoriasis, is attenuated with age,
and remains increased even after controlling for traditional cardio-
vascular risk factors. Patients in whom the psoriasis was classified
as severe had a higher risk of myocardial infarction than patients
with mild psoriasis, consistent with the hypothesis that greater
immune activity in psoriasis is related to a higher risk of myocardial
infarction and cardiovascular death.185,186
3.7.5.2 Rheumatoid arthritis
Patients with rheumatoid arthritis are twice as likely as the general
population to suffer a myocardial infarction. They also have a
higher mortality rate after myocardial infarction, which may only
partially explain their reduced life expectancy (5–10 years
shorter than patients without the condition). CVD risk is increased
at an early stage of the disease, and this risk excess beyond trad-
itional risk parameters is possibly related to systemic inflammation
and a prothrombotic state.
Modification of traditional risk factors through lifestyle changes,
including dietary modification, smoking cessation, and increased
daily exercise, and appropriate drug prescription may be of par-
ticular importance in reducing risk in individuals with psoriasis or
rheumatoid arthritis.
Non-randomized observational studies report reductions in
rates of vascular events and cardiovascular death among both
rheumatoid arthritis and psoriasis patients being treated with
weekly methotrexate in doses ranging from 10 to 20 mg.187,188
3.7.5.3 Lupus erythematosus
Systemic lupus erythematosus is associated with endothelial dys-
function and an increased risk of CHD that is not fully explained
by classic CHD risk factors.
Chronic systemic inflammation in patients with systemic lupus
erythematosus results in coronary microvascular dysfunction,
with abnormalities in absolute myocardial blood flow and coronary
flow reserve. Coronary microvascular dysfunction is an early
marker of accelerated coronary atherosclerosis and may contrib-
ute to the increased cardiovascular morbidity and mortality in
these patients.189
3.7.6 Periodontitis
Periodontitis is associated with endothelial dysfunction, athero-
sclerosis, and an increased risk of myocardial infarction and
stroke. Confounding factors, however, such as low socio-economic
status and cigarette smoking probably play a significant role. Peri-
odontitis can be considered a risk indicator for a generally
decreased cardiovascular health status and its treatment is indi-
cated as well as management of the underlying cardiovascular
risk factors.190
3.7.7 Vascular disease after radiation exposure
The incidence of ischaemic heart disease and stroke is increased
many years after radiation exposure for treatment of lymphomas
and for breast cancer, as well as for head and neck cancer.191,192
From descriptive studies, the lesions exhibit typical features of
atherosclerosis, including lipid accumulation, inflammation, and
thrombosis.193 Patients after radiation exposure should make
great efforts to optimize their risk factor profile. The use of
statins may be reasonable.
3.7.8 Vascular disease after transplantation
Cardiac allograft vasculopathy is the leading cause of late morbidity
and mortality in heart transplant patients. Although it is a complex
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multifactorial process arising from immune and non-immune
pathogenic mechanisms, the approach to cardiac allograft vasculo-
pathy has been modification of underlying traditional risk factors
and optimization of immune suppression. Important non-immune
risk factors include hyperlipidaemia, hypertension, diabetes melli-
tus, and hyperhomocysteinaemia. Administration of statins
improves endothelial dysfunction, slows the development of
cardiac allograft vasculopathy, and benefits survival.194
Most important new information
† Treatment of periodontitis improves endothelial dysfunction,
one of the earliest signs of atherosclerosis.
Remaining gaps in the evidence
† Randomized studies are lacking except in patients with vascular
disease after transplantation.
4. How can cardiovascular disease
prevention be used?
4.1 Principles of behaviour change
Key message
† Cognitive-behavioural methods are effective in supporting
persons in adopting a healthy lifestyle.
4.1.1 Introduction: why do individuals find it hard to
change their lifestyle?
‘Lifestyle’ is usually based on long-standing behavioural patterns.
These patterns are framed during childhood and adolescence by
an interaction of environmental and genetic factors, and are main-
tained or even promoted by the individual’s social environment as
an adult. Consequently, marked differences in health behaviour
between individuals but also between social groups can be
observed. In addition, these factors impede the ability to adopt a
healthy lifestyle, as does complex or confusing advice from
medical caregivers. Increased awareness of these factors facilitates
empathy and counselling (simple and explicit advice), thus facilitat-
ing behavioural change.
4.1.2 Effective communication and cognitive-behavioural
strategies as a means towards lifestyle change
A friendly and positive interaction is a powerful tool to enhance an
individual’s ability to cope with illness and adhere to recommended
lifestyle changes and medication use. Social support provided by
caregivers may be of importance in helping individuals maintain
healthy habits and follow medical advice. It is of special importance
to explore each individual patient’s experiences, thoughts and
worries, previous knowledge, and circumstances of everyday life.
Individualized counselling is the basis for evoking and gaining the
patient’s motivation and commitment. Decision-making should be
shared between caregiver and patient (also including the indivi-
dual’s spouse and family) to the greatest extent possible, thus
ensuring the active involvement of both the individual and family
in lifestyle change and medication adherence. Use of the following
principles of communication will facilitate treatment and
prevention of CVD (Table 7).
Recommendations for behavioural change
Recommendations Classa Levelb GRADE Ref C
Established cognitive-
behavioural strategies (e.g. 
motivational interviewing) to 






professionals (e.g. nurses, 
dieticians, psychologists, etc.) 






In individuals at very high 
CVD risk, multimodal 
interventions, integrating 
education on healthy lifestyle 
and medical resources, 
exercise training, stress 
management, and counselling 











Table 7 Principles of effective communication to
facilitate behavioural change
• Spend enough time with the individual to create a therapeutic 
 relationship—even a few more minutes can make a difference.
• Acknowledge the individual’s personal view of his/her disease and 
 contributing factors.
• Encourage expression of worries and anxieties, concerns, and
 self-evaluation of motivation for behaviour change and chances of 
 success.
• Speak to the individual in his/her own language and be supportive of 
 every improvement in lifestyle.
• Ask questions to check that the individual has understood the advice 
 and has any support they require to follow it.
• Acknowledge that changing life-long habits can be difficult and that 
 gradual change that is sustained is often more permanent than a 
 rapid change.
• Accept that individuals may need support for a long time and that 
 repeated efforts to encourage and maintain lifestyle change may be 
 necessary in many individuals.
• Make sure that all health professionals involved provide consistent 
 information.
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In addition, caregivers can build on cognitive-behavioural
strategies to assess the individual’s thoughts, attitudes, and beliefs
concerning the perceived ability to change behaviour, as well as
the environmental context in which attempts to change are
made, and subsequently to maintain the lifestyle change. Behav-
ioural interventions such as ‘motivational interviewing’201 increase
motivation and self-efficacy.196 Previous negative, unsuccessful
attempts to change behaviour often result in a lower self-efficacy
for future change and often lead to another failure. A crucial
step in changing negative into positive experiences is to help the
individual to set realistic goals; goal setting combined with self-
monitoring of the chosen behaviour are the main tools needed
to achieve a positive outcome.202 This will in turn increase self-
efficacy for the chosen behaviour; thereafter, new goals can be
set. Moving forward in small, consecutive steps is one of the key
points in changing long-term behaviour.202 The way of offering
relevant information must be sensitive to the particular patient’s
thoughts and feelings. As this is a specific clinical skill, communica-
tion training is important for health professionals.
The following ‘Ten strategic steps’ have been shown to enhance
counselling on behavioural change effectively (Table 8).203
4.1.3 Multimodal, behavioural interventions
Combining the knowledge and skills of clinicians (such as physicians,
nurses, psychologists, and experts in nutrition, cardiac rehabilitation,
and sports medicine) into multimodal, behavioural interventions can
help to optimize the preventive efforts.35,202,204,205
Multimodal, behavioural interventions are especially recommended
for individuals at very high risk and for individuals with clinically mani-
fest CVD. These interventions include promoting a healthy lifestyle
through behaviour change including nutrition, exercise training, relax-
ation training, weight management, and smoking cessation pro-
grammes for resistant smokers.204 They enhance coping with
illness, and improve adherence with prescribed medication, efforts
to change behaviour, and cardiac outcome.195,197,198 Psychosocial
risk factors (stress, social isolation, and negative emotions) that may
act as barriers against behaviour change should be addressed in tai-
lored individual or group counselling sessions.195,204
There is evidence that more extensive/longer interventions may
lead to better long-term results with respect to behaviour change
and somatic outcome.195,202 Individuals of low socio-economic
status, of older age, or female gender may need tailored
programmes in order to meet their specific needs regarding infor-
mation and emotional support.202,206
Most important new information
† Evidence has confirmed cognitive-behavioural strategies to be
essential components of interventions targeting lifestyle change.
Remaining gaps in the evidence
† There is limited evidence to determine which interventions
are the most effective in specific groups (e.g. young–old,
male–female, high–low socio-economic status).
4.2 Smoking
Key messages
† Changing smoking behaviour is a cornerstone of improved CVD
health.
† Public health measures including smoking bans are crucial for the
public’s perception of smoking as an important health hazard.
4.2.1 Introduction
Smoking is an established cause of a plethora of diseases and is re-
sponsible for 50% of all avoidable deaths in smokers, half of these
due to CVD. Smoking is associated with increased risk of all types
Recommendations regarding smoking
Recommendations Classa Levelb GRADE Ref C
All smoking is a strong and 
independent risk factor for 




Exposure to passive smoking 





Young people have to be 
encouraged not to take up 
smoking.
I C Strong 211
All smokers should be given 









Table 8 ‘Ten strategic steps’ to enhance counselling
on behavioural change203
1. Develop a therapeutic alliance.
2. Counsel all individuals at risk of or with manifest cardiovascular 
 disease.
3.  Assist the individuals to understand the relationship between their 
 behaviour and health.
4. Help individuals assess the barriers to behaviour change.
5. Gain commitments from individuals to own their behaviour change.
6. Involve individuals in identifying and selecting the risk factors to 
 change.
7. Use a combination of strategies including reinforcement of the 
 individual’s capacity for change.
8. Design a lifestyle modification plan.
9. Involve other healthcare staff whenever possible.
10. Monitor progress through follow-up contact.
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of CVD—CHD, ischaemic stroke, PAD, and abdominal aortic an-
eurysm. According to estimations from SCORE, 10-year fatal car-
diovascular risk is approximately doubled in smokers. However,
while the relative risk of myocardial infarction in smokers .60
years of age is doubled, the relative risk in smokers ,50 years is
five-fold higher than in non-smokers.214,215
Although the rate of smoking is declining in Europe, it is still very
common among individuals who have received little education; and
widening education-related inequalities in smoking-cessation rates
have been observed in many European countries in recent
years.214,216,217 In the EUROASPIRE III survey 30% of the partici-
pants were smokers up to the time of their coronary event and
this had dropped by one-half after a median of 1.5 years. The
survey also found that evidence-based treatment for smoking ces-
sation was underused.33
Historically, smoking was taken up mainly by men, but in recent
years women have caught up or even surpassed the level of
smoking among men in many regions. Risk associated with
smoking is proportionately higher in women than in men.215,218
This could be related to differences in nicotine metabolism as
women metabolize nicotine faster than men, especially women
taking oral contraceptives,219 with possible effects on compensa-
tory smoking.
4.2.2 Dosage and type
The risk associated with smoking is primarily related to the amount
of tobacco smoked daily and shows a clear dose–response rela-
tionship with no lower limit for deleterious effects.220 Duration
also plays a role, and, while cigarette smoking is the most
common, all types of smoked tobacco, including low-tar (‘mild’
or ‘light’) cigarettes, filter cigarettes, cigars, and pipes, are
harmful.211 Smoking is deleterious regardless of how it is
smoked, including by waterpipe.221,222 Tobacco smoke is more
harmful when inhaled, but smokers who claim not to inhale the
smoke (e.g. pipe smokers) are also at increased risk of
CVD.211,220 Also smokeless tobacco is associated with a small
but statistically significant increased risk of myocardial infarction
and stroke.223
4.2.3 Passive smoking
Accumulated evidence shows that passive smoking increases the
risk of CHD, with a higher relative risk than might be
expected.209,224,225 A non-smoker living with a smoking spouse
has an estimated 30% higher risk of CVD,224 and exposure in
the work place is associated with a similar risk increment.226
Owing to the high incidence of CHD and the widespread exposure
to environmental tobacco smoke, a large health benefit is expected
to result from reducing environmental tobacco smoke. Indeed, re-
cently imposed public smoking bans in different geographical loca-
tions have led to a significant decrease in the incidence of
myocardial infarction.210 Thus exposure to environmental
tobacco smoke should be minimized in both asymptomatic indivi-
duals and individuals with CHD.
4.2.4 Mechanism by which tobacco smoking increases risk
Although the exact mechanisms by which smoking increases the
risk of atherosclerotic disease are not fully understood, it is clear
that smoking enhances both the development of atherosclerosis
and the occurrence of superimposed thrombotic phenomena.
Mechanisms have been elucidated through observational cohort
studies, experimental observations, and laboratory studies in
humans and animals,225,227–229 and point towards the effect of
smoking on endothelial function,230,231 oxidative processes,232
platelet function,233 fibrinolysis, inflammation,234 –238 and modifica-
tion of lipids and vasomotor function. Reactive oxygen species—
free radicals—present in inhaled smoke cause oxidation of
plasma LDL; oxidized LDL triggers the inflammatory process in
the intimae of the arteries through stimulation of monocyte adhe-
sion to the vessel wall, resulting in increased atheroscler-
osis.232,239 – 242 In experimental studies, several of these effects
are fully or partly reversible within a very short time.243,244 A bi-
phasic response to smoking cessation of CVD risk is thus compat-
ible with the dual effects of smoking—acute and reversible effects
on haemostasis and plaque stability and a more prolonged effect
on plaque formation. Plaque formation is not thought to be fully
reversible and thus smokers would never be expected to reach
the risk level of never-smokers concerning CVD. Most current evi-
dence suggests that nicotine exposure from smoking has only
minor effects on the atherosclerotic process,227,245 and nicotine
replacement has shown no adverse effect on outcomes in patients
with cardiac disease.246,247
4.2.5 Smoking cessation
The benefits of smoking cessation have been extensively
reported.1,37,248 Some of the advantages are almost immediate;
others take more time. Studies of subjects without established
CVD find risk in former smokers to be moderate between that
of current and never-smokers.248 Stopping smoking after a myo-
cardial infarction is potentially the most effective of all preventive
measures: a systematic review and meta-analysis of 20 cohort
studies of smoking cessation after myocardial infarction showed
a mortality benefit of 0.64 [95% confidence interval (CI) 0.58–
0.71] compared with continued smokers.249 The mortality
benefit was consistent over gender, duration of follow-up, study
site, and time period. The risk is rapidly reduced after cessation,
with significant morbidity reductions reported within the first 6
months.250 Also, evidence from randomized trials supports the
beneficial effect of smoking cessation.251,252 Further evidence
points towards risk of CVD approaching the risk of never-smokers
within 10–15 years, without ever quite reaching the same level.248
Smoking reduction cannot generally be recommended as an al-
ternative to quitting smoking due to compensatory smoking to
avoid nicotine abstinence symptoms, which causes harm reduction
to be disproportionately smaller than assumed. Smoking reduction
has not been shown to increase probability of future smoking ces-
sation, but some advocate nicotine-assisted smoking reduction in
smokers unable or unwilling to quit.11,253
Quitting must be encouraged in all smokers (Table 9). There is
no age limit to the benefits of smoking cessation. Non-smokers
at high risk and patients with established CVD should be advised
about the effects of passive smoking and recommended to avoid
exposure. Public health measures such as smoking bans, tobacco
taxation, and media campaigns are efficient aids in preventing
smoking uptake and supporting smoking cessation.
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Quitting smoking is a complex and difficult process because the
habit is strongly addictive both pharmacologically and psychologic-
ally. The most important predictor of successful quitting is motiv-
ation, which can be increased by professional assistance. The
physician’s firm and explicit advice that the person should stop
smoking completely is important in starting the smoking-cessation
process and increases the odds of success (OR 1.66, 95% CI 1.42–
1.94).225,254 The momentum for smoking cessation is particularly
strong at the time of diagnosing CVD and in connection with an
invasive treatment such as CABG, percutaneous transluminal cor-
onary angioplasty, or vascular surgery. Assessing whether the
person is willing to try to quit, brief reiteration of the cardiovascu-
lar and other health hazards, and agreeing on a specific plan with a
follow-up arrangement are the decisive first steps of the brief initial
advice in clinical practice (Figure 7).
Table 9 The ‘Five As’ for a smoking cessation strategy
for routine practice
A–SK:
Systematically inquire about smoking status at 
every opportunity.
A–ADVISE: Unequivocally urge all smokers to quit.
A–ASSESS:
Determine the person’s degree of addiction and 
readiness to quit
A–ASSIST:
Agree on a smoking cessation strategy, including 
setting a quit date, behavioural counselling, and 
pharmacological support.





Advise to quit in a clear, strong and personalised manner.
"Tobacco use increases the risk of developing a heart attack and/or stroke.
Quitting tobacco use is the one most important thing you can do
to protect your heart and health, you have to quit now."
Are you willing to make a quit attempt now?
Yes No
Assist in preparing a quitting plan
  • Set quit date
  • Inform family and friends
  • Ask for their support
  • Remove cigarettes/tobacco
  • Remove objects/articles that prompt you
    to smoke
  • Arrange follow-up visita
At follow-up visit
  • Congratulate success and reinforce
  • If patient has relapsed consider more
    intensive follow-up and support from family
Provide information
on health hazards of
tobacco and give
leaflet to the patient
Reinforce message that






aIdeally second follow-up visit is recommended within the same month and every month thereafter for 4 months and evaluation after one year.
If not feasible, reinforce counselling whenever the patient is seen for blood pressure monitoring.
Taken with permission from WHO CVD risk management package.
Figure 7 Modified World Health Organization (WHO) smoking cessation algorithm.
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Smoking cessation initiated during hospital admission should
continue for a prolonged period after discharge to increase
success.255 A smoking history including daily tobacco consumption
and degree of addiction (most commonly assessed by the Fager-
stro¨m test256) should guide the degree of support and pharmaco-
logical aid. Smokers should be advised about expected weight gain
of on average 5 kg and that the health benefits of tobacco cessa-
tion far outweigh the risks from weight gain.
4.2.6 Pharmacological aids
Most quitters quit unassisted. However, pharmacological aid con-
sistently improves quit rates. Consequently, in addition to advice
and encouragement, nicotine replacement therapy (NRT) and, in
some cases, varenicline or bupropion should be offered to assist
cessation. NRT, varenicline, or bupropion should normally be
prescribed as part of an abstinent-contingent treatment, in
which the smoker makes a commitment to stop smoking on a
particular date.253 NRT in the form of chewing gum, transdermal
nicotine patches, nasal spray, inhaler, and sublingual tablets has
been widely used in helping quitters manage the difficult initial
weeks or months of smoking cessation.225 All available forms
of NRT are effective: in a systematic review, the OR for abstin-
ence with NRT vs. control was 1.58 (95% CI 1.50–1.66).213
The use of nicotine patches has been successfully tested,
without adverse effects, in patients who have CHD.257 The anti-
depressant bupropion aids long-term smoking cessation with a
similar efficacy to NRT. A meta-analysis of 36 trials comparing
long-term cessation rates using bupropion vs. control yielded a
relative success rate of 1.69 (95% CI 1.53–1.85), whereas evi-
dence of any additional effect of adding bupropion to NRT was
insufficient.258
The partial nicotine receptor agonist varenicline has been shown
to increase the chances of successful long-term smoking cessation
between two- and three-fold compared with pharmacologically
unassisted quit attempts, including in patients with CVD.259,260
Trials suggested a modest benefit of varenicline over NRT and bu-
propion.258,261 Side effects are rare, but, due to links with serious
adverse events, including depressed mood, agitation, and suicidal
thoughts, a psychiatric history and suicide risk assessment should
be taken before prescription. Current morbidity or distress may
suggest use of cessation counselling and postponement of drugs
other than NRT. A meta-analysis based on 14 RCTs including
8216 patients has indicated a small but significantly increased risk
of cardiovascular events associated with the use of varenicline.262
Following that, the European Medicines Agency has announced
that the slightly increased risk of cardiovascular events associated
with varenicline does not outweigh the benefits of the drug in
helping people to stop smoking.263 Cytisine, a low cost partial
nicotine receptor agonist available in some European countries,
also seems to increase the chances of quitting, but the evidence
at present is not conclusive.264
The antidepressant nortriptyline and the antihypertensive drug
clonidine aid smoking cessation,258,265 but, owing to side effects,
are second-line choices. All pharmacological smoking-cessation
therapies should be used short term since long-term safety and ef-
ficacy data are lacking.
4.2.7 Other smoking-cessation interventions
Both individual and group behavioural interventions are effective in
helping smokers quit.225,266–268 Support from the partner and family
is very important. Getting other family members who smoke to quit
together with the patient is of great help. Physicians and caregivers
must set an example by not smoking. There is no consistent evi-
dence that acupuncture, acupressure, laser therapy, hypnotherapy,
or electrostimulation are effective for smoking cessation.269
Most important new information
† New evidence on the health effects of passive smoking strength-
ens the recommendation on passive smoking.
Remaining gaps in the evidence
† More efficient, safe, and cost-effective smoking cessation aids.
4.3 Nutrition
Key messages
† A healthy diet has the following characteristics:
† Energy intake should be limited to the amount of energy needed
to maintain (or obtain) a healthy weight, i.e. a BMI ,25 kg/m2.
† In general, when following the rules for a healthy diet, no dietary
supplements are needed.
• Saturated fatty acids to account for <10% of total energy intake, 
 through replacement by polyunsaturated fatty acids.
• Trans-unsaturated fatty acids: as little as possible, preferably no intake 
 from processed food, and <1% of total energy intake from natural 
 origin.
• <5 g of salt per day.
• 30–45 g of fibre per day, from wholegrain products, fruits, 
 and vegetables.
• 200 g of fruit per day (2–3 servings).
• 200 g of vegetables per day (2–3 servings).
• Fish at least twice a week, one of which to be oily fish.
• Consumption of alcoholic beverages should be limited to two glasses 
 per day (20 g/day of alcohol) for men and one glass per day
 (10 g/day of alcohol) for women.
Recommendation regarding nutrition
Recommendations Classa Levelb GRADE Ref C
A healthy diet is 
recommended as being 


















Dietary habits are known to influence cardiovascular risk, either
through an effect on risk factors such as serum cholesterol, BP,
body weight, and diabetes, or through an effect independent of
these risk factors. A healthy diet also reduces the risk of other
chronic diseases such as cancer. Most evidence on the relation-
ship between nutrition and cardiovascular diseases is based on
observational studies. The impact of diet can be studied on differ-
ent levels. The most detailed way is looking at specific nutrients.
Looking at foods or food groups is another way of evaluating
diet, which is more easily translated into dietary recommenda-
tions. Finally, there is growing interest in dietary patterns, of
which the Mediterranean diet is the most studied. The dietary
pattern approach can be seen as the equivalent of the shift
from evaluating single risk factors to evaluating total risk profiles.
A recent publication of the EHN provides an extensive overview
of diet and CVDs.277
4.3.2 Nutrients
The nutrients of interest with respect to CVD are fatty acids
(which mainly affect lipoprotein levels), minerals (which mainly
affect BP), vitamins, and fibre.
4.3.2.1 Fatty acids
In the prevention of CVD through dietary changes, the fat
content and fatty acid composition of the diet have been the
focus of attention since the 1950s. In prevention, the fatty acid
composition of the diet is more important than the total fat
content. Our knowledge on the effects of subclasses of fatty
acids (saturated, monounsaturated, and polyunsaturated) as well
as on specific fatty acids within these subclasses (e.g. n-3 and
trans fatty acids) on different lipoprotein fractions in the blood
has improved considerably.
Saturated fatty acids
In 1965, Keys et al.278 described how replacing saturated fat in
the diet by unsaturated fatty acids lowered serum total choles-
terol levels. Given the effect on serum cholesterol levels, an
impact on CVD occurrence is plausible. However, after .40
years of research, the impact of saturated fatty acid intake on
the occurrence of CVD is still debated. Recently, a
meta-analysis of cohort studies did not show an increase in
the relative risk for CHD or CVD with higher intake of satu-
rated fat,279 although there may be several methodological
issues explaining this null finding.280 A number of studies
adjusted the effect of saturated fatty acids on CVD for serum
cholesterol levels—an example of overadjustment. Another im-
portant aspect is by which nutrient saturated fatty acids are
replaced. The evidence from epidemiological, clinical, and mech-
anistic studies is consistent in finding that the risk of CHD is
reduced by 2–3% when 1% of energy intake from saturated
fatty acids is replaced with polyunsaturated fatty acids.270 The
same has not been clearly shown for the replacement with car-
bohydrates and monounsaturated fatty acids. Therefore, lower-
ing saturated fatty acid intake to a maximum of 10% of energy
by replacing it with polyunsaturated fatty acids remains import-
ant in dietary prevention of CVD.
Unsaturated fatty acids
Monounsaturated fatty acids have a favourable effect on HDL chol-
esterol levels when they replace saturated fatty acids or carbohy-
drates in the diet.281 Polyunsaturated fatty acids lower LDL
cholesterol levels, and to a lesser extent HDL cholesterol levels,
when they replace saturated fatty acids. The polyunsaturated fatty
acids can be largely divided into two subgroups: n-6 fatty acids,
mainly from plant foods, and n-3 fatty acids, mainly from fish oils
and fats. The fatty acids eicosapentaenoic acid and docosahexaenoic
acid, representatives of the n-3 group, are important. They do not
have an impact on serum cholesterol levels, but have been shown
to reduce CHD mortality and to a lesser extent stroke mortal-
ity.271,282 In various studies, low doses of eicosapentaenoic acid
and docosahexaenoic acid are associated with a lower risk of fatal
CHD but not of non-fatal CHD. A hypothesis for this differential
effect is that they could prevent fatal cardiac arrhythmia.271
The subclass of unsaturated fatty acids with a so-called ‘trans
configuration’, the trans fatty acids, have been shown to increase
total cholesterol and decrease HDL cholesterol levels. These
fatty acids are found in margarine and bakery products. The food
industry has eliminated part of the trans fatty acids from their pro-
ducts, but there is still more to be gained from further elimination.
A small amount of trans fat in the diet will remain, coming from
ruminant fat in dairy and meat products. Replacing 1% energy of
trans fatty acids with saturated, monounsaturated, or polyunsatur-
ated fatty acids decreases the total cholesterol/HDL cholesterol
ratio by 0.31, 0.54, and 0.67, respectively.283 A meta-analysis of
prospective cohort studies has shown that, on average, a higher
trans fatty acid intake of 2% of energy increases the risk of CHD
by 23%.272 It is recommended to derive ,1% of total energy
intake from trans fatty acids, the less the better.
Dietary cholesterol
The impact of dietary cholesterol on serum cholesterol levels is
weak compared with that of the fatty acid composition of the
diet. When guidelines are followed to lower saturated fat intake,
this usually also leads to a reduction in dietary cholesterol
intake. Some guidelines (including this) on a healthy diet do not
therefore give specific guidance on intake of dietary cholesterol;
others recommend a limited intake of ,300 mg/day.
4.3.2.2 Minerals
Sodium
The effect of sodium intake on BP is well established. A
meta-analysis estimated that even a modest reduction in sodium
intake of 1 g/day reduces SBP by 3.1 mmHg in hypertensive
patients and 1.6 mmHg in normotensive patients.284 The DASH
trial showed a dose–response relationship between sodium reduc-
tion and BP reduction.285 In most western countries salt intake is
high (9–10 g/day), whereas the recommended maximum
intake is 5 g/day.1 Optimal intake levels might be as low as 3 g/
day. Processed foods are an important source of sodium intake.
A recent simulation study estimated that for the USA, a reduction
in salt intake of 3 g/day would result in a reduction of 5.9–9.6% in
the incidence of CHD (low and high estimate based on different
assumptions), a reduction of 5.0–7.8% in the incidence of stroke,
and a reduction of 2.6–4.1% in death from any cause.286
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Potassium is another mineral that affects BP. The main sources of po-
tassium are fruits and vegetables. A higher potassium intake has been
shown to reduce BP. Risk of stroke varies greatly with potassium
intake: the relative risk of stroke in the highest quintile of potassium
intake (average of 110 mmol/day) is almost 40% lower than that in
the lowest quintile of intake (average intake of 61 mmol/day).287
4.3.2.3 Vitamins
Vitamins A and E
Many case–control and prospective observational studies have
observed inverse associations between levels of vitamin A and E
and risk of CVDs. This protective effect was attributed to their
antioxidant properties. However, intervention trials designed to
confirm the causality of these relationships have failed to
confirm the results from observational studies.288
B-vitamins (B6, folic acid, and B12) and homocysteine
The B-vitamins B6, B12, and folic acid have been studied for their
potential to lower homocysteine levels, which has been postulated
as a risk factor for CVDs.289 However, the question remained
whether homocysteine was merely a marker of risk or a causally
related factor. The Cochrane Collaboration concluded in a
recent meta-analysis of eight RCTs that homocysteine-lowering
interventions did not reduce the risk of fatal/non-fatal myocardial
infarction (RR 1.03, 95% CI 0.94–1.13), stroke (RR 0.89, 95% CI
0.73–1.08), or death by any cause (RR 1.00, 95% CI 0.92–
1.09).290 Thereafter three large secondary prevention trials have
been completed and published.291 – 293 All trials [Study of the Ef-
fectiveness of Additional Reductions in Cholesterol and Homo-
cysteine (SEARCH), VITAmins TO Prevent Stroke (VITATOPS),
and Supplementation with Folate, vitamin B6 and B12 and/or
OMega-3 fatty acids (SU.FOL.OM3)] concluded that supplementa-
tion with folic acid and vitamin B6 and/or B12 offers no protection
against the development of CVD. Thus, B-vitamin supplementation
to lower homocysteine levels does not lower risk.
Vitamin D
Some epidemiological studies have shown associations between
vitamin D deficiency and cardiovascular disease. Conclusive evi-
dence showing that vitamin D supplementation improves cardio-
vascular prognosis is however lacking, but trials are underway.294
4.3.2.4 Fibre
Consumption of dietary fibre reduces the risk of CVD. Although
the mechanism is not elucidated completely, it is known that a
high fibre intake reduces post-prandial glucose responses after
carbohydrate-rich meals, and lowers total and LDL cholesterol
levels.295 Important sources of fibre are wholegrain products,
legumes, fruits, and vegetables. The American Institute of Medicine
recommends an intake of 3.4 g/MJ, equivalent to an intake of
30–45 g/day for adults.296 This intake is assumed to be the
optimal preventive level.
4.3.3 Foods and food groups
Fruits and vegetables
Observational studies have shown a protective effect of consump-
tion of fruits and vegetables on CVD prevention. Most of the
evidence comes from prospective cohort studies, while RCTs
are scarce. Individual studies have shown weak or non-significant
effects of fruit and vegetable intake on CVD risk. Because measure-
ment of diet is complex, measurement error is likely to attenuate
the observed relationships. Furthermore, since it is known that
individuals who consume a lot of fruits and vegetables differ in
many respects from those who eat few fruits and vegetables (e.g.
with respect to other dietary habits, smoking status, levels of phys-
ical activity), residual confounding, also after adjustment, may
remain. Nevertheless, results in different cohort studies have
been quite homogeneous, and several meta-analyses have reported
statistically significant effect estimates. Dauchet et al. reported a
decrease in CHD risk of 4% (RR 0.96, 95% CI 0.93–0.99) for
each additional serving of fruits and vegetables per day.273 In a
meta-analysis of seven large prospective cohort studies, a 5% re-
duction in risk of stroke for each additional serving of fruits and
vegetables was reported.273 He et al. updated this estimate by
adding two additional cohorts, and reported a pooled RR of
stroke of 0.89 (95% CI 0.83–0.97) for those eating 3–5 servings
of fruits and vegetables daily compared with those eating ,3 ser-
vings, and a pooled RR of 0.74 (95% CI 0.69–0.79) for those eating
.5 servings.274 One serving is equivalent to 80 g.
The protective effect of fruits and vegetables seems to be slightly
stronger for the prevention of stroke compared with the prevention
of CHD. One of the reasons for this can be the effect of fruits and
vegetables on BP, based on the fact that they are a major source of
potassium. The DASH trial has shown that increasing fruit and vege-
table intake contributed to the observed decrease in BP in the inter-
vention arm.297 Other constituents of fruits and vegetables that can
contribute to the effect are fibre and antioxidants.
The recommendation is to eat at least 200 g of fruit (2–3 ser-
vings) and 200 g of vegetables (2–3 servings) per day.
Fish
The protective effect of fish on CVD is attributed to the n-3 fatty
acid content. Pooled risk estimates show that eating fish at least
once a week results in a 15% reduction in risk of CHD (RR
0.85, 95% CI 0.76–0.96).271 Another meta-analysis showed that
eating fish 2–4 times a week reduced the risk of stroke by 18%
(RR 0.82, 95% CI 0.72–0.94) compared with eating fish less than
once a month.282 The relationship between fish intake and cardio-
vascular risk is not linear. In particular, in the range of no or very
low intake to moderate intake there is a strong increase in cardio-
vascular risk. The public health impact of a small increase in fish
consumption in the general population is therefore potentially
large. A modest increase in fish consumption of 1–2 servings a
week would reduce CHD mortality by 36% and all-cause mortality
by 17%.298 The recommendation, therefore, is to eat fish at least
twice a week, of which once oily fish.
Alcoholic beverages
Results from epidemiological studies show a protective effect of
moderate alcohol consumption on the occurrence of CVD. The
relationship is J-shaped, which is not explained by special charac-
teristics of abstainers. There seems to be a favourable effect of
red wine in particular, which may be due to the effect of polyphe-
nols (especially resveratrol).299 Based on a meta-analysis,275 the
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optimal level of intake with respect to all-cause mortality is 20 g/
day for men and 10 g/day (equivalent to approximately one drink)
for women. With respect to the prevention of CVDs, the optimal
level of intake is somewhat higher. The recommendation is that
drinkers should limit their alcohol intake to a maximum of one
glass/day for women (10 g of alcohol) or two glasses/day for
men (20 g of alcohol) to obtain the lowest level of chronic
disease risk.
Soft drinks
Sugar-sweetened soft drinks are the largest single food source of
calories in the US diet and are also important in Europe. In children
and adolescents, beverages may now even account for 10–15% of
the calories consumed. A meta-analysis has suggested that for
energy consumed in the form of a liquid, compensation of
caloric intake at subsequent meals could be less complete than
for energy from solid food.1 The regular consumption of soft
drinks has been associated with overweight and type 2 diabetes.300
Similarly, regular consumption of sugar-sweetened beverages (i.e.
two servings per day compared with one serving per month)
was associated with a 35% higher risk of CHD in women, even
after other unhealthy lifestyle and dietary factors were accounted
for, whereas artificially sweetened beverages were not associated
with CHD.301
4.3.4 Functional foods
Functional foods containing phytosterols (plant sterols and stanols)
are effective in lowering LDL cholesterol levels by on average 10%,
when consumed in amounts of 2 g/day. The cholesterol-lowering
effect is additional to that obtained with a low-fat diet or use of
statins.302 Some recent research indicates that, especially for
stanols, further cholesterol reduction can be obtained with
higher doses.303 No studies with clinical endpoints have been per-
formed as yet.
4.3.5 Dietary patterns
In accordance with the shift from evaluating and treating single risk
factors to evaluating a person’s total risk profile, more research is
focusing on dietary patterns instead of on single nutrients. Studying
the impact of a total dietary pattern theoretically shows the full
preventive potential of diet, because it yields a combined estimate
of the impact of several favourable dietary habits. The Seven Coun-
tries Study showed a large difference in cardiovascular mortality
rates between northern and southern Europe. Even at similar chol-
esterol levels, and after adjusting for BP and smoking, the difference
in cardiovascular risk remained (Figure 8).304 The diet consumed in
the Mediterranean cohorts of the Seven Countries Study is prob-
ably an important factor underlying the large difference in CVD
rates between southern and northern Europe.
The concept of the Mediterranean diet comprises many of the
nutrients and foods that have been discussed previously: a high
intake of fruits, vegetables, legumes, wholegrain products, fish,
and unsaturated fatty acids (especially olive oil), a moderate con-
sumption of alcohol (mostly wine, preferably consumed with
meals), and a low consumption of (red) meat, dairy products,
and saturated fatty acids.
A number of studies have demonstrated the protective effect of
this diet, and recently a meta-analysis has been performed.276 Ad-
herence to the Mediterranean diet was operationalized by a
scoring system (Mediterranean diet score), in which one point is
obtained for each component of the diet, where the intake is
above the median intake level for the study population (fruits,
vegetables, legumes, cereals, fish, moderate consumption of red
wine) or below the median (red and processed meats, dairy pro-
ducts). Depending on the number of food items for which informa-
tion was obtained, the score could range from 0 to 7–9. The
meta-analysis showed that greater adherence to the Mediterranean
diet, by a 2-point higher score, was associated with a 10% reduc-
tion in cardiovascular incidence or mortality (pooled RR 0.90,
95% CI 0.87–0.93) and also with an 8% reduction in all-cause mor-





























Figure 8 Cumulative 25-year coronary heart disease (CHD) mortality rates in different cohorts of the Seven Countries Study, according to
baseline quartiles of total cholesterol level, adjusted for age, smoking, and blood pressure.304
Joint ESC Guidelines 1667








It is clear that dietary modifications should form the basis for CVD
prevention. Some changes in the diet will be reflected in favourable
changes in measurable risk factors, such as BP and cholesterol
levels. However, it should be kept in mind that dietary habits
that do not show their effect on levels of BP or blood lipids can
also make an important contribution to the prevention of CVD.
The requirements for a healthy diet are summarized in the key
messages at the beginning of this section.
The challenge for coming years is to translate nutritional guide-
lines into diets that are attractive to people and to find ways in
which to make people change their (long-standing) dietary habits.
Since it is not yet clear which specific substances cause the pro-
tective effect, it is recommended to eat a varied diet, based on
the above-mentioned principles. In general, when eating a
healthy diet, no supplements are needed, but when they are
used they should not replace the consumption of ‘real foods’.
For some aspects of diet, legislation can help to change product
formulation by the industry (trans fatty acids and salt reduction).
The industry can make an important contribution in reducing the
salt content of processed foods.
Most important new information
† Accumulated new evidence supports the view that homocyst-
eine is not a causal risk factor for CVD.
† More evidence on the impact of total diet/dietary patterns has
become available; the Mediterranean type of diet in particular
has gained interest in recent years.
Remaining gaps in the evidence
† The biggest challenge in dietary prevention of CVDs is to
develop more effective strategies to make people change their
diet (both quantitatively and qualitatively) and to maintain that
healthy diet and a normal weight.
† Research into the substances in foods that underlie the protect-
ive effects is ongoing.
4.4 Physical activity
Key message
† Participation in regular physical activity and/or aerobic exercise
training is associated with a decrease in cardiovascular mortality.
4.4.1 Introduction
Regular physical activity and aerobic exercise training are related to
a reduced risk of fatal and non-fatal coronary events in healthy indi-
viduals,305 – 307,311 subjects with coronary risk factors,312 and
cardiac patients309 310 over a wide age range. A sedentary lifestyle
is one of the major risk factors for CVD.313 Physical activity and
aerobic exercise training are therefore suggested by guidelines as
a very important non-pharmacological tool for primary and sec-
ondary cardiovascular prevention.37,204,314 In the EU, ,50% of
the citizens are involved in regular aerobic leisure-time, and/or oc-
cupational physical activity,315,316 and the observed increasing
prevalence of obesity is associated with a sedentary lifestyle;317,318
moreover, probably fewer than one-third of patients eligible for
cardiac rehabilitation are offered this service.33 Thus a large gap
exists in Europe between required and actual primary and second-
ary cardiovascular prevention exercise-based interventions,319 es-
pecially when considering that some of the Eastern European
countries that recently joined the EU show age-related mortality
rates for CVD among the highest in the world.320
4.4.2 Biological rationale
Regular aerobic physical activity results in improved exercise per-
formance, which depends on an increased ability to use oxygen to
derive energy for work. These effects are attained for regular
aerobic physical activity intensities ranging between 40% and 85%
of VO2 [maximum volume (V) of oxygen (O2) in mL] or heart
rate reserve, with higher intensity levels being necessary the
higher the initial level of fitness, and vice versa.321 Aerobic exercise
also results in decreased myocardial oxygen demands for the same
level of external work performed, as demonstrated by a decrease
Recommendations regarding physical activity
Recommendations Classa Levelb GRADE Ref C
Healthy adults of all ages 
should spend 2.5–5 h a 
week on physical activity or 
aerobic exercise training of 
at least moderate intensity, 
or 1–2.5 h a week on 
vigorous intense exercise. 
Sedentary subjects should 
be strongly encouraged to 






exercise training should be 
performed in multiple bouts 
each lasting ≥10 min and 
evenly spread throughout the 




Patients with previous acute 
myocardial infarction, CABG, 
PCI, stable angina pectoris, or 
stable chronic heart failure 
should undergo moderate-
to-vigorous intensity aerobic 
exercise training ≥3 times a 
week and 30 min per session. 
Sedentary patients should 
be strongly encouraged to 
start light-intensity exercise 



















in the product of heart rate × SBP, so reducing the likelihood of
myocardial ischaemia.322
Moreover, myocardial perfusion can be improved by aerobic ex-
ercise, with an increase in the interior diameter of major coronary
arteries, an augmentation of microcirculation, and an improvement
of endothelial function.323,324 Additional reported effects of
aerobic exercise are antithrombotic effects that can reduce the
risk of coronary occlusion after disruption of a vulnerable
plaque, such as increased plasma volume, reduced blood viscosity,
decreased platelet aggregation, and enhanced thrombolytic
ability,325 and a reduction of arrhythmic risk by a favourable modu-
lation of autonomic balance.326
Physical activity also has a positive effect on many of the estab-
lished risk factors for CVDs, preventing or delaying the develop-
ment of hypertension in normotensive subjects and reducing BP
in hypertensive patients, increasing HDL cholesterol levels,
helping to control body weight, and lowering the risk of developing
non-insulin-dependent diabetes mellitus.37,311 Moreover, exercise
training has been shown to induce ischaemic pre-conditioning of
the myocardium, a process by which transient myocardial ischae-
mia during exercise enhances tolerance of the myocardium to sub-
sequent more prolonged ischaemic stress, thereby reducing
myocardial damage and the risk of potentially lethal ventricular
tachyarrhythmias. Such cardioprotective mechanisms include ana-
tomical alterations in the coronary arteries, induction of myocar-
dial heat shock proteins, increase of myocardial
cyclooxygenase-2 activity, elevation of endoplasmic reticulum
stress proteins and nitric oxide production, improved function of
sarcolemmal and/or mitochondrial adenosine triphosphate (ATP)-
sensitive potassium channels and myocardial antioxidant capacity,
up-regulation of key antioxidant enzymes, and induction of
changes in mitochondrial phenotype that are protective against
apoptotic stimuli.327
4.4.3 Healthy subjects
In healthy subjects, growing levels of both physical activity and car-
diorespiratory fitness are associated with a significant reduction
(20–30%) in risk of all-cause and cardiovascular mortality, in a
dose–response fashion.305 – 308,311,328,329 The evidence suggests
that the risk of dying during a given period continues to decline
with increasing levels of physical activity and cardiorespiratory
fitness; this seems to be true for both men and women and
across a broad range of ages from childhood to the very elderly.
As these conclusions are based on the results of observational
studies, selection bias may be linked on the one hand to the exist-
ence of subclinical, undiagnosed diseases that may have made some
individuals decrease their physical activity level before the start of
the study, and on the other hand to the tendency to associate
healthier habits (e.g. avoiding smoking and eating a healthier diet)
with physically active individuals. However, studies controlling for
these potential confounders still observed an inverse association
between physical activity or cardiorespiratory fitness and all-cause
and cardiovascular mortality.
Most of such a mortality-reduction effect seems to rely on a de-
crease in cardiovascular and CHD mortality, and the level of
decreased coronary risk attributable to regular aerobic physical ac-
tivity is similar to that of other lifestyle factors such as avoiding
cigarette smoking. The risk of CVD (including CHD and stroke)
or CHD alone is significantly reduced in more physically active
or fit persons, with a relative risk reduction nearly twice as great
for cardiorespiratory fitness than for physical activity increase at
all percentiles .25th.308,328,329 A possible explanation for the
stronger dose–response gradient for fitness than for physical activ-
ity is that fitness is measured objectively, whereas physical activity
is assessed by self-reports that may lead to misclassification and
bias towards finding weaker physical activity or health benefit
associations.
Physical activity intensity and volume
The volume of moderate-intensity physical activity or aerobic ex-
ercise training able to provide a reduction in all-cause and cardio-
vascular mortality ranges from 2.5 to 5 h/week;306– 308,311,312 the
longer the total duration of physical activity/aerobic exercise train-
ing performed over the week the greater the observed benefits. Of
note, similar results are obtainable by performing 1–1.5 h/week of
vigorous-intensity physical activity/aerobic exercise training or an
equivalent combination of moderate-intensity and
vigorous-intensity physical activity/aerobic exercise training. More-
over, the available evidence suggests that the total weekly volume
of physical activity/aerobic exercise training can be obtained by
summing multiple daily bouts of exercise, each lasting ≥10 min,
and that physical activity/aerobic exercise training should be dis-
tributed over most days of the week.
Examples of physical activity/aerobic exercise training involve
not only sport-related activities such as hiking, running or
jogging, skating, cycling, rowing, swimming, cross-country skiing,
and performing aerobic classes, but also lifestyle-common activities
such as walking briskly, climbing stairs, doing more housework and
gardening work, and engaging in active recreational pursuits. A
moderate-intensity physical activity should be defined in relative
terms as an activity performed at 40–59% of VO2 or heart rate
reserve, or at a rate of perceived exertion of 5–6 in the CR10
Borg scale, which would correspond to an absolute energy
expenditure of 4.8–7.1 metabolic equivalents (METs) in the
young, 4.0–5.9 METs in the middle-aged, 3.2–4.7 METs in the
old, and 2.0–2.9 METs in the very old.140 Analogously,
vigorous-intensity physical activity is performed at 60–85% of
VO2 or heart rate reserve, or at a rate of perceived exertion of
7–8 in the CR10 Borg scale, corresponding to an absolute
energy expenditure of 7.2–10.1 METs in the young, 6.0–8.4
METs in the middle-aged, 4.8–6.7 METs in the old, and 3.0–4.2
METs in the very old.140
Risk assessment
The methodology according to which healthy subjects should be
evaluated prior to engaging in regular physical activity/aerobic ex-
ercise training is controversial. Generally speaking, the
exercise-related risk of major cardiovascular events in ostensibly
healthy people is exceedingly low, ranging from 1 in 500 000 to
1 in 2 600 000 patient-hours of exercise.330,331 As recently pro-
posed for leisure-time sport activities in middle-aged/senior sub-
jects,332 the risk assessment accuracy should be tailored to the
individual’s cardiac risk profile, the current level of habitual physical
activity, and the intended level of physical activity/aerobic exercise
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training, with a more aggressive screening (i.e. exercise testing)
possibly reserved for people who are sedentary and/or with car-
diovascular risk factors and/or willing to engage in
vigorous-intensity activities. Individuals who exercise only occa-
sionally seem to have an increased risk of acute coronary events
and sudden cardiac death during or after exercise.330,331 Generally
speaking, starting with a low-intensity activity is recommended in
sedentary subjects and in those with cardiovascular risk factors.
4.4.4 Patients with known cardiovascular disease
Aerobic physical activity in patients with known CVD is usually
considered as an aerobic exercise training intervention included
in a cardiac rehabilitation programme. Hence available data deal
almost exclusively with cardiovascular fitness measurements and
not with evaluation of habitual physical activity level. This is due
to the need for a formal evaluation of both exercise capacity and
exercise-associated risk in patients with established cardiac
disease. In this context, the effects of physical activity alone on car-
diovascular risk may not be easily discernible. However, a
meta-analysis including mainly middle-aged men, most of whom
had a previous acute myocardial infarction and the rest with a pre-
vious CABG or percutaneous transluminal coronary angioplasty or
affected by stable angina pectoris, showed a 30% reduction in
total cardiovascular mortality for aerobic exercise training pro-
grammes of at least 3-months’ duration; this percentage rose to
35% when only deaths from CHD were considered.333 Insuffi-
cient data were available as to the effects of aerobic exercise train-
ing on revascularization rates; moreover, aerobic exercise training
did not show any effect on the occurrence of non-fatal myocardial
infarction. More extensive use of revascularization techniques and
drug treatments during recent years has progressively resulted in a
relatively low-risk general population of cardiac patients, in whom
significant survival improvements are less likely to occur as a result
of any added intervention. In any case, recent data confirm the exist-
ence of an inverse dose–response relationship between cardiovascu-
lar fitness (evaluated by treadmill stress testing and expressed in
METs) and all-cause mortality in large populations of both male
and female cardiovascular patients [a history of angiographically docu-
mented CHD, myocardial infarction, CABG, coronary angioplasty
(PCI), chronic heart failure, peripheral vascular disease, or signs or
symptoms suggestive of CHD during an exercise testing]. The
results were the same irrespective of use of beta-blocking
agents.334,335 Finally, aerobic exercise training in low-risk patients
has been shown to be at least as effective in improving clinical
status and myocardial perfusion, and associated with fewer cardiovas-
cular events as compared with an invasive strategy such as a PCI.336
The effects of aerobic exercise training on the cardiac mortality
rate in patients with chronic heart failure have been evaluated in a
meta-analysis.310 Overall, moderate to vigorous intensity aerobic
exercise training resulted in improved survival in patients with
chronic heart failure due to left ventricular systolic dysfunction,
and time to readmission to hospital was also significantly extended.
Prognosis improvement was higher in patients with ischaemic aeti-
ology, lower left ventricular ejection fraction and peak VO2, and
higher New York Heart Association class. Adherence to pre-
scribed aerobic exercise training intensity emerged as a crucial
issue in determining such prognostic gains, as demonstrated by
the results of the recent Heart Failure and A Controlled Trial In-
vestigating Outcomes of Exercise TraiNing (HF-ACTION) trial.337
Physical activity intensity and volume
In patients with CVD, available data do not allow definition of an
aerobic exercise training weekly volume as precise as that indicated
for healthy subjects,309,310 and exercise prescription must be tai-
lored to the clinical profile of the individual. Patients at low clinical
risk with a previous acute myocardial infarction, CABG, PCI, or
affected by stable angina pectoris or chronic heart failure can be
assigned an aerobic exercise training of moderate to vigorous in-
tensity of 3–5 sessions per week, 30 min per session, with fre-
quency, duration, and supervision of aerobic exercise training
sessions to be in any case adapted to their clinical characteristics.
Patients at moderate to high clinical risk should follow an even
more strictly individualized exercise prescription, depending on
the metabolic load known to evoke abnormal signs or symptoms.
However, even in the more limited patients, small amounts of
properly supervised physical activity are beneficial in order to
enable maintenance of independent living and counteract
disease-related depression. Information is available for evidence-
based aerobic exercise training prescription in specific subpopula-
tions of cardiac patients.205
Clinical risk assessment
In patients with CVD, exercise prescription is strongly determined
by exercise-related risk. Available risk stratification algorithms help
to identify patients who are at increased risk for exercise-related
cardiovascular events and who may require more intensive
cardiac monitoring,338,339 and the safety of medically supervised
exercise programmes that follow such indications for
exercise-related risk stratification is well established. The occur-
rence of major cardiovascular events during supervised aerobic ex-
ercise training in cardiac rehabilitation programmes is rare: from 1
in 50 000 to 1 in 120 000 patient-hours of exercise, with fatality
incidence ranging between 1 in 340 000 and 1 in 750 000 patient-
hours of exercise.340,341 The same is also true for patients with
chronic heart failure and reduced left ventricular function,
New York Heart Association class II– IV symptoms, and treated
with optimal, guideline-based background heart failure therapy.342
Most important new information
† No major pieces of new information have emerged in this field
in recent years.
Remaining gaps in the evidence
It remains to be established whether:
† Prognostic gains can be achieved with less (duration/intensity)
physical activity, in groups that are not able to meet the recom-
mendations (elderly, deconditioned, patients with advanced
chronic heart failure).
† The dose–response relationship between cardiorespiratory
fitness and reduction in cardiovascular risk observed in
primary prevention also holds in the secondary prevention
setting.
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† Regular physical activity yields a long-term prognostic gain in
patients with chronic heart failure.
† High-intensity interval training is superior to moderate-intensity
continuous training in improving functional capacity and inducing
favourable left ventricular remodelling in chronic heart failure
patients
4.5 Management of psychosocial factors
Key message
† Psychological interventions can counteract psychosocial stress
and promote healthy behaviours and lifestyle.
4.5.1 Introduction
Psychological interventions aim to counteract psychosocial stress
and promote health behaviours and lifestyle. The interventions
include individual or group counselling on psychosocial risk
factors and coping with illness, cognitive-behavioural therapy,
stress management programmes, meditation, autogenic training,
biofeedback, breathing, yoga, and/or muscular relaxation.199,200
Psychological interventions are likely to have additional beneficial
effects on physiological risk factors and distress, even when
added to standard rehabilitation.199 Two recent meta-analyses
and two recent RCTs86,199,343,348 have also shown their additional
impact on the prevention of clinical CHD, especially in patients
who achieved their behavioural goals.349 There is evidence that
intervention programmes should be individualized based on indi-
vidual risk constellations and include gender-specific aspects.199,350
4.5.2 Specific interventions to reduce depression,
anxiety, and distress
Several RCTs and one meta-analysis have specifically targeted
depression in CVD patients. Coronary patients with clinically
significant depression can be safely and effectively treated with psy-
chotherapy84,85,351–353 or selective serotonin re-uptake inhibi-
tors,354 – 356 although evidence for a beneficial effect on cardiac
endpoints is inconclusive. Whereas most studies could show no
significant beneficial effect,84,351 –356 a recent RCT revealed
fewer depressive symptoms as well as fewer major adverse
cardiac events.85 A secondary analysis of another RCT found bene-
ficial cardiovascular effects in white men only,344 and in patients
who responded to antidepressant treatment.346 Results from non-
randomized studies indicate that selective serotonin re-uptake inhi-
bitors may also have the potential to improve CVD prognosis in
depressed patients with345 and without347 previously documented
CVD.
In contrast to depression, until now very few studies specifically
targeted anxiety in CVD patients. One RCT involving a nurse-led,
home-based intervention in post-CABG patients revealed benefi-
cial effects on anxiety, but the sample was too small and the
follow-up period too short to demonstrate an impact on cardiac
events.357
While waiting for conclusive results to show that treating de-
pression or anxiety will alter CVD prognosis, a prudent approach
at present is to offer patients with clinically significant depression
or anxiety treatment with psychotherapy and antidepressant/
anxiolytic medication. Those not accepting treatment should be
followed closely, and treatment offered again if symptoms persist
for .4–6 weeks.
In addition to the treatment of mood symptoms, there are
several other approaches to psychosocial intervention that have
proved useful. Stress-management programmes have repeatedly
been shown to improve not only subjective well-being but also
risk factor levels and CVD outcomes.199,200,358 In hostile CHD
patients, a group-based hostility-control intervention may lead
not only to decreases in behaviourally assessed hostility levels,
but also to decreased levels of depression, resting heart rate,
and cardiovascular reactivity to mental stress, as well as to
increased social support and satisfaction with life.359,360 For
women, specific behavioural group treatments may be useful for
reducing distress.348,350,361 Recently, a group-based stress-
reduction programme for women was shown to prolong lives in-
dependent of other prognostic factors.348,358
Work reorganizations aimed at improving autonomy and in-
creasing control at work may result in improved social
support and reduction in physiological stress responses.
Hence, reduction of work stress in managers and supervisors
may have beneficial health effects on the target individuals and
may also improve perceived social support in their
subordinates.362
Most important new information
† Evidence is accumulating to suggest that psychological interven-
tions counteract psychosocial stress, promote healthy beha-
viours, and contribute to the prevention of CVD.
Recommendations on the management of psychosocial
factors
Recommendations Classa Levelb GRADE RefC
Multimodal behavioural 
interventions, integrating 
health education, physical 
exercise, and psychological 
therapy for psychosocial 
risk factors and coping with 





In the case of clinically 
significant symptoms of 
depression, anxiety, and 
hostility, psychotherapy, 
medication, or collaborative 
care should be considered. 
This approach can reduce 
mood symptoms and enhance 
health-related quality of 
life, although evidence for 
a definite beneficial effect 
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Remaining gaps in the evidence
† Evidence that treatment of clinically significant depression and
anxiety will improve cardiac endpoints is inconclusive.
4.6 Body weight
Key messages
† Both overweight and obesity are associated with a risk of death
in CVD.363 –365
† There is a positive linear association of BMI with all-cause
mortality.363
† All-cause mortality is lowest with a BMI of 20–25 kg/m2.363 – 365
† Further weight reduction cannot be considered protective
against CVD.366 –369
4.6.1 Introduction
In many countries, a reduction in major risk factors such as high
blood cholesterol and BP and more recently smoking habit has
translated into reduced cardiovascular mortality. The exceptions
to these trends are body weight and diabetes, which have tended
to increase as other risk factors have declined. Obesity is becoming
a worldwide epidemic in both children and adults.370 The scenario
has changed to such a degree that in the USA, if obesity trends
from 2005 to 2020 continue unchecked, obesity will increasingly
offset the positive effects of declining smoking rates.371 In Europe,
a recent study of nearly 360 000 participants from nine European
countries showed that general obesity and abdominal adiposity
are both associated with increased risk of death.372
4.6.2 Body weight and risk
It is now clear that one of the components of abdominal fat, visceral
adipose tissue, is a metabolically active endocrine organ capable of
synthesizing and releasing into the bloodstream an important
variety of peptides and non-peptide compounds that may play a
role in cardiovascular homeostasis.373 This process impacts on
CVD risk factors and hence on risk, and the mechanical effects of
overweight impact on non-cardiovascular causes of morbidity and
mortality. The health effects of increasing body weight are summar-
ized in Table 10. Interestingly, the effects of multivariable adjustment
on the association between lipid levels and risk and between body
weight and risk are different. Raised blood cholesterol and reduced
HDL cholesterol levels remain independently associated with risk
after adjustment for other major risk factors, whereas the associ-
ation between weight and risk tends to lose significance. This
should not be interpreted as indicating that body weight is not im-
portant; rather, it may be critically important because it exerts its
effect on risk by its adverse effects on many risk factors.
4.6.3 Which index of obesity is the best predictor of
cardiovascular risk?
Body mass index [weight (kg)/length (m)2] has been used exten-
sively to define categories of body weight. In adults, overweight
is defined by a BMI ranging from 25 to 29.9 kg/m2, and obesity
by a BMI ≥30 kg/m2. Increasing BMI is highly associated with risk
of CVD. However, regional distribution of adipose tissue was
hypothesized to be more important in determining cardiovascular
risk than total body weight. This has led to increased interest in an-
thropometric measures of risk and in a more precise distribution
between fat and lean mass (Table 11). Most data are available for
BMI, waist:hip circumference ratio, and simple waist circumference.
The optimal level for measurement of waist circumference is
midway from the lower rib margin to the anterior superior iliac
crest, in the standing position. The WHO374 thresholds for waist
circumference are the most widely accepted in Europe; two
action levels are recommended:
† Action level 1—waist circumference ≥94 cm in men and
≥80 cm in women represents the threshold at which no
further weight should be gained.
† Action level 2—waist circumference ≥102 cm in men and
≥88 cm in women represents the threshold at which weight re-
duction should be advised.
These thresholds have been calculated based on Caucasians
and it is apparent that different cut-off points for anthropometric
measurements are required in different races and ethnicities.
Some prospective studies have found evidence of stronger asso-
ciations of abdominal adiposity measures with CHD than with BMI
Recommendation regarding body weight
Recommendations Classa Levelb GRADE Ref C
Weight reduction in 
overweight and obese people 
is recommended as this is 
associated with favourable 
effects on blood pressure and 









Table 10 Potential adverse cardiovascular effects of
increasing body weight
• Increases in insulin resistance (glucose intolerance, type 2 diabetes 
 mellitus).
• Increased blood pressure.
• Increased systemic inflammation and prothrombotic state.
• Albuminuria.
• Dyslipidaemia (elevated total cholesterol, LDL cholesterol, non-HDL 
 cholesterol, triglycerides, apolipoprotein B, small dense LDL particles, 
 decreased HDL cholesterol, apolipoprotein A1).
• Cardiovascular and cerebrovascular abnormalities (endothelial 
 dysfunction, heart failure, coronary heart disease, atrial fibrillation, 
 stroke, abnormal left ventricular geometry, systolic and diastolic 
 dysfunction, increased sym athetic activity).
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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and CHD in women375,376 but not in men; these studies have gen-
erally been small. A large, case–control prevalence study found
that the waist:hip ratio was to a greater extent associated with
myocardial infarction than BMI in both men and women.377
It is possible that waist circumference might be more strongly
associated than BMI with diabetes in women but not in men. A
recent meta-analysis of 32 studies found no overall difference
between BMI, waist circumference, and waist:hip ratio in their as-
sociation with incident diabetes,378 and showed no important dif-
ferences between the sexes. However, the authors could only
investigate heterogeneity in findings related to sex in a limited
way because of the small number of studies in each group.
Recent findings from the Prospective Studies Collaboration,363 in-
volving .900 000 participants, found positive linear associations of
BMI from 22.5 to 25.0 with all-cause mortality.
In a revised pooled analysis of 19 prospective studies (1.46
million white adults),364 all-cause mortality was lowest with a
BMI of 20.0–24.9. In an Asian population (1.1 million persons
recruited in 19 cohorts),365 the lowest risk of death was seen
with a BMI in the range of 22.6–27.5. The risk was elevated with
BMI levels either higher or lower than these ranges, with a
U-shaped association. The finding that the same optimal weight
range is associated with the lowest risk of death both in this
study and in previous studies of European origin argues against
the use of race- or ethnicity-specific BMI cut-off points to define
overweight and obesity.363
In the multicentre European Prospective Investigation into
Cancer and Nutrition (EPIC) cohort study, BMI, waist circumfer-
ence, and waist:hip ratio were all independently associated with all-
cause mortality; the authors recommended the use of waist circum-
ference or waist:hip ratio in addition to BMI for assessing risk of
death; however, no direct comparisons of the magnitudes of
associations between the different measures were made.372 The
data are consistent with the results of four cohorts of adults from
the British Women’s Heart and Health Study, the Caerphilly Pro-
spective Study, the Boyd Orr Study, and the Maidstone–Dewsbury
Study.379 The data from these studies explain the slightly stronger
associations of central adiposity with all-cause mortality by
reverse causality, which is likely to affect BMI (because of general
total body muscle wasting and fat loss) more so than adiposity.380
On the basis of evidence regarding the poorer accuracy and re-
liability of measuring waist circumference and hip circumfer-
ence,381 – 383 it is not possible to establish these measures of
visceral adiposity as alternatives to BMI in routine practice; it is
also notable that BMI was not a stronger predictor of any out-
comes than were the other measures, whereas measures of
central obesity had somewhat stronger associations with all-cause
mortality and type 2 diabetes. An additional related question is
whether measurements of regional adiposity would add value to
the predictive ability of BMI in identifying those at risk of future
CVD. On the other hand, calls for more direct measurements of
fat mass, such as by bioelectrical impedance analysis or the use
of skinfold thickness, may be problematic in routine clinical and
public health practice because of difficulties with accurate and re-
liable measurements.383 –386 Several measurements have been
described for assessing the anatomical distribution of fat, such as
computed tomography, ultrasound (particularly at the epicardial
level), dual-energy X-ray absorptiometry, and MRI. All of these
techniques can be used to monitor changes in intra-abdominal
fat. They are, however, expensive and time consuming, and are
to be regarded as specialist research tools rather than everyday
risk assessment tools in common practice.
Currently, there does not appear to be strong evidence that mea-
surements of waist or direct measurement of fat mass should
replace BMI in routine public health surveillance or clinical practice.
4.6.4 The obesity paradox in established coronary artery
disease
If, at the population level, obesity is associated with an increased
risk of CVD incidence and mortality, among those with established
coronary artery disease, the evidence is contradictory. Systematic
reviews of patients with coronary artery disease or undergoing PCI
have suggested an ‘obesity paradox’ whereby obesity appears pro-
tective against an adverse prognosis.366 –369
4.6.5 Treatment
Although diet, exercise, and behaviour modifications are the main-
stay therapies for overweight and obesity (Table 12), they are often
unsuccessful for long-term treatment. Medical therapy with orli-
stat388 and/or bariatric surgery389 for patients with a BMI
≥40 kg/m2 or a BMI ≥35 kg/m2 in the presence of high-risk co-
morbid conditions are the only options. These patients should
have attempted prior conventional methods of diet and exercise,
should be free of uncontrolled psychiatric disorders, and should
be sufficiently healthy that the benefits of surgery outweigh the
risks. The major issues in the field of bariatric surgery are the
lack of consensus in terms of the diverse procedures available
and of the refinement of techniques that will evolve to decrease
the associated risks.
Table 11 Measures of general obesity and abdominal
adiposity
Measures of general obesity
 Body mass index




Direct measures of fat mass
 Bioelectrical impedance analysis
 Skinfold thicknesses
Measures of general obesity and abdominal adiposity
 Dual-energy X-ray absorptiometry
 Ultrasound
 Computed tomography
 Magnetic resonance imaging
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Most important new information
† It cannot be ruled out that being underweight is associated with
increased cardiovascular morbidity and mortality.
Remaining gaps in evidence
† Whether measurements of regional adiposity add value to the
predictive ability of BMI in identifying those at risk of future
CVD.
† To identify the relative roles of diet, exercise, and behaviour
modification in the management of overweight and obese people.
4.7 Blood pressure
Key message
† Elevated BP is a major risk factor for CHD, heart failure, cere-
brovascular disease, PAD, renal failure, and atrial fibrillation.
Table 12 Classification of body weight according to
body mass index in adults387





 Class 1 30–34.9
 Class 2 35–39.9
 Class 3 ≥40
 Class 4 ≥50
 Class 5 ≥60
The National Institute of Health and WHO classification schemes do not include
class 4 and 5 obesity.
Recommendations on blood pressure
Recommendations Classa Levelb GRADE Ref C
Lifestyle measures such as weight control, increased physical activity, alcohol moderation, sodium restriction, and 
increased consumption of fruits, vegetables, and low-fat dairy products are recommended in all patients with 




All major antihypertensive drug classes (i.e. diuretics, ACE inhibitors, calcium antagonists, angiotensin receptor 
antagonists, and beta-blockers) do not differ significantly in their BP-lowering efficacy and thus should be 
recommended for the initiation and maintenance of antihypertensive treatment.
I A Strong 394
Beta-blockers and thiazide diuretics are not recommended in hypertensive patients with multiple metabolic risk 
factors increasing the risk of new-onset diabetes. 
III A Strong 395, 396
In patients with diabetes, an ACE inhibitor or a renin–angiotensin receptor blocker is recommended. I A Strong 397–399
Risk stratification using the SCORE risk chart is recommended as a minimal requirement in each hypertensive 
patient.
I B Strong 45, 400
However, as there is evidence that subclinical organ damage predicts cardiovascular death independently of 
SCORE, a search for subclinical organ damage should be encouraged, particularly in individuals at low or moderate 
risk (SCORE 1–4%).
IIa B Weak 45, 400
Drug treatment is recommended to be initiated promptly in patients with grade 3 hypertension, as well as in 
patients with grade 1 or 2 hypertension who are at high or very high total cardiovascular risk. 
I C Strong 401
In patients with grade 1 or 2 hypertension and at moderate total cardiovascular risk, drug treatment may be 
delayed for several weeks, and in grade 1 hypertensive patients without any other risk factor, for several months 
while trying lifestyle measures.
IIb C Weak 401
Systolic BP should be lowered to <140 mmHg (and diastolic BP <90 mmHg) in all hypertensive patients. IIa A Strong 402–404
All hypertensive patients with established cardiovascular disease, or with type 2 diabetes, or with an estimated
10-year risk of cardiovascular death ≥5% (based on the SCORE chart) should be considered for statin therapy. IIa B Strong 405
Antiplatelet therapy, in particular low-dose aspirin, is recommended for hypertensive patients with cardiovascular 
events. 
I A Strong 398
Antiplatelet therapy may be considered in hypertensive patients without a history of cardiovascular disease, but 
with reduced renal function or at high cardiovascular risk.
IIb A Weak 406–408













In a number of epidemiological studies, elevated BP has been iden-
tified as a risk factor for CHD, heart failure, cerebrovascular
disease, PAD renal failure, and, more recently, atrial fibrillation
(AF).409,410 Observational evidence is also available that BP levels
correlate negatively with cognitive function and that hypertension
is associated with an increased incidence of dementia.411 Observa-
tional data involving .1 million individuals have indicated that
death from both CHD and stroke increases progressively and lin-
early from BP levels as low as 115 mmHg systolic and 75 mmHg
diastolic upwards.412
A wide pulse pressure (SBP minus DBP) has been shown in
some studies to be a better predictor of adverse cardiovascular
outcomes than either SBP or DBP individually,413 and to identify
patients with systolic hypertension who are at particularly high
risk.414 However, in the largest meta-analysis of observational
data from 61 studies (70% of which have been conducted in
Europe),412 pulse pressure was less predictive than both SBP and
DBP. This meta-analysis also confirmed the increasing contribution
of pulse pressure after age 55 years.
Individuals with an elevated BP more commonly have other risk
factors for CVD (diabetes, insulin resistance, dyslipidaemia) and
target organ damage. Because risk factors may interact, the
overall risk of hypertensive patients is increased although the BP
elevation is only mild or moderate.
4.7.2 Definition and classification of hypertension
The definition and classification of hypertension are shown in
Table 13.
Isolated systolic hypertension should be graded (1,2, and 3)
according to SBP values in the ranges indicated, provided that dia-
stolic values are , 90 mmHg. Grades 1, 2, and 3 correspond to
classification into mild, moderate, and severe hypertension, re-
spectively. These terms have now been omitted to avoid confusion
with quantification of total cardiovascular risk.
4.7.3 Diagnostic evaluation
The current European Society of Hypertension–ESC guidelines401
suggest the following tests to be performed routinely in hyperten-
sive patients: fasting plasma glucose and serum tests for total chol-
esterol, LDL cholesterol, and HDL cholesterol, fasting triglycerides,
potassium, uric acid, creatinine, estimated creatinine clearance
(using the Cockcroft–Gault formula) or estimated GFR [eGFR;
using the Modification of Diet in Renal Disease (MDRD)
formula; the CKD-EPI equation is more accurate than the
MDRD study equation overall and across most subgroups but par-
ticularly for eGFR .60 mL/min/1.73 m2], haemoglobin, and haem-
atocrit, urine analysis (microalbuminuria dipstick test and sediment,
quantitative proteinuria if dipstick test positive), and ECG; whereas
echocardiography, carotid ultrasound, ABI, fundoscopy, and meas-
urement of pulse wave velocity are listed as recommended tests. If
fasting plasma glucose is .5.6 mmol/L (100 mg/dL) or glycated
haemoglobin (HbA1c) is 5.7–6.4% [Diabetes Control and Compli-
cations Trial (DCCT) standardization], the glucose tolerance test is
recommended (see Section 4.8). Blood pressure measurement at
home or 24-h ambulatory BP monitoring is included among the
recommended tests.
4.7.4 Blood pressure measurement
Blood pressure should be measured in each individual several
times, on several separate occasions. If the BP is only slightly ele-
vated, repeated measurements should be made over a period of
several months to achieve an acceptable definition of the indivi-
dual’s ‘usual’ BP and to decide about initiating drug treatment. If
the BP is more markedly elevated or accompanied by target
organ damage, other cardiovascular risk factors, or established car-
diovascular or renal disease, repeated BP measurements are
required within a shorter period in order to make treatment deci-
sions. Repeated BP measurements on several occasions are neces-
sary to identify the relatively large number of persons in whom BP
elevation disappears following the first few visits. These individuals
may need to undergo BP measurement more frequently than the
general population, but drug treatment may not be necessary
because their cardiovascular risk is probably low.
In post-myocardial infarction patients treated for hypertension
before their infarction, BP may remain much lower, or even
return to normotensive values without antihypertensive treatment.
In such instances, BP has to be measured frequently to detect
whether hypertensive values are regained, and treatment restarted
without delay.
4.7.5 Office or clinic blood pressure measurement
As medical use of mercury has been banned in some European
countries, non-mercury BP measuring devices are becoming
Table 13 Definitions and classification of blood
pressure levelsa




Optimal <120 and <80
Normal 120–129 and/or 80–84
High normal 130–139 and/or 85–89
Grade 1 hypertension 140–159 and/or 90–99
Grade 2 hypertension 160–179 and/or 100–109




BP ¼ blood pressure.
aBP levels in untreated individuals.
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increasingly important. These devices should be properly tested
and validated according to standardized protocols.415 Devices
measuring BP in the fingers or on the wrist should be avoided
because of their possible inaccuracy. The auscultatory technique
with a trained observer and a mercury sphygmomanometer con-
tinues to be the method of choice for measurement in the office
or clinic.
4.7.6 Ambulatory and home blood pressure monitoring
Both ambulatory and home BP values are closely related to prog-
nosis.416 Measurement may be useful not only in untreated sub-
jects but also in treated patients, with the aim of monitoring the
effects of treatment and increasing compliance with drug
therapy. They also allow two specific clinical conditions to be diag-
nosed, namely ‘white coat’ or isolated clinic hypertension charac-
terized by higher office BP with normal ambulatory BP values,
and ‘masked’ hypertension characterized by normal office BP
with high ambulatory BP values.417 BP thresholds for the definition
of hypertension by 24-h ambulatory and home BP monitoring
differ from those measured at office or clinic (Table 14).
Diagnosis of hypertension and assessment of treatment are still
largely based on office or clinic blood pressure.
4.7.7 Risk stratification in hypertension
The decision to start pharmacological treatment depends not only
on the BP level but also on total cardiovascular risk, which calls for
a proper history, physical examination, and laboratory examination
to identify the:
† presence of clinically established cardiovascular or renal disease
† presence of subclinical CVD
† co-existence of other cardiovascular risk factors.
Established cardiovascular or renal disease (Table 15) dramatically
increases the risk of subsequent cardiovascular events regardless of
BP level. This is also the case for the association of hypertension
and other cardiovascular risk factors, not least diabetes.
The co-existence of other risk factors (smoking, increased
plasma cholesterol, diabetes mellitus, family history of premature
CVD) also greatly adds to the risk associated with mild BP
elevation.45 Risk stratification using the SCORE risk chart is a
minimal requirement in each hypertensive patient.
Owing to the importance of target organ damage as an inter-
mediate stage in the continuum of vascular disease and as a deter-
minant of overall cardiovascular risk, signs of organ involvement
should be sought carefully.
Electrocardiographic left ventricular hypertrophy (LVH),
detected by the Sokolow–Lyons index, Cornell voltage QRS dur-
ation product, or the recently developed Novacode estimate,418 is
an independent predictor of cardiovascular events. ECG LVH can
be used as a tool documenting LVH regression, possibly associated
with a reduced incidence of new-onset AF.419 A recent prospect-
ive study focused on the R-wave voltage in the aVL lead as a prog-
nostic sign in hypertensive patients without ECG LVH.
Echocardiography is more sensitive than electrocardiography in
diagnosing LVH and in predicting cardiovascular risk, and may help
in more precise stratification of the overall risk and in directing
therapy. Cardiac abnormalities detected by echocardiography
more precisely quantify left ventricular mass and geometric LVH
patterns, and have an additional predictive power.420
Carotid ultrasound with measurement of IMT or the presence
of plaques predicts both stroke and myocardial infarction.421 Ultra-
sound scans limited to the common carotid arteries (an infrequent
site of atherosclerosis) are likely to detect vascular hypertrophy
only, whereas assessment of atherosclerosis also requires scanning
of bifurcations and/or internal carotids where plaques are more
frequent. These alterations are common in untreated hypertensive
individuals without target organ damage on routine examination;
thus, carotid ultrasound may often detect vascular damage and
make risk stratification more precise.
Evidence of arterial damage may also be suggested by an ABI
,0.9. A low ABI indicates advanced atherosclerosis,422 whereas
carotid IMT measurements are able to detect earlier changes.421
Measurement of carotid–femoral pulse wave velocity provides a
comprehensive non-invasive assessment of arterial stiffness423 and
has an independent predictive value for all-cause and cardiovascu-
lar morbidity, coronary events, and strokes in patients with uncom-
plicated essential hypertension as well as in the general population.
Although the relationship between aortic stiffness and events is
continuous, a threshold .12 m/s has been suggested as a conser-
vative estimate of significant alterations of aortic function in
middle-aged hypertensive patients.
The diagnosis of hypertension-induced renal damage is based on
the finding of a reduced renal function and/or the detection of ele-
vated urinary albumin excretion. Renal insufficiency is classified
according to the eGFR calculated using the MDRD, Cockroft–
Gault formula, or CKD-EPI. The three formulae help to detect
mildly impaired renal function, particularly if serum creatinine
values are still within the normal range and the body weight low
and/or the age advanced.
In hypertensive patients with and without diabetes, microalbu-
minuria, even below the currently used threshold values, predicts
cardiovascular events,424 and a continuous relationship between
cardiovascular as well as non-cardiovascular mortality and
urinary protein/creatinine ratios ≥3.9 mg/g in men and ≥7.5 mg/
g in women has been reported in several studies. Microalbuminuria
can be measured from spot urine samples (24-h or night-time
Table 14 Blood pressure thresholds for definition of
hypertension with different types of blood pressure
measurement
SBP (mmHg) DBP (mmHg)
Office or clinic 140 90




BP ¼ blood pressure; DPB ¼ diastolic blood pressure; SBP ¼ systolic blood
pressure.
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urine samples are discouraged due to the inaccuracy of urinary
sample collection) by indexing the urinary albumin concentration
to the urinary creatinine concentration.
In conclusion, there is evidence that subclinical organ damage
predicts cardiovascular death independently of SCORE, and the
combination may improve risk prediction, especially in subjects
at low or moderate risk (SCORE 1–4%).400
4.7.8 Whom to treat, and when to initiate
antihypertensive treatment
The decision to start antihypertensive treatment depends on BP
(Table 13) and total cardiovascular risk (Table 15). All patients in
whom repeated BP measurements show grade 2 or 3 hypertension
are candidates for treatment; a large number of placebo-controlled
trials have conclusively demonstrated that in patients with these BP
values, BP reduction lowers cardiovascular morbidity and mortality
independently of their level of total risk.
The evidence for the benefit of treating patients with grade 1
hypertension is admittedly scantier, because earlier trials in mild
hypertension included patients mostly at high risk.
Promptness in the initiation of pharmacological therapy depends
on the level of total cardiovascular risk. A delay in achieving BP
control in high-risk hypertensive patients is associated with a
worse outcome. Drug treatment should be initiated promptly in
grade 3 hypertension, as well as in patients with grade 1 and 2
hypertension who are at high or very high total cardiovascular
risk. In patients with grade 1 or 2 hypertension at moderate
total cardiovascular risk, drug treatment may be delayed for
several weeks, and in those with grade 1 hypertension without
any other risk factor it may be delayed for several months.
Table 15 Factors influencing prognosis in hypertension
Risk factor Target organ damage Diabetes mellitus Established CVD or renal disease
SBP and DBP Electrocardiographic LVH 
(Sokolow–Lyons >38 mm or 
Cornell >2440 mm/ms); or 
Novacode LVMI >130 g/m2 (M), 
>115 g/m2 (F).
Fasting plasma glucose 
≥7.0 mmol/L (126 mg/dL)
or post-load plasma 
glucose 
>11.0 mmol/L (198 mg/dL).
Cerebrovascular disease: ischaemic stroke, 
cerebral haemorrhage, transient ischaemic 
attack.
Pulse pressure (in the elderly) Echocardiographic LVHa 
[LVMI ≥125 g/m2 (M), 
≥110 g/m2 (F)]
Heart disease: myocardial infarction, angina, 
coronary revascularization, heart failure. 
Age (M >55 years, F >65 years) Carotid wall thickening 
(IMT >0.9 mm) or plaque 
Renal disease: diabetic nephropathy, renal 
impairment [serum creatinine >133 µmol/L 
(1.5 mg/dL) (M), >124 µmol/L (1.4 mg/dL) 
(F)], proteinuria (>300 mg/24 h).
Smoking Carotid–femoral PWV >12 m/s PAD
Dyslipidaemia: TC >5.0 mmol/L (190 mg/dL); 
or LDL cholesterol >3.0 mmol/L (115 mg/dL); 
or HDL cholesterol <1.0 mmol/L (40 mg/dL) 
(M), <1.2 mmol/L (46 mg/dL) (F); 
or TG >1.7 mmol/L (150 mg/dL)
ABI <0.9 Advanced retinopathy: haemorrhages or 
exudates, papilloedema.
Fasting plasma glucose 
5.5–6.9 mmol/L (100–125 mg/dL)
Slight increase in plasma 
creatinine: 115–133 µmol/L 
(1.3–1.5 mg/dL) (M), 107–124 
µmol/L (1.2–1.4 mg/dL) (F)
Abnormal glucose tolerance test Low eGFRb (<60 mL/min/1.73 m2) 
or creatinine clearancec (<60 mL/
min)
Abdominal obesity: waist circumference 
>102 cm (M), >88 cm (F)
Microalbuminuria 30–300 mg/24 
h or albumin/creatinine ratio: 
≥22 mg/g (≥2.5 mg/mmol)
(M), ≥31 mg/g (≥3.5 mg/mmol) (F)
Family history of premature CVD: 
age <55 years (M), <65 years (F).
ABI ¼ ankle–brachial index; CVD ¼ cardiovascular disease; DBP ¼ diastolic blood pressure; eGFR ¼estimated glomerular filtration rate; F, females; HDL ¼ high-density
lipoprotein; IMT ¼ intima-media thickness; LDL ¼ low-density lipoprotein; LVH, left ventricular hypertrophy; LVMI ¼ left ventricular mass index; M ¼ males; PAD ¼ peripheral
artery disease; PWV ¼ pulse wave velocity; SBP ¼ systolic blood pressure; TC ¼ total cholesterol; TG ¼ triglycerides.
aRisk maximal for concentric LVH: increased LVMI with a wall thickness/radius ratio ≥0.42.
bModification of Diet in Renal Disease (MDRD) formula.
cCockcroft–Gault formula.
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However, even in these patients, lack of BP control after a suitable
period of non-pharmacological measures may lead to adding drug
treatment.
In general, early BP-lowering treatment before organ damage
develops or becomes irreversible appears a prudent recommenda-
tion. This is because, in high-risk hypertensive patients, even
intense cardiovascular drug therapy—although beneficial—
cannot lower total cardiovascular risk below the high-risk
threshold.
Initiation of antihypertensive drug therapy in patients with dia-
betes with high normal BP is presently unsupported by prospective
trial evidence. For the time being, it appears prudent to recom-
mend treatment initiation in patients with diabetes and high
normal BP if subclinical organ damage (particularly microalbumi-
nuria or proteinuria) is present.
In subjects with high normal BP (SBP 130–139 or DBP 85–
89 mmHg) uncomplicated by diabetes or previous cardiovascular
events, no trial evidence is available of treatment benefits,
except for a delayed onset of hypertension.
Lifestyle measures and close BP monitoring should be the rec-
ommendation for individuals with high normal BP who are at
low or moderate added risk.401
4.7.9 How to treat
4.7.9.1 Lifestyle
Lifestyle interventions alone may be sufficient for patients with
mildly elevated BP, and should always be advised for patients re-
ceiving antihypertensive drugs as they may reduce the dosage of
antihypertensives needed to achieve BP control.
Lifestyle interventions include: weight reduction in overweight
individuals; reduction in the use of sodium chloride to ,5 g/day;
restriction of alcohol consumption to no more than 20 g/day
ethanol in men and to no more than 10 g/day ethanol in women;
and regular physical activity in sedentary individuals.
As the BP-lowering effect of increased potassium has been well
documented in the DASH diet (rich in fruits, vegetables, and
low-fat dairy products with a reduced content of dietary choles-
terol as well as saturated and total fat), patients with hypertension
should generally be advised to eat more fruits and vegetables (4–6
servings per day, i.e. 400 g) and to reduce intake of saturated fat
and cholesterol.
As tobacco smoking has a particularly adverse effect on cardio-
vascular risk, intensive efforts should be made to help hypertensive
smokers stop smoking, with nicotine replacement, bupropione
therapy, or varenicline considered. Because the acute pressure
effect of smoking may raise daytime BP,425 this may also directly
favour BP control, at least in heavy smokers. As long-term compli-
ance with lifestyle changes may be poor, reinforcement in connec-
tion with BP measurements is needed.
4.7.9.2 Antihypertensive drugs
The large number of randomized trials of antihypertensive
therapy, both those comparing active treatment vs. placebo,
and those comparing treatment regimens based on different
compounds, confirm that: (i) the main benefits of antihyperten-
sive treatment are due to lowering of BP per se, and are
largely independent of the drugs employed; and (ii) thiazide
and thiazide-like diuretics (chlorthalidone and indapamide), beta-
blockers, calcium antagonists, ACE inhibitors, and angiotensin re-
ceptor antagonists can adequately lower BP, and significantly
reduce risk of cardiovascular morbidity and mortality. These
drugs are thus all recommended for initiation and maintenance
of antihypertensive treatment, either as monotherapy or in
combination.
The position of beta-blockers as first-choice antihypertensive
drugs has been questioned in the past decade. The latest
meta-analysis of 147 randomized trials394 reports only a slight in-
feriority of beta-blockers in preventing stroke (17% reduction
rather than 29% reduction with other agents) but a similar effect
to other agents in preventing coronary events and heart failure,
and higher efficacy than other drugs in patients with a recent cor-
onary event. These findings are consistent with the longitudinal
United Kingdom Prospective Diabetes Study (UKPDS) follow-
up.426 They also concur with a large observational study of patients
treated with different antihypertensive treatment regimens for
longer periods than in randomized trials, and in which the inci-
dence of cardiovascular outcomes was not higher on atenolol-
based treatment vs. other antihypertensive agents.405
However, as beta-blockers induce weight gain, have adverse
effects on lipid metabolism,395 and increase (compared with
other drugs) the incidence of new-onset diabetes, they should
not be preferred in hypertensive patients with multiple metabolic
risk factors (i.e. abdominal obesity, impaired fasting glucose, and
impaired glucose tolerance), conditions that increase the risk of
new-onset diabetes. This also applies to thiazide diuretics, which
have dyslipidaemic and diabetogenic effects, particularly when
used at high doses. Thiazides have often been administered to-
gether with beta-blockers in trials showing a relative excess of
new-onset diabetes, thus making a distinction between the contri-
butions of the two agents difficult to dissociate. However, this may
not apply to vasodilating beta-blockers such as carvedilol and nebi-
volol, which have less or no dysmetabolic action, as well as a
reduced incidence of new-onset diabetes compared with conven-
tional beta-blockers. Furthermore, it is still unclear whether
drug-induced diabetes carries the same negative prognosis as nat-
urally occurring diabetes.
Trials assessing moderate endpoints suggest other differences
between various antihypertensive agents or compounds: ACE inhi-
bitors and angiotensin receptor antagonists are particularly effect-
ive in reducing LVH, including the fibrotic component; they are also
quite effective in reducing microalbuminuria and proteinuria and in
preserving renal function and delaying end-stage renal disease;
calcium antagonists, besides being effective in LVH, appear particu-
larly beneficial in slowing down progression of carotid hypertrophy
and atherosclerosis.
Evidence concerning the benefits of other classes of agents is
much more limited. Alpha1-blockers, centrally acting agents [alpa2-
adrenoreceptor agonists and imidazoline (I1) receptor agonists],
and antialdosterone drugs effectively lower BP. However, there
are no data documenting the ability of these drugs to reduce car-
diovascular morbidity and mortality in hypertension. All of these
agents, however, have frequently been used as added drugs in
trials documenting cardiovascular protection and can thus be
used for combination treatment.
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Aliskiren, which inhibits the effect of renin and pro-renin on
their specific receptors, effectively lowers BP in hypertension427
and has an antiproteinuric effect. However, its effect on cardiovas-
cular morbidity and mortality has not yet been proven, but a
number of studies are under way.
Cost considerations should never predominate over the efficacy,
tolerability, and safety for the individual patient. Drugs with 24-h
efficacy should be preferred. Simplification of treatment improves
adherence to therapy, while effective 24-h BP control is prognos-
tically important in addition to ‘office’ BP control. Long-acting
drugs also minimize BP variability, which may offer protection
against progression of organ damage and risk of cardiovascular
events.
4.7.9.3 Combination treatment
Combination treatment is needed to control BP in most patients.
The addition of a drug from another class should thus be regarded
as a recommendable treatment strategy unless the initial drug
needs to be withdrawn because of side effects or the absence of
any BP-lowering effects. The extra BP reduction from combining
drugs from two different classes is approximately five times
greater than doubling the dose of one drug.428 The combination
of two drugs may also offer advantages for treatment initiation,
particularly in patients at high risk in whom early BP control may
be desirable. Fixed-dose combinations simplify treatment and
may thus improve patient compliance. Trial evidence of outcome
reduction has been obtained particularly for the combination of
a diuretic with an ACE inhibitor or an angiotensin receptor antag-
onist or calcium antagonist.429,430
Despite the trial evidence of outcome reduction, the beta-
blocker/diuretic combination favours the development of diabetes
and should thus be avoided unless required for other reasons. The
combination of an ACE inhibitor and an angiotensin receptor
blocker is associated with a consistent increase in serious side
effects.431 Specific benefits in nephropathic patients with protein-
uria (because of a superior antiproteinuric effect) await confirm-
ation in event-based trials.
In 15–20% of hypertensive patients, a combination of three
drugs is needed to achieve BP control; the most rational combina-
tions appear to be a blocker of the renin–angiotensin system, a
calcium antagonist, and a diuretic at effective doses.
4.7.9.4 Blood pressure goals
There is sufficient evidence to recommend that SBP be lowered to
,140 mmHg (and DBP to ,90 mmHg) in all hypertensive
patients. Evidence is only missing in the elderly hypertensive
patient, in whom the benefit of lowering SBP ,140 mmHg has
not been tested in randomized trials.
The recommendation of previous guidelines401 to aim at a lower
SBP goal (,130 mmHg) in patients with diabetes and those at very
high cardiovascular risk (previous cardiovascular events) is not
consistently supported by trial evidence. Post-hoc analyses of
large-scale trials (e.g. ONTARGET, INVEST, and VALUE), although
suffering from the limitation posed by comparisons of non-
randomized groups, suggest that at least in high-risk hypertensive
patients, there may be no advantage or even harm in lowering sys-
tolic BP below 130 mmHg, except perhaps for stroke. A J-curve
phenomenon for achieved SBP below 130 mmHg cannot be
excluded.432
Despite their obvious limitations and a lower strength of evi-
dence, post-hoc analyses of trial data indicate a progressive reduc-
tion in incidence of cardiovascular events with progressive
lowering of SBP down to 120 mmHg and DBP down to
75 mmHg,412 although the additional benefit at low BP values
becomes rather small. A J-curve phenomenon is unlikely to
occur down to these values except, perhaps, in patients with
advanced atherosclerotic disease.
Based on current data, it may be prudent to recommend lower-
ing SBP/DBP to values within the range 130–139/80–85 mmHg
and, possibly, close to lower values in this range, in all hypertensive
patients. More critical evidence from specific RCTs is desirable.
4.7.9.5 Hypertension in special conditions
Diabetes mellitus (see Section 4.8)
In patients with diabetes, antihypertensive treatment should always
be initiated when the BP is ≥140/90 mmHg. Initiation of treatment
in the high-normal BP range is at present not sufficiently supported
by outcome evidence from trials.
Meta-analyses of available trials show that, in diabetes, all major
antihypertensive drug classes protect against cardiovascular com-
plications, probably because of the protective effect of BP lowering
per se. They can thus all be considered for treatment. Combination
treatment is commonly needed to lower BP effectively in diabetes.
A renin–angiotensin system blocker (ACE inhibitor/angiotensin re-
ceptor blocker) should always be included because of the evidence
of its superior protective effect against initiation or progression of
nephropathy.
Hypertension in the elderly
Large meta-analyses confirm that treatment is highly beneficial in
the elderly hypertensive patient. The proportional benefit in
patients aged .65 years is no less than that of younger patients.
The claim that antihypertensive drug classes differ significantly in
their ability to lower BP and to exert cardiovascular protection,
both in younger and in elderly patients, has not been proven.
Thus the choice of the drugs should not be guided by age. Thiazide
diuretics, ACE inhibitors, calcium antagonists, angiotensin receptor
antagonists, and beta-blockers can be considered for initiation and
maintenance of treatment also in the elderly.
In the elderly, outcome trials have only addressed patients with
an entry SBP ≥160 mmHg, and no trial achieved an average SBP
,140 mmHg. Evidence from outcome trials addressing lower
entry and achieving lower on-treatment values is thus needed.
Evidence is now available from an outcome trial that antihyper-
tensive treatment also has benefits in patients aged ≥80 years.
Treatment with BP-lowering drugs should be continued or initiated
when patients turn 80, starting with monotherapy and adding a
second drug if needed. Because patients in the Hypertension in
the Very Elderly Trial (HYVET) were generally in a good condi-
tion,433 the extent to which HYVET data can be extrapolated to
more fragile octogenarians is uncertain. The decision to treat
should be taken on an individual basis, and patients should
always be carefully monitored during treatment, with BP also mea-
sured in the standing position.
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4.7.9.6 Duration of treatment
Generally, antihypertensive therapy should be maintained indefin-
itely. Cessation of therapy in hypertensive patients is mostly fol-
lowed by the return of BP to pre-treatment levels.
4.7.9.7 Lipid-lowering drugs
All hypertensive patients with established cardiovascular disease or
with type 2 diabetes or with an estimated 10-year risk of cardiovas-
cular death ≥5% (based on the SCORE chart) should be consid-
ered for statin therapy aiming at goals referred to in Section 4.9.
4.7.9.8 Antiplatelet therapy
Antiplatelet therapy, in particular low-dose aspirin, should be pre-
scribed to hypertensive patients with cardiovascular events. It can
also be considered in hypertensive patients without a history of
cardiovascular disease, with reduced renal function, or at high car-
diovascular risk. In patients receiving aspirin, careful attention
should always be paid to the increased possibility of bleeding, par-
ticularly gastrointestinal.
Important new information
† Subclinical organ damage in hypertension predicts cardiovascu-
lar death independently of SCORE, and a combination of both
may improve risk prediction, particularly in individuals at low
and moderate risk (SCORE 1–4%).
† Antihypertensive treatment is beneficial in patients aged ≥80
years.
Remaining gaps in the evidence
† Should drugs be prescribed to all individuals with grade 1 hyper-
tension, even when their total cardiovascular risk is low or
moderate?
† Should drugs be prescribed to the elderly with grade 1 hyper-
tension, and should their BP goal be set ,140/90 mmHg?
† Should drug treatment be initiated in patients with diabetes or
those with a previous cerebrovascular or cardiovascular event
when the BP is still within the high-normal range, and should
the BP goal be ,130/80 mmHg in these patients?
† What are the lowest safe BP values to achieve by treatment in
different clinical conditions?
† Are lifestyle measures known to reduce BP also capable of re-
ducing morbidity and mortality in hypertension?
4.8 Treatment targets in patients with
type 2 diabetes
Key messages
† Intensive management of hyperglycaemia in diabetes reduces
the risk of microvascular complications and, to a lesser extent,
that of cardiovascular disease.
† Intensive treatment of BP in diabetes reduces the risk of macro-
vascular and microvascular outcomes.
† Multiple antihypertensive drugs are usually required to reach the
target.
Recommendations on diabetes mellitus
Recommendations Classa Levelb GRADE Ref C
The target HbA1c for the prevention of CVD in diabetes of <7.0% (<53 mmol/mol) is recommended. I A Strong 434, 435
Statins are recommended to reduce cardiovascular risk in diabetes. I A Strong 166, 436
Hypoglycaemia and excessive weight gain must be avoided and individual approaches (both targets and drug 




Metformin should be used as first-line therapy if tolerated and not contraindicated IIa B Strong 439
Further reductions in HbA1c to a target of <6.5% (<48 mmol/mol) (the lowest possible safely reached HbA1c) may 
be useful at diagnosis. For patients with a long duration of diabetes this target may reduce risk of microvascular 
outcomes.
IIb B Weak 435
BP targets in diabetes are recommend to be <140/80 mmHg. I A Strong 440, 441
Target LDL cholesterol is <2.5 mmol/L, for patients without atherosclerotic disease total cholesterol may be 
<4.5 mmol/L, with a lower LDL cholesterol target of <1.8 mmol/L (using higher doses of statins) for diabetic 
patients at very high CVD risk.
IIb B Weak 442
Antiplatelet therapy with aspirin is not recommended for people with diabetes who do not have clinical evidence 
of atherosclerotic disease.
III A Strong 443














Cardiovascular disease is the leading cause of morbidity and mor-
tality in people with diabetes mellitus. Aggressive control of hyper-
tension and lowering cholesterol levels with statins reduce the risk
of cardiovascular events, and there is conclusive evidence that im-
proving glycaemic control significantly reduces the risk of develop-
ing diabetic microvascular complications (retinopathy,
nephropathy, and neuropathy). While existing data indicate a rela-
tionship between increased levels of glycaemia and cardiovascular
events, until recently there has been little evidence that specifically
targeting glycaemic control can reduce the frequency of cardiovas-
cular endpoints.
4.8.2 Evidence for current recommendations on
cardiovascular disease prevention in diabetes
With the exception of glucose management, prevention of CVD
follows the same general principles as for people without diabetes.
A multifactorial approach to treatment and achieving low BP levels
and low LDL and total cholesterol concentrations is particularly
important, and many of the treatment targets are tougher for
patients with diabetes. The typical patient with type 2 diabetes
has multiple cardiovascular risk factors, each of which should be
treated in accordance with existing guidelines.
4.8.3 Glucose control
The UKPDS evaluated the effect of improved metabolic control on
the risk of developing CHD or other cardiovascular out-
comes.434,439 The study demonstrated a 16% risk reduction for
myocardial infarction that was not statistically significantly (P ¼
0.052) associated with the 0.9% difference in HbA1c that was
obtained between the intensive and conventional treatment
groups. The average HbA1c in the intensive group was 7.0%
(53 mmol/mol). In overweight patients treated with metformin, a
significant reduction in risk of myocardial infarctions was seen
(P, 0.01).
Most patients in the UKPDS were followed for a further 10
years of post-trial observational monitoring.444 No attempt was
made to maintain previously assigned therapies and the glycaemic
control in the two groups rapidly converged. The intensive treat-
ment group had a 17% relative risk reduction in diabetes-related
death (P ¼ 0.01), a 15% reduction in risk of myocardial infarction
(P ¼ 0.01), and a 13% reduction in risk of death from any cause
(P ¼ 0.007). This so-called ‘legacy’ effect also occurred in the met-
formin arm, in which patients treated with metformin maintained a
reduction in cardiovascular events compared with those on con-
ventional therapy. Similar legacy effects of early, intensive glycaemic
control were seen in patients with type 1 diabetes in the DCCT/
EDIC trial.445
4.8.4 Glucose targets
Three recent trails were conducted to see if cardiovascular events
could be reduced further with lower target HbA1c levels.
435,438,446
In the ACCORD study, .10 000 patients with type 2 diabetes and
either a history of CVD or additional cardiovascular risk factors
were randomized to intensive therapy, with a target HbA1c
,6.0% (42 mmol/mol) or standard glycaemic control (target
HbA1c 7.0–7.9%, 53–63 mmol/mol). HbA1c dropped rapidly in
the intensive group, with a median HbA1c of 6.7% (50 mmol/
mol) within 4 months and 6.4% (46 mmol/mol) at 1 year. The
trial was stopped prematurely at 3.5 years due to a significantly
increased total mortality in the intensive treatment group: 257
vs. 203 (P ¼ 0.04) for deaths due to any cause and 135 vs. 94
(P ¼ 0.02) for deaths due to cardiovascular causes. There were sig-
nificantly more cases of hypoglycaemia requiring assistance in the
intensive group, who also experienced significantly more weight
gain. The reason for the poorer outcome in the intensive group
is not clear, but may be associated with hypoglycaemia.
The Action in Diabetes and Vascular Disease Trial (ADVANCE)
randomized .11 000 patients with type 2 diabetes to either stand-
ard or intensive glucose control.435 The target HbA1c was 6.5%
(48 mmol/mol) (0.5% higher than in ACCORD). Final mean
HbA1c levels were similar to those in the ACCORD trial, but
the reduction in HbA1c in the intensive group was achieved
more slowly in ADVANCE, with mean HbA1c at 6 months of 7%
(53 mmol/mol) and not reaching the final value of 6.5%
(48 mmol/mol) until 36 months. Intensive control significantly
reduced the total number of major macrovascular events (death
from cardiovascular causes, non-fatal myocardial infarction, non-
fatal stroke) and major microvascular events (new or worsening
nephropathy or retinopathy), but only the reduction in micro-
vascular events was statistically significant. Weight gain and hypo-
glycaemia were less frequent than in the ACCORD study.
The smaller Veterans Affairs Diabetes Trial (VADT) achieved a
median HbA1c of 6.9% (52 mmol/mol) in the intensive group com-
pared with 8.4% (68 mmol/mol) in the standard group.438 There
was no significant difference between groups for any of the individ-
ual composites of the primary outcome or for all-cause mortality.
4.8.5 Meta-analysis and systematic reviews
A meta-analysis of intensive glucose control including data from
UKPDS, Prospective Pioglitazone Clinical Trial in Macrovascular
Events (PROactive), ACCORD, ADVANCE, and VADT447
showed a significant reduction in non-fatal myocardial infarction
and CHD events, but no effect on stroke or total mortality. This
analysis can be criticized as the PROactive trial was a study of pio-
glitazone vs. placebo and not a trial of intensive glucose control.448
A more recent meta-analysis examined trials of intensive vs. con-
ventional glycaemic control, but did not include PROactive, and
again identified the UKPDS, ACCORD, ADVANCE, and VADT
trials.449 Similar results were found with a significant reduction in
CHD and CVD events, but no reduction in cardiovascular mortal-
ity or total mortality. A similar result was also found in another sys-
tematic review of the same data.450
4.8.6 Blood pressure
Hypertension is more common in patients with type 2 diabetes
compared with the general population. The effect of BP reduction
on the risk of developing CVD has been studied in trials including
diabetic as well as non-diabetic patients, and much of the existing
evidence is based on subgroup analysis from these combined trials.
For example, in the Systolic Hypertension in the Elderly Program
(SHEP) and Systolic Hypertension in Europe (Syst-Eur) studies,
treatment effects were generally bigger in diabetic groups than in
non-diabetic groups. The Hypertension Optimal Study (HOT),
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which compared different DBP goals, showed the benefit from
more aggressive treatment of BP (DBP goal: 80 mmHg), resulting
in a reduction in risk of cardiovascular events in diabetic vs. non-
diabetic individuals.440
In a substudy of the UKPDS, patients with hypertension were
randomized to intensive (mean BP 144/82 mmHg) or less intensive
antihypertensive therapy.441 There was a marked and significant
44% risk reduction for stroke and a non-significant 21% risk reduc-
tion for myocardial infarction associated with a 10 mmHg reduc-
tion in SBP and a 5 mmHg reduction in DBP. Post-trial
monitoring of the UKPDS substudy showed no legacy effect (i.e.
intensive BP control has to be maintained for continued
benefit).426 In the ADVANCE BP study, lowering BP to a mean
of 135/75 mmHg further reduced the risk of cardiovascular
events and total mortality.397
In diabetic patients, antihypertensive treatment should be
initiated when the BP is ≥140/80 mmHg. The SBP goal traditionally
recommended in diabetes (i.e. ,130 mmHg) is based on epi-
demiological evidence, and not on evidence from randomized
trials. It has also been very difficult to achieve in most patients.
The recent ACCORD BP study451 tested the hypothesis that a
target SBP of ,120 mmHg would be of further benefit in reducing
cardiovascular events in patients with type 2 diabetes. There was
no improvement in the primary endpoint, with slight reductions
in the secondary endpoint of strokes, and an increase in side
effects with a lower target.
Meta-analyses of available trials show that, in diabetes, all major
antihypertensive drug classes protect against cardiovascular com-
plications, probably because of the protective effect of BP lowering
per se. Thus all of these drugs can be considered in this population.
Combination treatment is commonly needed to lower BP effect-
ively in diabetes. An ACE inhibitor or angiotensin receptor antag-
onist should always be included because of the evidence of
superior protective effects against initiation or progression of
nephropathy.
4.8.7 Dyslipidaemia
The Heart Protection Study (HPS) demonstrated that treatment
with simvastatin 40 mg reduced the risk of CHD and stroke in dia-
betic and non-diabetic individuals without prior myocardial infarc-
tion or angina pectoris.436 The reactive treatment effect was
independent of baseline cholesterol, although the absolute risk
and treatment effect increased with rising cholesterol concentra-
tion. The Collaborative AtoRvastatin Diabetes Study (CARDS), a
specifically designed RCT in type 2 diabetic patients without clin-
ically manifest CVD, also showed that cholesterol lowering with
atorvastatin 10 mg reduced the risk of CHD and stroke
events.166 Meta-analysis has confirmed the benefits of lipid lower-
ing with statins compared with placebo in people with diabetes.452
A subgroup analysis of 1501 diabetic patients included in the
Treating to New Targets (TNT) study, which compared intensive
statin therapy (atorvastatin 80 mg) with standard statin therapy
(atorvastatin 10 mg), showed a reduction in risk of primary
events, cerebrovascular events, and all cardiovascular events in
patients in the intensive statin therapy group.442
Earlier and intensive prevention using lipid-lowering drugs irre-
spective of basal LDL cholesterol and aiming at lower lipid level
goals, particularly in patients with type 2 diabetes, is needed. For
patients with type 2 diabetes who have overt CVD or CKD and
have one or more other CVD risk factors, the optimal level of
LDL cholesterol should be ,1.8 mmol/L (70 mg/dL).
However, it has to be stressed that in patients with type 2 diabetes,
LDL cholesterol often remains within the normal range or is just
moderately elevated, while one of the major CVD risk factors in
these patients is diabetic dyslipidaemia characterized by hypertri-
glyceridaemia and low HDL cholesterol. Studies examining pos-
sible benefits of lipid lowering with fibrates in diabetes have
given inconsistent results.
4.8.8 Antithrombotic therapy
Patients with type 1 or type 2 diabetes have an increased tendency
to develop thrombotic phenomena. The Antiplatelet Trialists’ Col-
laboration meta-analysis demonstrated benefits of antithrombotic
therapy in diabetic patients with clinically established CHD, cere-
brovascular disease, or other forms of atherothrombotic
disease.453 They analysed data from 4500 diabetic patients in
the trials and concluded that treatment with antiplatelet drugs
(mainly aspirin) resulted in a 25% significant reduction in risk of
cardiovascular events.
The role of aspirin in primary prevention remains unproven. In
the HOT study, 75 mg of aspirin further reduced the risk of
major cardiovascular events in well-controlled hypertensive
patients with diabetes, but non-fatal major bleeds were significantly
more common among patients receiving aspirin.440 A further ana-
lysis by the Antithrombotic Trialists’ Collaboration demonstrated a
non-significant 7% reduction in risk of vascular events in patients
who were at high risk because of the presence of diabetes.454 A
recent meta-analysis of six RCTs found no statistically significant
reduction in the risk of major cardiovascular events or all-cause
mortality when aspirin was compared with placebo or no aspirin
in people with diabetes and no pre-existing CVD.443 Aspirin signifi-
cantly reduced the risk of myocardial infarction in men, but not in
women. Evidence relating to harm was inconsistent.
4.8.9 Microalbuminuria and multifactorial intervention
Microalbuminuria (urinary albumin excretion from 30 to 300 mg/
24 h) predicts the development of overt diabetic nephropathy in
patients with type 1 or type 2 diabetes, while the presence of
overt proteinuria (.300 mg/24 h) generally indicates established
renal parenchymal damage. In both diabetic and non-diabetic
hypertensive patients, microalbuminuria—even below the current-
ly used threshold values—predicts cardiovascular events, and a
continuous relationship between cardiovascular as well as non-
cardiovascular mortality and urinary protein/creatinine ratios has
been reported in several studies. Microalbuminuria can be mea-
sured from spot urine samples (24-h or night-time urine samples
are discouraged due to the inaccuracy of urinary sample collection)
by indexing the urinary albumin concentration to the urinary cre-
atinine concentration. Patients with microalbuminuria and protein-
uria should be treated with an ACE inhibitor or angiotensin II
receptor antagonist regardless of baseline BP.
The Steno-2 study included 160 high-risk patients with type 2
diabetes and microalbuminuria who were randomized to conven-
tional treatment, as provided in general practice, or an intensified
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multifactorial intervention including glucose management, statins,
ACE inhibitors, other antihypertensive agents, aspirin, and lifestyle
interventions (smoking cessation, increased physical activity, and
diet).455 The benefit of the intensive multifactorial intervention
was demonstrated by a significant reduction in the incidence of
microvascular complications after 4 years, and a significant 53%
risk reduction in macrovascular complications after 8 years.455
After a further 5 years of observational follow-up this was asso-
ciated with a significant reduction in cardiovascular mortality.456
Thus in high-risk patients polypharmacological multifactorial inter-
vention is needed to obtain the maximum risk reduction.
Most important new information
† The usual treatment target for HbA1c has been increased from
,6.5% to ,7.0%.
† Aspirin is no longer recommended for primary prevention in
people with diabetes.
Remaining gaps in the evidence
† The most appropriate way of reaching the target HbA1c without
excessive weight gain or hypoglycaemia has not been
established.
† The possible cardiovascular benefits of new antidiabetic drugs
with low risks of hypoglycaemia, such as dipeptidyl peptidase-4
inhibitors, which are weight neutral, or glucagon-like peptide 1
receptor agonists, which are associated with weight loss, are
currently being studied in RCTs.
4.9 Lipids
Key messages
† Increased plasma cholesterol and LDL cholesterol are among
the main risk factors for CVD.
† Hypertriglyceridaemia and low HDL cholesterol are independ-
ent CVD risk factors.
† Statin therapy has a beneficial effect on atherosclerotic CVD
outcomes.
4.9.1 Introduction
Genetic and pathological studies, as well as observational and
interventional studies, have established the crucial role of dyslipi-
daemia, especially hypercholesterolaemia, in the development of
CVD.
In blood plasma, lipids such as cholesterol and triglycerides
are bound to various proteins (apoproteins) to form lipopro-
teins. HDLs do not cause atherosclerosis; on the contrary,
they have antiatherogenic properties. In contrast, LDLs, particu-
larly small, dense LDLs, are atherogenic. Chylomicrons and very
low-density LDLs (VLDLs) are not atherogenic but high concen-
trations of these triglyceride-rich lipoproteins can cause
pancreatitis.
4.9.2 Low-density lipoprotein cholesterol
Most of the cholesterol in blood plasma is normally carried in LDLs
and, over a wide range of cholesterol concentrations, there is a
strong and graded positive association between total as well as
Recommendations on management of hyperlipidaemia
Recommendations Classa Levelb GRADE Ref C
The recommended target levels are <5 mmol/L (less than ~190 mg/dL) for total plasma cholesterol and 
<3 mmol/L (less than ~115 mg/dL) for LDL cholesterol for subjects at low or moderate risk.
I A Strong 457,458
In patients at high CVD risk, an LDL cholesterol goal <2.5 mmol/L (less than ~100 mg/dL) is recommended. I A Strong 459–461
In patients at very high CVD risk, the recommended LDL cholesterol target is <1.8 mmol/L (less than ~70 mg/dL) 
or a ≥50% LDL cholesterol reduction when the target level cannot be reached. I A Strong
459, 462, 
463
All patients with familial hypercholesterolaemia must be recognized as high-risk patients and be treated with 
lipid-lowering therapy.
I A Strong 464, 465
In patients with an ACS, statin treatment in high doses has to be initiated while the patients are in hospital. I A Strong 466–468
Prevention of non-haemorrhagic stroke: treatment with statins must be started in all patients with established 
atherosclerotic disease and in patients at high risk for developing CVD. Treatment with statins must be started 
in patients with a history of non-cardioembolic ischaemic stroke. 
I A Strong 469, 470
Occlusive arterial disease of the lower limbs and carotid artery disease are CHD risk-equivalent conditions and 
lipid-lowering therapy is recommended.
I A Strong 471, 472
Statins should be considered as the first-line drugs in transplant patients with dyslipidaemia. IIa B Strong 473
Chronic kidney disease (stages 2–5, i.e. GFR <90 mL/min/1.73 m2) is acknowledged as a CHD risk-equivalent and 
the LDL cholesterol target in these patients should be adapted to the degree of renal failure.
IIa C Strong 474




Joint ESC Guidelines 1683







LDL cholesterol and risk of CVD.457 This association applies to
individuals (women as well as men) without CVD as well as to
patients with established disease.
The evidence that reducing plasma LDL cholesterol reduces
CVD risk is unequivocal; the results of epidemiological studies as
well as trials with angiographic or clinical endpoints confirm that
the reduction of LDL cholesterol must be of prime concern in
the prevention of CVD.42
Meta-analyses of many trials show a clear dose-dependent rela-
tive reduction in CVD with LDL cholesterol lowering. Every
1.0 mmol/L reduction in LDL cholesterol is associated with a cor-
responding 20–25% reduction in CVD mortality and non-fatal
myocardial infarction. More recently trials have confirmed that
lowering LDL cholesterol to ≤1.8 mmol/L (70 mg/dL) is asso-
ciated with the lowest risk of recurrent CVD events in secondary
prevention populations.459 Therefore, for very high-risk subjects,
the target LDL cholesterol level should be ,1.8 mmol/L
(70 mg/dL) or a ≥50% reduction from baseline LDL cholesterol.
4.9.3 Apolipoprotein B
Because apoB (the main apoprotein of atherogenic lipoproteins)
levels have so frequently been measured in outcome studies in par-
allel with LDL cholesterol, apoB can be substituted for LDL chol-
esterol,475 but it does not add further to the risk assessment.
Based on the available evidence, it appears that apoB is a similar
risk marker to LDL cholesterol and a better index of the adequacy
of LDL-lowering therapy.476 Also, there appears to be less labora-
tory error in the determination of apoB than LDL cholesterol, par-
ticularly in patients with hypertriglyceridaemia, and laboratories
could easily and inexpensively provide standardized measurements
of apoB. However, apoB is not presently being measured in most
laboratories but, if measured, it should be ,80 and ,100 mg/dL
for subjects with very high or high CVD risk, respectively.
4.9.4 Triglycerides
Hypertriglyceridaemia is a significant independent CVD risk factor,
but it seems that the association is not as strong as for hyperchol-
esterolaemia.55 The risk is associated more strongly with moderate
than with very severe hypertriglyceridaemia (.10 mmol/L or
900 mg/dL), which is on the other hand a risk factor for pancrea-
titis. There are, however, no randomized trials to provide sufficient
evidence to derive target levels for triglycerides.
At present, fasting triglycerides .1.7 mmol/L (150 mg/dL)
continue to be considered as a marker of increased risk, but con-
centrations ≤1.7 mmol/L are not evidence-based target levels for
therapy. There is evidence that non-fasting triglycerides may
predict CHD risk even better, as individuals are in the post-
prandial state most of the time.477 However, due to the lack of
standardization, measuring non-fasting triglycerides is not
recommended.
4.9.5 High-density lipoprotein cholesterol
Low concentrations of HDL cholesterol are independently asso-
ciated with higher CVD risk, therefore HDL cholesterol is also
included in new SCORE charts.478 The combination of moderately
elevated triglycerides and low concentrations of HDL cholesterol
is very common in high-risk patients with type 2 diabetes,
abdominal obesity, insulin resistance, and who are physically in-
active. It is part of a pattern of deranged plasma lipoproteins char-
acterized by a triad of increased triglycerides, the presence of
small, dense, and very atherogenic LDL particles, and low concen-
trations of HDL cholesterol. Low concentrations of HDL choles-
terol may even rival hypercholesterolaemia (due to high
concentrations of LDL cholesterol) as a risk factor for CHD.479
However, there is still not sufficient scientific evidence for any
HDL cholesterol value to be considered as a goal of therapy, al-
though HDL cholesterol ,1.0 mmol/L (40 mg/dL) in men and
,1.2 mmol/L (45 mg/dL) in women may be regarded as a
marker of increased risk.
4.9.6 Lipoprotein(a)
Lipoprotein(a) is a low-density lipoprotein to which is attached an
additional protein called apolipoprotein(a). High concentrations of
Lp(a) are associated with increased risk of CHD and ischaemic
stroke, although there is no randomized intervention showing
that reducing Lp(a) decreases CVD risk.480 There is no justification
for screening the general population for Lp(a) at present, and no
evidence that any value should be considered as a target.
4.9.7 Apolipoprotein B/apolipoprotein A1 ratio
Apolipoprotein A1 (apoA1) is the major apoprotein of HDL. It is
beyond doubt that the apoB:apoA1 ratio is one of the strongest
risk markers.475,481 However, it is still not established whether
this variable should be used as a treatment goal. As the measure-
ment of apolipoproteins is not available to all physicians in Europe,
is more costly than currently used lipid variables, and does not add
more information, its use is not as yet generally recommended.
4.9.8 Calculated lipoprotein variables
Low-density lipoprotein cholesterol
Low-density lipoprotein cholesterol can be measured directly, but
is usually calculated using the Friedewald formula:482
In mmol/L: LDL cholesterol ¼ total cholesterol – HDL choles-
terol – (0.45 × triglycerides)
In mg/dL: LDL cholesterol ¼ total cholesterol – HDL cholesterol
– (0.2 × triglycerides)
The calculation is valid only when the concentration of triglycer-
ides is ,4.5 mmol/L (400 mg/dL) as the triglyceride/cholesterol
ratio in triglyceride-carrying lipoproteins (VLDL and chylomicrons)
progressively increases as hypertriglyceridaemia increases in
severity.
Non-high-density lipoprotein cholesterol
Non-HDL cholesterol comprises the cholesterol in LDL,
intermediate-density lipoprotein, and VLDL particles. Non-HDL
cholesterol predicts CVD risk similarly to or even better than
LDL cholesterol.483 LDL limits may be transferred to non-HDL
limits by adding 0.8 mmol (30 mg/L). Calculated by simply subtract-
ing HDL cholesterol from total cholesterol, non-HDL choles-
terol—unlike LDL cholesterol—does not require the triglyceride
concentration to be ,4.5 mmol/L (400 mg/dL). Therefore, it is
a better measure than calculated LDL cholesterol, particularly
for patients with high non-fasting triglyceride concentrations. Like
apoB, non-HDL cholesterol is a measure of the concentration of
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atherogenic lipoproteins in plasma but it is more readily available
than measurements of apoB and apoA1.
4.9.9 Exclusion of secondary dyslipidaemia
The presence of dyslipidaemias secondary to other conditions
must be excluded before beginning treatment, especially with
drugs, as often the treatment of underlying disease improves
hyperlipidaemia and no other antilipaemic therapy is necessary.
This is particularly true for hypothyroidism.
Secondary dyslipidaemias can also be caused by alcohol abuse,
diabetes, Cushing’s syndrome, diseases of the liver and kidneys,
and several drugs (e.g. corticosteroids, isotretinoin and etretinate,
cyclosporin). Patients who could have genetic dyslipidaemias such
as familial hypercholesterolaemia should, if possible, be referred
for specialist evaluation, which might include a molecular genetic
diagnosis.
4.9.10 Who should be treated and what are the goals?
In general, total plasma cholesterol should be ,5 mmol/L
(190 mg/dL), and LDL cholesterol should be ,3 mmol/L
(115 mg/dL). In subjects with higher CVD risk, the treatment
goals should be lower (see below).
The highest priority for treatment are patients with CVD irre-
spective of their lipid levels.484 In these patients at very high
CVD risk (see page 1653), the LDL cholesterol goal is
,1.8 mmol/L (less than 70 mg/dL) or a ≥50% LDL cholesterol
reduction when the target level cannot be reached.
In patients at high CVD risk (see page 1653), an LDL cholesterol
goal ,2.5 mmol/L (less than 100 mg/dL) should be considered.
In subjects at moderate risk (a SCORE level ≥1 to ,5%), an
LDL cholesterol goal ,3.0 mmol/L (less than 115 mg/dL)
should be considered.
In asymptomatic individuals, the first step is to assess total
cardiovascular risk and to identify those components of risk that
are to be modified.42 Risk assessment should be repeated at
5-year intervals if the absolute CVD risk is low and/or there are
no significant changes in the recommended values of the major
risk factors.
The assessment of total risk does not pertain to patients with
familial hypercholesterolaemia, since total cholesterol .8 mmol/
L (320 mg/dL) and LDL cholesterol .6 mmol/L (240 mg/dL)
by definition places such patients at high total risk of CVD. Familial
hypercholesterolaemia is a dominantly inherited condition affecting
1 in 500 people of European descent (heterozygous) most com-
monly caused by a mutation of the LDL receptor, and is character-
ized by very high levels of LDL cholesterol (usually 5–10 mmol/L
or 200–400 mg/dL).42
The benefit of cholesterol-lowering therapy depends on initial
levels of risk: the higher the risk, the greater the benefit
(Table 16). There are no differences in beneficial effects of choles-
terol lowering between men and women and between younger







70 to <100 mg/dL
1.8 to <2.5 mmol/L
100 to <155 mg/dL
2.5 to <4.0 mmol/L
155 to <190 mg/dL
4.0 to <4.9 mmol/L
>190 mg/dL
>4.9 mmol/L
<1 No lipid intervention No lipid intervention Lifestyle intervention Lifestyle intervention
Lifestyle intervention, 
consider drug if 
uncontrolled
Classa/Levelb I/C I/C I/C I/C IIa/A
≥1 to <5 Lifestyle intervention Lifestyle intervention
Lifestyle intervention, 
consider drug if 
uncontrolled
Lifestyle intervention, 
consider drug if 
uncontrolled
Lifestyle intervention, 
consider drug if 
uncontrolled
Classa/Levelb I/C I/C IIa/A IIa/A I/A






and immediate drug 
intervention
Lifestyle intervention
and immediate drug 
intervention
Lifestyle intervention
and immediate drug 
intervention
Classa/Levelb IIa/A IIa/A IIa/A I/A I/A




and immediate drug 
intervention
Lifestyle intervention
and immediate drug 
intervention
Lifestyle intervention
and immediate drug 
intervention
Lifestyle intervention
and immediate drug 
intervention
Classa/Levelb IIa/A IIa/A I/A I/A I/A
Reference table.42
CV ¼ cardiovascular; LDL ¼ low-density lipoprotein.
aClass of recommendation.
bLevel of evidence.
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and older age groups, even individuals .75 years of age, although
the benefits in healthy women are not proven.485
Although low HDL cholesterol is an independent risk factor for
CVD, no specific treatment goals are as yet defined, but may be
considered at concentrations ,1.0 mmol/L (40 mg/dL) in men
and ,1.2 mmol/L (45 mg/dL) in women. Similarly, fasting trigly-
cerides should be .1.7 mmol/L (150 mg/dL).
4.9.11 Patients with peripheral artery disease
Occlusive arterial disease of the lower limbs and carotid artery
disease are CHD risk-equivalent conditions, and lipid-lowering
therapy is recommended in these patients irrespective of their
plasma lipid levels.472,486 However, increased carotid IMT
without evidence of atherosclerotic plaques is not an indication
for lipid-lowering treatment in patients without proven CVD or
other risk factors.
Although abdominal aortic aneurysm is also a CHD
risk-equivalent condition, there is no conclusive evidence that
treatment with statins reduces perioperative CVD morbidity and
mortality in these patients.220,487 The benefit of lipid-lowering
treatment in atherosclerosis in other types of arteries (e.g.
retinal arteries) remains to be proven.488
4.9.12 Stroke prevention
In contrast to earlier observations, recent studies have now shown
that high cholesterol levels are a risk factor for ischaemic but not
haemorrhagic stroke.489 Major statin trials reported significant
reductions in stroke rates in patients with CHD or at high risk
due to a reduction in the rates of ischaemic stroke.469 Increased
concentrations of triglycerides and low HDL cholesterol are also
associated with non-haemorrhagic stroke.490,491 Therefore,
patients with ischaemic cerebrovascular disease merit the same
degree of attention to treatment of plasma lipids as do patients
with CHD.
In the prevention of stroke, treatment with statins should be
started in all patients with established atherosclerotic disease and
in patients at high risk for developing CVD. After a cerebrovascular
event, statins should be started in patients with a history of non-
cardioembolic ischaemic stroke or transient ischaemic attack for
prevention of further cardiovascular events but should be
avoided following haemorrhagic stroke unless there is evidence
of atherosclerotic disease or high CVD risk.
4.9.13 Patients with kidney disease
Chronic kidney disease is characterized by mixed dyslipidaemia (high
triglycerides, high LDL cholesterol, and low HDL cholesterol).492
Microalbuminuria is a risk factor for CVD, which rises progressively
from a normal GFR to end-stage renal disease. CKD (stages 2–5,
i.e. GFR ,90 mL/min/1.73 m2) is acknowledged as a CHD
risk-equivalent, and the LDL cholesterol target in these patients
has been adapted to the degree of renal failure (see page 1653).42
The statin dose should be modified according to GFR. Statin
therapy has a beneficial effect on CVD outcomes in CKD stages
2 and 3 and slows the rate of kidney function loss.493
4.9.14 Transplant patients
Dyslipidaemia is common in patients who have undergone organ
transplantation due to a combination of factors relating to the
underlying disease, lifestyle, and treatments, including immunosup-
pressive therapy. CVD risk management is a priority in this patient
population, and pharmacotherapy is commonly required. Statins
are recommended as the first-line drugs.
Initiation should be at low doses with careful up-titration and
with caution regarding potential drug–drug interactions, particu-
larly for those on cyclosporin. In patients who are intolerant of
statins or who have significant dyslipidaemia and a high residual
risk despite a maximally tolerated dose of statin, an alternative
or additional therapy may be considered: ezetimibe for those
with high LDL cholesterol as the main finding, fibrates (with
caution if in combination with a statin) or niacin for those with
hypertriglyceridaemia and/or low HDL cholesterol.494
4.9.15 Patients with an acute coronary syndrome
In all patients with an ACS, statin treatment in high doses has to be
initiated as early as possible while the patients are in the hospital,
aiming to reach the LDL cholesterol level of ,1.8 mmol/L
(70 mg/dL).466,467 The early drug treatment should be combined
with effective lifestyle changes and particularly dietary counselling
after hospital discharge. Blood lipids should be checked 4–6
weeks after the ACS to determine whether the target level has
been reached and the treatment has to be continued with the
same dose or the dose should be adapted accordingly.
4.9.16 Drugs
The currently available lipid-lowering drugs include inhibitors of 3--
hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates,
bile acid sequestrants (anion exchange resins), niacin (nicotinic
acid), and selective cholesterol absorption inhibitors (e.g.
ezetimibe).
Statins, by decreasing LDL cholesterol, reduce cardiovascular
morbidity and mortality as well as the need for coronary artery
interventions.166,436 Statins at doses that effectively reduce LDL
cholesterol by 50% also seem to halt progression or even contrib-
ute to regression of coronary atherosclerosis.495 Therefore, they
should be used as the drugs of first choice in patients with hyper-
cholesterolaemia or combined hyperlipidaemia.
Higher activity of liver enzymes in plasma occurs occasionally,
and in most cases is reversible: 5–10% of patients receiving
statins develop myopathy, but rhabdomyolysis is extremely rare.
The risk of myopathy can be minimized by identifying vulnerable
patients and/or by avoiding statin interactions with specific drugs
(Table 17). Because statins are prescribed on a long-term basis,
possible interactions with other drugs deserve particular and con-
tinuous attention, as many patients will receive pharmacological
therapy for concomitant conditions.496
In general, the safety profile of statins is acceptable, and earlier
observations that lipid-lowering treatment may contribute an in-
crease in non-cardiovascular mortality (e.g. cancers, suicides, de-
pression) or mental disorders have not been confirmed. There
are reports indicating increased blood sugar and HbA1c levels,
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i.e. increased risk of type 2 diabetes, as a possible adverse effect of
long-term statin therapy, but the benefits of statins far outweigh
the risks for the vast majority of patients.497,498
Non-statin treatment: selective cholesterol absorption inhibitors
are not used as monotherapy to decrease LDL cholesterol con-
centrations. Bile acid sequestrants also decrease total and LDL
cholesterol but tend to increase triglyceride concentrations.
Fibrates and niacin are used primarily for triglyceride lowering
and increasing HDL cholesterol, while fish oils (omega-3 fatty
acids) in doses of 2–4 g/day are used for triglyceride
lowering.479,499
When triglycerides exceed 10 mmol/L (900 mg/dL), in order
to prevent pancreatitis triglycerides must be reduced not only by
drugs but also by restriction of alcohol, treatment of diabetes
with insulin, withdrawal of oestrogen therapy, etc. In the rare
patients with severe primary hypertriglyceridaemia, it is necessary
to restrict absolutely the intake of alcohol and severely restrict
long-chain fat of both animal and vegetable origin. Fibrates are
the drugs of choice for these patients, and prescription omega-3
fatty acids might be added if elevated triglycerides are not
decreased adequately.
4.9.17 Drug combinations
Patients with dyslipidaemia, particularly those with established
CVD, diabetes, or asymptomatic high-risk individuals, may not
always reach treatment targets. Therefore, combination treatment
may be needed.
Combinations of a statin and a bile acid sequestrant or a combin-
ation of a statin and ezetimibe can be used for greater reduction of
LDL cholesterol than can be achieved with either drug alone.
Another advantage of combination therapy is that lower doses
of statins can be used, thus diminishing the risk of adverse
effects associated with high doses. However, statins should be
used in the highest tolerable doses to reach the LDL cholesterol
target level before combination therapy.500
Combinations of niacin and a statin increase HDL cholesterol
and decrease triglycerides better than either of these drugs
alone, but flushing is the main adverse effect of niacin, which
may affect compliance. Adding laropiprant to niacin might help in
reducing the incidence of this adverse effect.
Fibrates, particularly fenofibrate, may be useful, not only for de-
creasing high triglyceride concentrations and increasing low HDL
cholesterol, but can further lower LDL cholesterol when applied
together with a statin. Other drugs metabolized through cyto-
chrome P450 should be avoided when this combination is pre-
scribed. Fibrates should preferably be taken in the morning and
statins in the evening to minimize peak dose concentrations and
decrease the risk of myopathy. Patients have to be instructed
about warning symptoms (myalgia) even though these adverse
effects are very rare. Avoiding the addition of gemfibrozil to a
statin regimen is advised.
If target levels cannot be reached even on maximal doses of
lipid-lowering therapy or drug combinations, patients will still
benefit from treatment to the extent to which dyslipidaemia has
been improved. In these patients, increased attention to other
risk factors may help to reduce total risk.
4.9.18 Low-density lipoprotein apheresis
Rare patients with severe hypercholesterolaemia, especially homo-
zygous familial hypercholesterolaemia, require specialist evaluation
of the need for LDL apheresis. By this demanding and expensive
but effective technique, LDL is removed from plasma during extra-
corporeal circulation, weekly or every other week. LDL apheresis
should be combined with treatment with lipid-lowering drugs.
Most important new information
† LDL cholesterol is recommended as the primary lipid analysis
for screening and risk estimation as well as target for treatment.
† HDL cholesterol is also a strong risk factor and is recommended
to be used for risk estimation, but is not recommended as a
target for treatment.
Remaining gaps in the evidence
† There is still insufficient evidence for any triglyceride or HDL
cholesterol value to be considered as the target for therapy
that would reduce CVD events and mortality.
† There is insufficient evidence to prove whether Lp(a) lowering
against background statin therapy can reduce the risk of CVD.
† Non-HDL cholesterol is a better measure than calculated LDL
cholesterol, but there is as yet no information on the practical
implication.
† Evidence is lacking that some functional foods with a
lipid-lowering effect can reduce the risk of CVD.
† There are insufficient data to prove whether combination treat-
ment with different lipid-lowering drugs can reduce the risk of
CVD events and mortality.
Table 17 Selected drugs that may increase risk of
myopathy and rhabdomyolysis when used
concomitantly with statin (CYP3A4 inhibitors/
substrates or other mechanisms)
Cyclosporin, tacrolimus
Macrolides (azithromycin, clarithromycin, erythromycin)
Azole antifungals (itraconazole, ketoconazole, fluconazole)
Calcium antagonists (mibefradil, diltiazem, verapamil)
Nefazodone




 Digoxin, niacin, fibrates (particularly gemfibrozil)
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4.10.1 Antiplatelet therapy in individuals without overt
cardiovascular disease
Primary prevention in individuals without overt cardiovascular or
cerebrovascular disease was investigated using long-term aspirin
vs. control in a systematic review of six trials including 95 000 indi-
viduals. A risk reduction from 0.57% to 0.51% per year of serious
vascular events was found by the Antithrombotic Trialists’ Collab-
oration.507 This 12% proportional risk reduction was due mainly to
a reduction in non-fatal myocardial infarction. There was a slight
increase in haemorrhagic stroke and a reduction of ischaemic
stroke. The net effect on stroke was not statistically significant.
Major gastrointestinal and extracranial bleeds increased by 0.03%
per year. Risk of vascular mortality was not changed by treatment
with aspirin. Aspirin cannot be recommended in primary preven-
tion due to its increased risk of major bleeding. In individuals
with multiple risk factors, clopidogrel was tested vs. aspirin in
the Clopidogrel for High Athero-thrombotic Risk and Ischemic
Stabilisation, Management, and Avoidance (CHARISMA) trial and
was not of significant benefit.514
4.10.2 Antiplatelet therapy in individuals with overt
cardiovascular or cerebrovascular disease
In the acute state of cerebral ischaemia, aspirin reduced the risk of
new vascular events within 2–4 weeks (RR 0.78, 95% CI 0.76–
0.80) by preventing four recurrent strokes and five vascular
deaths per 1000 patients treated.515
Following an episode of acute coronary ischaemia [unstable
angina, NSTEMI, ST-elevation myocardial infarction (STEMI)],
dual antiplatelet therapy with clopidogrel and aspirin reduced the
risk of myocardial infarction, stroke, and death over 14 days
from 10.1% to 9.2% (P ¼ 0.002) in STEMI [Clopidogrel and Meto-
prolol in Myocardial Infarction Trial (COMMIT)],504 and from 6.4%
to 4.5% (P ¼ 0.03) over a period of 8 months in NSTEMI patients
[Clopidogrel in Unstable Angina to Prevent Recurrent Events
(CURE)].505
In patients with ACS for whom an early invasive strategy is
planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor
or prasugrel) added to aspirin was superior to clopidogrel and
aspirin. With ticagrelor given for 12 months the composite end-
point of death from vascular causes, myocardial infarction, or
stroke occurred in 9.8% as compared with 11.7% of those receiv-
ing clopidogrel (HR 0.84, 95% CI 0.77–0.92; P, 0.001). No signifi-
cant difference in rate of major bleeding was found.501 –503
With prasugrel, the primary efficacy endpoint occurred in 9.9%
of patients as compared with 12.1% receiving clopidogrel (HR 0.81,
95% CI 0.73–0.90; P, 0.001). The risk of major bleeding was
increased with prasugrel.501
In long-term secondary prevention after myocardial infarction,
stroke, or PAD, aspirin is the most studied drug. In a meta-analysis
of 16 trials comprising 17 000 individuals, the Antithrombotic Tri-
alists’ Collaboration, 2009507 found that allocation to aspirin was
associated with serious vascular events in 6.7% of patients per
year vs. 8.2% of controls. The risk of total stroke was 2.08% per
year vs. 2.59% (P ¼ 0.002) and coronary events 4.3% per year
vs. 5.3% (P ¼ 0.0001). Aspirin was associated with a 10% reduction
in total mortality (RR 0.90, 95% CI 0.82–0.99), and was also asso-
ciated with a significant excess of major bleeds; nevertheless, the
benefits of aspirin exceeded the bleeding hazards.
In patients with prior myocardial infarction, stroke, or peripheral
vascular disease, clopidogrel was tested against aspirin in the Clo-
pidogrel versus Aspirin in Patients at Risk of Ischaemic Events
Recommendations on antithrombotic therapy
Recommendations Classa Levelb GRADE RefC
In the acute phase of coronary artery syndromes and for the following 12 months, dual antiplatelet therapy with a 
P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin is recommended unless contraindicated due to such as 
excessive risk of bleeding. 
I B Strong 501–503
Clopidogrel (600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor 
or prasugrel.
I A Strong 504, 505
In the chronic phase (>12 months) after myocardial infarction, aspirin is recommended for secondary prevention. I A Strong 506, 507
In patients with non-cardioembolic transient ischaemic attack or ischaemic stroke, secondary prevention with 
either dipyridamole plus aspirin or clopidogrel alone is recommended. 
I A Strong 508–511
In the case of intolerance to dipyridamole (headache) or clopidogrel, aspirin alone is recommended. I A Strong 506, 507
In patients with non-cardioembolic cerebral ischaemic events, anticoagulation is not superior to aspirin and is not 
recommended.
III B Weak 512, 513
Aspirin or clopidogrel cannot be recommended in individuals without cardiovascular or cerebrovascular disease 
due to the increased risk of major bleeding.












(CAPRIE) trial,509 which showed a slight superiority of clopidogrel;
the rate of serious vascular events was 5.32% per year with clopi-
dogrel vs. 5.83% with aspirin (P ¼ 0.043). There were slightly more
bleeds with aspirin.
Dual antiplatelet therapy with clopidogrel plus aspirin vs. clopi-
dogrel in patients with transient ischaemic attack and ischaemic
stroke was associated with an excess of serious bleeds in the Man-
agement of Atherothrombosis with Clopidogrel in High-risk
Patients with Recent Transient Ischaemic Attack or Ischaemic
Stroke (MATCH) trial,510 and is not recommended in cerebral
ischaemia.
In patients with prior non-cardioembolic ischaemic stroke, dual
antiplatelet therapy with dipyridamole plus aspirin showed super-
iority over aspirin.511 In such patients oral vitamin K antagonists
are not superior to aspirin but are associated with a higher bleed-
ing risk.512,513
In patients with transient ischaemic attack or ischaemic stroke, a
direct comparison of dipyridamole plus aspirin vs. clopidogrel
alone508 showed that the two regimens had similar rates of recur-
rent stroke, including haemorrhagic stroke (916 vs. 898; HR 1.01,
95% CI 0.92–1.11). There was a higher frequency of major haem-
orrhagic events with dipyridamole plus aspirin (4.1% vs. 3.6%).
Stroke, myocardial infarction, and vascular death occurred in
13.1% in both groups. The two regimens may be considered
equivalent.
Finally for the guidance on the use of cardioprotective drugs
after acute coronary syndromes we refer to the existing guidelines
for this condition; it will not be dealt with in the prevention
guidance.
4.10.3 Antithrombotic therapy in atrial fibrillation
Stroke is the most serious complication of AF. AF is often unrec-
ognized and untreated in patients admitted with acute ischaemic
stroke. Recommendations for antithrombotic therapy should be
based on the presence (or absence) of risk factors for stroke
and thrombo-embolism, and we refer further to the recent guide-
lines of the Task Force for the Management of Atrial Fibrillation of
the European Society of Cardiology.516,517
Most important new information
† In patients with ACS, dual antiplatelet therapy with a P2Y12 in-
hibitor plus aspirin is superior to clopidogrel plus aspirin.
Remaining gaps in the evidence
† Long-term experience with new antiplatelet drugs is still limited.
4.11 Adherence
Key messages
† Adherence to medication in individuals at high risk and in
patients with CVD is still low.
† Several types of interventions are effective in improving medica-
tion adherence.
4.11.1 Why do patients not adhere to prescribed
medication?
Numerous studies have shown that adherence to medication in
individuals at high risk and in patients with CVD is low, resulting
in worse outcomes and higher healthcare costs. For example, 1
month after acute myocardial infarction, 25–30% of patients
Recommendations on patients adherence
Recommendations Classa Levelb GRADE Ref C
Physicians must assess 
adherence to medication, 
and identify reasons for non-
adherence in order to tailor 
further interventions to the 
individual needs of the patient 




In clinical practice, reducing 
dosage demands to the 
lowest acceptable level is 
recommended. In addition, 
repetitive monitoring 
and feedback should be 
implemented. If feasible, 
multisession or combined 
behavioural interventions 
should be offered in the case 
of persistent non-adherence.




Table 18 Reasons for medication non-adherence





Poor quality of provider–patient relationship; 
poor knowledge on medication and/or low 
acceptance of guidelines; poor communication 
(e.g. limited, complex, or confusing advice); lack 
of access to healthcare; lack of continuity of care.
Condition
Asymptomatic chronic disease (lack of physical 
cues); co-morbid mental health disorders 
(e.g. depression).
Patient
Physical impairments (e.g. vision problems 
or impaired dexterity); cognitive impairment; 
psychological/behavioural factors (e.g. lack of 
motivation, low self-efficacy, impulsivity); 
younger age.
Therapy Complexity of regimen; side effects.
Socio-economic
Low literacy; high medication costs; poor social 
support.
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stop at least one medication, with a progressive decline in adher-
ence over time. After 1 year, ,50% of patients report persistent
use of statins, beta-blockers, or antihypertensive therapy.518,519
The reasons for poor adherence are multifactorial. As outlined
in Table 18, the WHO has categorized potential reasons for medi-
cation non-adherence into five broad groupings that include health
system-related, condition, patient, therapy, and socio-economic
factors.518
Cost-related medication non-adherence is a relevant problem in
many healthcare systems, especially in the elderly and people of
low socio-economic status. For example, in American veterans, ad-
herence to lipid-lowering medication decreased as co-payment
increased.521 Even the implementation of Medicare Part D in
order to spend on basic needs could not reduce cost-related medi-
cation non-adherence among the sickest beneficiaries. Depression
also doubles the risk for medication non-adherence, even after
control for age, ethnicity, education, social support, and measures
of cardiac disease severity.522
Reasons for non-adherence tend to cluster; for example,
complex medication regimens may be important in individuals
with chronic, asymptomatic disease or multiple risk factors, who
are lacking motivation and a clear understanding of the therapeutic
regimen. This situation places high demands on the physician to
provide explicit and clear advice and continuous care.519
However, physicians might fail to communicate critical elements
of medication use (e.g. possible adverse effects, how long to take
the medication, and the frequency or timing of dosing).523 Thus
there is need to train physicians to identify risk factors for non-
adherence and promote adherence to medication.
A recent systematic review has shown that several types of
interventions are effective in improving adherence in chronic
medical conditions; however, effect sizes on adherence varied
and so did medical outcome.520 Solely reducing dosage demands
resulted in strong effects (effect size 0.89–1.20), but other inter-
ventions such as repetitive monitoring and feedback (effect size
0.27–1.2), multisession information (effect size 0.35–1.13), and
combined behavioural interventions (effect size 0.43–1.20) have
shown effects ranging from low to strong.520
In clinical practice, physicians should assess adherence to medi-
cation, identify reasons for possible non-adherence, and promote
adherence according to established principles (Table 19).
In addition, as adherence with placebo also improves survival,524
physicians should be aware that adherence to medication may
reflect generally better health behaviour. Therefore, measures
should be taken to improve adherence and health behaviour in
general (see Section 4.1).
Reducing dosage demands in persons at high CVD risk may
result in the prescription of combination pharmacotherapy, the
‘polypill’.525,526 Recently, a randomized phase II trial in middle-aged
individuals without CVD demonstrated that the ‘Polycap’ formula-
tion could conveniently reduce multiple risk factors.527
Most important new information
† Evidence suggests that reducing dosage demands is the most
effective single approach to enhancing medication adherence.
Gaps in the evidence
† There is limited evidence about which interventions are the
most effective in whom (e.g. young–old, male–female, high–
low socio-economic status).
† The ‘polypill’ requires further evaluation before it can be judged
suitable for use in routine care.
5. Where should programmes be
offered?
Key message
† Cardiovascular disease is the single most important cause of
death for both men and women and can often be prevented!Table 19 Recommendations for promoting
medication adherence
• Provide clear advice regarding the benefits and possible adverse 
 effects of the medication, and the duration and timing of dosing.
• Consider patients’ habits and preferences.
• Reduce dosage demands to the lowest feasible level.
• Ask patients in a non-judgemental way how the medication works 
 for them, and discuss possible reasons for non-adherence (e.g. side 
 effects, worries).
• Implement repetitive monitoring and feedback.
• In the case of lack of time, introduce physicians assistants and/or 
 trained nurses whenever its necessary and feasible.
• In the case of persistent non-adherence, offer multisession or 
 combined behavioural interventions.
Recommendation on programme provision
Recommendations Classa Levelb GRADE Ref C
Actions to prevent 
cardiovascular disease 
should be incorporated 
into everyone’s daily lives, 
starting in early childhood 
and continuing throughout 
adulthood and senescence.













As mentioned in Section 2, prevention of CVD is a lifetime ap-
proach, starting ideally before birth by educating young parents,
and continuing in the pre-school age (kindergarten) and through-
out the advancing grades of the school system. During this
phase, the emphasis should be on conveying the pleasures of
healthy nutrition and the joys and feelings of wellbeing associated
with physical activity, rather than focusing on the prevention of
disease. Beginning in the sixth grade (age 11–12 years—or even
earlier, depending on the social environment), non-smoking behav-
iour should be actively encouraged.
In the adult age group—depending on the healthcare system—
different options are available to promote risk-adjusted prevention:
nurse-based activities in the community, preventive efforts of
general practitioners and practising cardiologists, hospital-based
programmes, and society-based programmes.
In addition, legislative activities, such as restricting the use of
trans fatty acids or protecting non-smokers from ‘second-hand’
smoke, banning tobacco commercials, and programmes to increase
risk factor awareness produced by non-governmental organiza-
tions and medical societies, can ideally supplement each other in
striving for a healthy population.
After a cardiovascular event, secondary preventive efforts within
a structured rehabilitation programme have been shown to be par-
ticularly important and cost-effective.
All of these programmes are important components for pre-
venting CVD, but to improve the health status of the citizens of
our communities we cannot rely on our health system alone; as
Brown and O’Connor formulated it: ‘We need to create healthy
communities and incorporate prevention into our daily lives as
health care providers and citizens.’529
Most important new information
† Smoking bans in public places, by law, lead to a decrease in in-
cidence of myocardial infarction.
5.1 Cardiovascular disease prevention in
primary care: role of nurses
Key message
† Nurse-co-ordinated prevention programmes are effective
across a variety of practice settings.
Nurse case management models tested in several randomized
trials of secondary prevention have shown significant improve-
ments in risk factors, exercise tolerance, glucose control, and ap-
propriate medication use, along with decreases in cardiac events
and mortality, regression of coronary atherosclerosis, and
improved patient perception of health compared with usual
care.530,531 Other studies have demonstrated the effectiveness of
nurse-led prevention clinics in primary care compared with usual
care, with greater success in secondary as opposed to primary pre-
vention.532 –534
5.1.1 Nurse-co-ordinated prevention programmes
effective in various healthcare systems
A nurse-co-ordinated multidisciplinary prevention programme in
both hospitals and primary care practices was evaluated in the
EUROACTION trial studying patients with CHD and those at
high risk of CVD in eight countries.35 The approach was family
centred and led to healthier lifestyle changes in terms of diet
and physical activity, improvements in lifestyle (diet and physical ac-
tivity), and more effective control of risk factors such as blood
pressure in both patients and their partners in the intervention
arm compared with usual care. A particular strength of the pro-
gramme was the demonstration of the feasibility of this type of
programme in hospitals and in general practice, outside of specialist
centres, and in eight different healthcare systems across Europe.
Differences are found in the degree of effectiveness of various
nurse-led programmes, which could reflect an inadequate dose
of the intervention, inconsistencies in the components of the inter-
vention, or lack of specific expertise, as well as the inherent diffi-
culty in achieving meaningful change in multiple factors. Nurse
case management models which were more intensive with more
sustained contact have shown the most successful outcomes, in-
cluding regression of atherosclerosis and decreased cardiac
events.535 The EUROACTION trial consisted of eight visits with
a multidisciplinary team, and attendance at a group workshop
and supervised exercise class over a 16-week period; other
studies have evaluated interventions of shorter duration.
5.1.2 Sustained contact is necessary for lifestyle change
Strategies used to elicit behavioural change and healthy lifestyles in
various trials included individualized assessment, risk communica-
tion, shared decision-making, inclusion of family, goal setting, indi-
vidual and group education, and motivational interviewing. Because
of differing intensity, duration, and intervention components in
these trials, the optimal ‘dose’ of contact or most effective and
cost-effective components needed for long-term results are not
known, or how they may vary by patient characteristics. Type
and duration of training for nurses to deliver the intervention
also differed in these trials, as has the involvement of multidiscip-
linary teams. The success of the interventions despite these differ-
ences support the basic concept that more sustained contact is
necessary to achieve changes in lifestyle and improvement of com-
pliance. Further research is needed to determine the optimal
format of interventions necessary to achieve sustained risk reduc-
tion, and how these can be titrated and adapted for people with
different risks and healthcare needs in a variety of healthcare and
community settings. Although there is evidence that these
Recommendation on nurse-co-ordinated care
Recommendations Classa Levelb GRADE Ref C
Nurse-co-ordinated 
prevention programmes 
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models are likely to be cost-effective,536,537 this needs further
evaluation, as does the greater challenge of conveying risk and
changing behaviours in primary prevention.
A recent consensus document led by the Preventive Cardiovas-
cular Nurses Association, the Council on Cardiovascular Nursing
and Allied Professions (CCNAP), and the Cardiovascular
Nursing Council of the AHA has issued a call to action for
nurses for greater activity in CVD prevention.531 This document
reviews the worldwide need for prevention, the evidence support-
ing nurse-led or co-ordinated programmes, life-course prevention,
public health and multilevel policies, and preparation for nurses as-
suming active roles in CVD prevention.
The evidence shows that nurse case management and
nurse-co-ordinated multidisciplinary prevention programmes are
more effective than usual care in reducing cardiovascular risk,
and can be adapted to a variety of healthcare settings. Nurses com-
prise a large portion of the healthcare workforce, and their educa-
tional preparation in many countries includes a focus on patient
education and counselling, communication, and achievement of be-
havioural change, which are the skills required for prevention pro-
grammes. Nurses are also viewed by the public as credible sources
of information and help, and nursing roles typically include co-
ordination of care and collaboration with multiple providers.
One challenge in Europe for this type of programme is the hetero-
geneity of different healthcare systems as well as the heterogeneity
of nursing education and practice across countries, and acceptance
of nurses moving beyond less autonomous traditional roles.
However, the need for effective prevention programmes is undeni-
able, and the evidence shows that nurses can successfully lead or
co-ordinate such schemes in a variety of settings.
Most important new information
† Nurse-led clinics or nurse-co-ordinated multidisciplinary pre-
vention programmes are more effective than usual care in redu-
cing cardiovascular risk, in a variety of healthcare settings.
Remaining gaps in the evidence
† The optimal (and most cost-effective) intensity and duration of
individual components of the intervention need to be estab-
lished to achieve sustained risk reduction in patients at high
risk or with vascular disease.
† Research is also needed to determine the knowledge and skills
needed for effective prevention programmes, and the education
required to ensure competence.
5.2 Cardiovascular disease prevention
in general practice
Key messages
† Risk factor screening including the lipid profile may be consid-
ered in adult men ≥40 years old and in women ≥50 years of
age or post-menopausal.42
† The physician in general practice is the key person to initiate, co-
ordinate, and provide long-term follow-up for CVD
prevention.538
General practitioners are critical to the implementation and
success of CVD prevention programmes in Europe. In most coun-
tries, they deliver .90% of consultations and provide most public
health medicine (preventive care, disease screening, chronic
disease monitoring, and follow-up). In the case of CVD prevention
they have a unique role in identifying individuals at risk of but
without established CVD and assessing their eligibility for interven-
tion based on their risk profile.
5.2.1 Identifying individuals at risk
Despite the enormous burden of CVD, many patients remain un-
diagnosed and untreated. Even among patients with established
disease, there are substantial treatment gaps; among patients re-
ceiving lipid-modifying therapy, 43% do not achieve total choles-
terol targets (,4.5 mmol/L, 175 mg/dL) in Europe,5 whereas
64% fail to reach LDL cholesterol targets in the USA.539 There is
also the issue of undermanagement and little improvement over
time in other CVD risk factors such as smoking, high BP, and
obesity.540
The performance of primary prevention of CVD is even worse,
at least partly because of additional difficulties in predicting those
at greater risk who may benefit from treatment interventions. Cal-
culation of global CVD risk involves replacing the ‘classical’ two-
sided classification (yes or no; present or absent) with the
concept of a continuum in risk in the development of CVD
events, such as the SCORE risk charts (see Section 3.1.3). Most
of the current CVD prevention risk calculators focus on short-
term (5 or 10 year) risk, and therefore inevitably are more likely
to classify the elderly as at high risk and the young as at low risk.
The development of lifetime risk calculators is intended to
provide another method for determining cardiovascular risk that
is less dependent on age. Presenting relative as opposed to abso-
lute risk is another option for discussing CVD risk with younger
adults.
5.2.2 Use of risk scoring in clinical practice
A number of studies have investigated the use of prediction rules
and risk calculators by primary care physicians. An ESC survey con-
ducted in six European countries indicates why physicians rely on
their own expertise for the prevention and treatment of CHD: al-
though most cardiologists and physicians (85%) knew they should
base CVD risk assessment on the combination of all CVD risk
factors, 62% of physicians used subjective methods to gauge risk
rather than using risk calculators.541 The most common barriers
to guideline implementation were government or local health
policy (40%), patient compliance (36%), and lack of time (23%).
Suggestions proposed to improve implementation included devel-
opment of clear, easy to use, and simpler guidelines (46%
prompted; 23% unprompted) and financial incentives (24%
unprompted).
Although preferred by many physicians, intuitive assessment
based on personal experience appears to underestimate the real
risk of CVD: physicians (110 general practitioners and 29 inter-
nists) estimated CVD risk as being less severe than detailed in
recommendations provided in the WHO–International Society
of Hypertension guidelines.542,543 Moreover, physicians were less
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willing to prescribe antihypertensive medications to patients iden-
tified as eligible in guidelines.
5.2.3 Barriers to implementing routine risk assessment
In addition to the limitations of risk scoring itself, several barriers
to implementing the existing risk assessments in clinical practice
have been identified by physicians. A survey among general practi-
tioners and internists working in clinical practice in two Swiss
regions revealed that 74% rarely or never used CVD prediction
rules,544 due to fears of oversimplification of risk assessment
(58%) or overuse of medical therapy (54%). More than half of
the physicians (57%) believed that the numerical information
resulting from prediction rules is frequently unhelpful for clinical
decision-making.544 A Dutch qualitative study of the use of risk
tables as a key component of risk assessments for primary preven-
tion reported that physicians’ knowledge of the risk tables and
ability to communicate that knowledge to the patient influenced
their implementation.545
Patients may have a limited understanding of risk tables and how
risk relates to disease development.546 Development of patient
educational materials may increase patient understanding, and
this may also facilitate physician–patient communication. The
length of routine patient consultations, which provides little time
for discussion, is widely recognized as a barrier to conducting
risk assessments.545,547
Physicians are also concerned about overestimating risk in na-
tional populations, which may lead to overuse of medical
therapy.545,547 Results of a Norwegian study suggest that using
the European SCORE assessment would double the number of
individuals who need drugs for primary prevention of CVD.548
Affected individuals would include men and elderly individuals
who would have a higher tendency to require lipid-lowering med-
ications. Increasing numbers of patients receiving medications may
result in higher healthcare costs. However, modelling strategies to
use resources efficiently and to identify 70% of the CVD burden in
the UK have reported that prioritizing patients by estimated CVD
risk may reduce healthcare costs by £45 000 compared with a dia-
betes and hypertension first strategy.547
5.2.4 Methods for improving awareness and
implementation of risk scoring
Improved awareness of global risk scoring is needed in patients,
healthcare providers (relevant clinicians), payers, and politicians, in-
cluding via the lay press. Perceived individual benefit is a key driver
for many patients. Improved implementation of risk scoring may be
improved by using two main approaches: incentives and computer-
ization. Incentives have been shown to be effective in the UK,
where the Quality and Outcomes Framework (QOF) scheme
links primary care income with achievement of specific evidence-
based targets in healthcare delivery.549 The QOF, a form of
performance-related remuneration, introduced a payment for
primary prevention risk scoring of patients on the hypertension
registry in 2009.
Computerization may take one of three approaches and ideally
involves all three. Patient self-assessments may be performed using
online risk-assessment tools such as SCORE. Online
risk-assessment calculators may be used regardless of whether
cholesterol or BP measurements are available. The disadvantage
of this approach is that it requires highly motivated and computer-
literate patients.
Assessment of high-risk patients may be performed using pre-
existing clinic population data, generating a list of individuals
ranked in terms of their likelihood to score highly on a formal vas-
cular risk assessment and enabling physicians to reduce costs by
calling in the most appropriate patients first. This approach
requires a robust electronic patient database and needs significant
financial support; however, it is inclusive of all patients and pro-
vides a rational approach to identifying patients most likely to
derive benefit from treatment in a priority sequence.
Finally, embedded CVD risk calculators automatically provide a
CVD risk score based on data extracted from the patient’s elec-
tronic record. For example, in New Zealand, system improvements
in primary care practice software were highly successful, increasing
the CVD risk assessment screening rate from 4.7% to 53.5% over
12 months (n ¼ 6570);550 integration of a web-based decision-
support system (PREDICT-CVD) with primary care electronic
medical record software improved CVD risk documentation four-
fold in a primary care practice of 3564 patients.551 The weakness of
this approach is the need to have an electronic record, the fact that
data are often missing, and the lack of uniformity in the scoring
method.
5.2.5 Better risk factor management
Although general practice will, in most countries, have a unique
role in screening or identifying patients eligible for CVD primary
prevention, primary care also has an essential role in better mon-
itoring and follow-up in those patients identified as at high risk and
warranting interventions. The implementation strategies for better
uptake of lifestyle advice and therapeutic interventions are
common across primary and secondary care.
Most important new information
† Barriers to implementation of risk-adjusted prevention are mul-
tiple: risk scoring is considered to be time consuming, simplifying
a complex situation, and may result in overmedication.
† Resource spent after risk assessment is more likely to reduce
future healthcare costs.
Remaining gaps in the evidence
† Application of risk scoring in general practice vs. individual risk
factor treatment has not been shown to reduce hard events.
† The use of risk scoring based on electronic patient records is
promising, but needs to be tested in a general practice setting.
5.3 Cardiovascular disease prevention in
primary care: role of the cardiologist
Key messages
† The practising cardiologist should be the advisor in cases where
there is uncertainty over the use of preventive medication or
when usual preventive options are difficult to apply.82,437,552
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† The practising cardiologist should regularly review the discharge
recommendations of the hospital after a cardiac event or
intervention.82,437,552
5.3.1 The cardiologist in general practice: consultant role
Cardiologists working out-of-hospital have an essential role in
CVD prevention, acting as consultants to general practitioners
and general internists. The practising cardiologist has a pivotal
role in the evaluation of patients with cardiovascular problems re-
ferred from the primary care physician. A thorough examination by
a practising cardiologist will often include assessment of exercise
capacity, measurement of ABI, evaluation of cardiac structure
and function by echocardiography, and assessment of preclinical
atherosclerosis by vascular ultrasound. This will in many patients
with perceived low risk often change the risk score profoundly.
Although the identification and basal treatment of risk factors
and advice for lifestyle modification is the task of the general prac-
titioner or the general internist, the practising cardiologist is the
advisor in cases where there is uncertainty about prevention
drug therapy or when the usual preventive modalities are difficult
to apply (e.g. nicotine addiction, resistant obesity, side effects, or
insufficient efficacy of medication).
The advice of a cardiologist is requested when balancing
hormone replacement therapy with symptoms and global cardio-
vascular risk. The cardiologist also advises on treatment with anti-
aggregatory drugs after PCI in patients with an additional need for
oral anticoagulation (e.g. in chronic AF or in patients with mechan-
ical heart valve prostheses).
5.3.2 Implementing evidence-based medicine
The cardiologist is the physician who, based on the current guide-
lines, reviews together with the patient the hospital discharge
recommendations after a cardiac event or an intervention, and
he or she implements the further treatment strategy. The cardiolo-
gist also helps the patient comply with the recommendations, by
providing them with written information and ensuring that, at
given intervals, treatment goals are reached.82,552 This approach
has a significant impact on mid-term prognosis.250,437
The higher the level of care based on the guidelines and per-
formance measures, the better the impact on prevention and re-
current events.82,437
5.3.3 Improving healthcare using electronic records
The increased use of electronic medical records could have a posi-
tive impact on CVD prevention at the practising cardiologist level.
The ability to identify systematically all patients with risk factors,
address and document their barriers to care, and control the
degree of implementation of risk reduction at pre-determined
intervals should result in better outcomes. A link exists between
accuracy in recordings and both quality of care and adherence to
guidelines.437
Specific training of practising cardiologists in using electronic
medical records for implementing and maintaining long-term pre-
vention strategies should be considered. Maintaining data confiden-
tiality is important.
Most important new information
† The higher the level of care based on guidelines and perform-
ance measures, the greater the impact on prevention and recur-
rent events.
Remaining gaps in the evidence
† The positive impact of electronic records on CVD prevention
through improved communication between different healthcare
providers needs to be tested and balanced against the danger of
losing control of data confidentiality.
5.4 Primary care-based self-help
programmes
In many countries, heart foundations (which also form part of the
EHN) support self-help programmes for cardiac patients who or-
ganize their own self-help groups. Most of these programmes are
organized by patients with CHD, irrespective of a history of myocar-
dial infarction, PCI, CABG, or congestive heart failure. Information
on the importance of guideline-orientated treatment is essential
for these patients in order to maintain optimal preventive treatment,
which has a tendency to be abandoned within 6 months of hospital
discharge after myocardial infarction, PCI, or CABG.250 Regular ex-
ercise sessions at weekly or 2-week intervals under the guidance of
a physiotherapist, with or without the supervision of a physician,
help to emphasize the importance of maintaining physical fitness.
On the other hand, increasing angina at higher exercise levels
than reached in daily life can provide an early signal that an examin-
ation by the cardiologist is necessary.
In self-help groups of patients with congestive heart failure, em-
phasis is on: weight management with proper diuretic use; a low
level of exercise training, including interval training; and the goal
to maintain muscle strength by individualized strength and resist-
ance training of single muscle groups in order to avoid overexer-
tion. All of these activities can also be offered in a structured
cardiac rehabilitation programme.205
Patients with AF or after valve replacement with mechanical valves
who need lifelong oral anticoagulation can be taught about the basic
Recommendation on self-help programmes
Recommendations Classa Levelb GRADE RefC
Patients with cardiac disease 
may participate in self-help 
programmes to increase 
or maintain awareness of 
the need for risk factor 
management, for maintaining 
physical fitness, or for diligent 
self-management of oral 
anticoagulation.












principles of this treatment; they can also be taught to determine (at
home) their international normalized ratio (INR) at weekly intervals,
and to dose the vitamin K antagonist medication in order to keep
the INR within the individually determined narrow target range
required to avoid bleeding or thrombo-embolic events. Although
there was no difference in hard endpoints, self-testing gives greater
independence and results in a better quality of life.553 In addition,
after mechanical valve replacement, patients may face problems
with intercurrent non-cardiac surgical procedures such as prostate
surgery, hip or knee replacement surgery, tumour surgery, tooth
extractions, or other surgical procedures where sophisticated peri-
operative anticoagulation management is needed as well as advice
for a prophylaxis against bacterial endocarditis.
Regularly published patient-orientated journals, usually issued by
heart foundations, can help to maintain patients’ awareness of the
need for optimal treatment by discussing the importance of im-
proving lifestyle to control risk factors or improving health
factors such as: maintaining a non-smoking status, increasing
levels of regular physical activity, and eating a Mediterranean-style
diet.554 Also, new developments in patient care or side effects of
commonly used medications such as statins, platelet inhibitors,
and amiodarone are discussed. The idea of the self-help pro-
grammes is to increase the responsibility of the patient for the
disease management and to make the patient a more educated
partner for counselling. Self-help programmes form a part of the
social network, which serves as a platform for mutual support,
and for the exchange of ideas and communication between
patients with the same disease. They can improve and facilitate
medical management and improve the quality of life of patients
who help each other manage their disease in daily life.
Most important new information
† Self-help groups increase independence and improve quality of
life.
Remaining gaps in the evidence
† There are no randomized studies to evaluate the effect of self-
help groups on hard cardiovascular endpoints.
5.5 Hospital-based programmes: hospital
services
5.5.1 Evidence-based discharge recommendations
necessary for optimal therapy
Guidelines for disease management after a cardiovascular event
recommend treatment modalities to minimize the risk of further
cardiovascular events. However, only about half of all patients
were discharged with optimal medical therapy in an observational
study of 5353 patients with acute myocardial infarction compared
with the standards in these guidelines.555
The percentage of patients discharged on optimal medical
therapy may vary in patients with different diagnoses, in elderly
vs. younger patients, in men vs. women, after different procedures,
or in different institutions;556 patients discharged on less than
optimal medical therapy have a worse 1-year prognosis.555 In the
national programme of the AHA—‘Get with the Guidelines’—dis-
charge medications with a prognostic impact were part of the
evaluation programme, which included ACE inhibitors, aspirin,
beta-blockers, and lipid-lowering therapies, as well as smoking ces-
sation advice and counselling. Defect-free (100%) compliance was
highest for PCI patients (71.5%), followed by CABG patients
(65.1%), then no-intervention patients (62.1%). Multivariable ana-
lysis adjusting for 14 clinical variables confirmed that compliance
with all performance measures was statistically significantly
higher for PCI patients than for CABG patients and was lowest
for non-intervention patients.556 The new ESC Guidelines
provide a check list of measures necessary at discharge from hos-
pital to ensure that intense risk factor modification and lifestyle
change are implemented in all patients following the diagnosis of
ACS including recommendation for enrolment in a cardiovascular
prevention and rehabilitation programme.557
5.5.2 Systematic quality improvement programmes are
essential
The introduction of an intensive, educational, and
process-orientated quality-improvement initiative, based on the
2001 American College of Cardiology/AHA secondary prevention
guidelines,558 resulted in significantly improved compliance rates at
discharge for aspirin, ACE inhibitors, lipid-lowering drugs, smoking
cessation counselling, and dietary counselling.559
A low-intensity quality-improvement programme in a rando-
mized national study of 458 hospitals after bypass surgery included
check lists, patient activation materials, and patient educational
materials that stressed the importance of secondary prevention
medications and lifestyle modification. A significant increase was
observed in the rate of optimal secondary prevention, with
better adherence to guidelines in all patient subgroups, particularly
women and the elderly; previously existing treatment gaps were
almost eliminated, and improvements were seen in the use of
lipid-lowering therapy, ACE inhibitor treatment, and tobacco-
cessation counselling. There appears to be a learning curve: over
the course of 2 years there was a continuous increase in guideline
adherence by the physicians at discharge of the patients.560
Thus structured programmes to implement guideline-defined
therapy at the time of hospital discharge should be offered in
order to achieve the highest possible percentage of patients with
guideline-advocated therapy—a prerequisite for good long-term
compliance with a guideline-orientated treatment regimen.
Recommendation on hospital-based programmes
Recommendations Classa Levelb GRADE Ref C
All patients with 
cardiovascular disease 
must be discharged from 
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Most important new information
† The introduction of quality-improvement programmes improves
discharge recommendations.
Remaining gaps in the evidence
† Still missing is evidence that efforts for optimal treatment at hos-
pital discharge result in better long-term maintenance of sec-
ondary prevention efforts and greater reduction in cardiac
events.




Following a cardiovascular event, long-term adherence to pre-
scribed medications is of similar importance to continued lifestyle
improvement in order to reduce the risk of a recurrent ischaemic
event. In randomized studies with a structured treatment regimen
and frequent follow-up following an ACS, the compliance rate is
high and the event rate low.561
5.6.1 Cardiac rehabilitation centres help improve lifestyle
In the usual care setting, compliance with lifestyle recommenda-
tions and treatment regimens starts to decline within 6 months
of discharge from hospital. Adherence to behavioural advice
(diet, exercise, and smoking cessation) after an ACS was associated
with a substantially lower risk of recurrent cardiovascular events
compared with non-adherence.250 Cardiac rehabilitation after
cardiac events or interventions in a specialized centre helps to
maintain long-term adherence to the optimal treatment pro-
gramme by educating the patient and repeatedly emphasizing the
importance of maintaining the prescribed treatments and recom-
mended lifestyle.
5.6.2 Cardiac rehabilitation is cost-effective
Cardiac rehabilitation is considered a cost-effective intervention
following an acute coronary event; it improves prognosis by redu-
cing recurrent hospitalizations and healthcare expenditure while
prolonging life.562 Cardiac rehabilitation after a cardiac event is a
Class I recommendation from the ESC, the AHA, and the Ameri-
can College of Cardiology.139,205,563,564
Whereas the core components and goals of cardiac rehabilita-
tion are standardized and documented in a position paper,205
the structure and type of cardiac rehabilitation units vary in differ-
ent countries. Traditions of the healthcare system and cost consid-
erations play important roles. Residential cardiac rehabilitation
centres, where the patient is removed from his or her usual envir-
onment and lives in an idealized environment for 2–3 weeks to
become familiar with the necessary medication and train a
healthy lifestyle, is one option in several European countries, and
is usually followed by ambulatory training sessions in the home en-
vironment. Other countries favour ambulatory rehabilitation units
where the patient participates once or twice per week in a re-
habilitation session over a period of several months and tries to im-
plement the lifestyle recommendations in his or her usual
environment, including after returning to work.
A 3-year, multicentre RCT was conducted to compare a long-
term, reinforced, multifactorial educational and behavioural inter-
vention co-ordinated by a cardiologist vs. usual care after a stand-
ard cardiac rehabilitation programme (residential or ambulatory)
following myocardial infarction in a cardiac rehabilitation centre.
The intervention proved effective in improving risk factors and in-
creasing medication adherence over time, with significant improve-
ment in lifestyle habits (i.e. exercise, diet, psychosocial stress, and
body weight). Clinical endpoints were also reduced by the inten-
sive intervention: cardiovascular mortality, non-fatal myocardial in-
farction, and stroke by 33% (P ¼ 0.02), and cardiac death plus
non-fatal myocardial infarction by 36% (P ¼ 0.02), total stroke by
32%, and total mortality by 21% (P ¼ not significant).565
5.6.3 Challenges for cardiac rehabilitation: female gender
and co-morbidities
Expected outcomes of all the cardiac rehabilitation interventions
are improved clinical stability and symptom control, reduced
overall cardiovascular risk, higher adherence to pharmacological
advice, and a better health behaviour profile, all leading to superior
quality of life and improved prognosis. However, dedicated long-
term efforts beyond the early phase are necessary to maintain
compliance with medications and lifestyle.
A particular challenge for the rehabilitation programmes are
older and female205,566 patients and patients with specific co-
morbid conditions, such as transient ischaemic attack or stroke,
chronic obstructive pulmonary disease, and chronic renal failure.
A new challenge all over Europe is how to meet the needs of
ethnic minorities with sometimes different cultural values, and
sometimes lack of fluency in the language of their country of resi-
dence.205 The success of the rehabilitative and secondary prevent-
ive efforts depends on a high level of individual care and support
with a careful clinical evaluation beyond cardiovascular function, in-
cluding psychosocial assessment and evaluation of co-morbid
conditions.
Recommendation for specialized prevention centres
Recommendations Classa Levelb GRADE Ref C
All patients requiring 
hospitalization or invasive 
intervention after an acute 
ischaemic event should 
participate in a cardiac 
rehabilitation programme 
to improve prognosis by 
modifying lifestyle habits 
















5.6.4 Repeated sessions improve compliance
From a large observational study, it was suggested that the number
of rehabilitation sessions attended (i.e. duration and intensity of the
intervention and motivation of the participant) correlated with
improved prognosis.67 This was supported by the results of the
Global Secondary Prevention Strategies to Limit Event Recurrence
After MI (GOSPEL) study, where a long-term intervention was
more effective than a short-term course.565
Whether the rehabilitation course is applied in an ambulatory
setting or as a residential course is probably of lesser importance;
the duration of the programme, the educational level, and the mo-
tivation of the patient are also important for long-term
outcome.205
The participation rate in a rehabilitation programme after a
cardiac event is far lower than desirable: only 30% of eligible
patients in Europe participate in such a programme, with consider-
able variation reported between countries.5 Although cardiac re-
habilitation is cost-effective from the perspective of society, it
will be a major challenge in the future to improve this low rate
of participation throughout Europe.
Most important new information
† Cardiac rehabilitation is cost-effective in reducing risk of cardio-
vascular events.
Remaining gaps in the evidence





† Non-governmental organizations are important partners to
healthcare workers in promoting preventive cardiology.
The EHN is a Brussels-based alliance of heart foundations and like-
minded non-governmental organizations throughout Europe, with
member organizations in 26 countries. The EHN plays a leading
role in prevention—in particular heart disease and stroke—
through advocacy, networking, education, and patient support, so
they may no longer be the major cause of premature death and dis-
ability throughout Europe.568
To achieve its aim, the EHN dedicates itself to influencing Euro-
pean policy-makers in favour of a heart-healthy lifestyle; creating
and nurturing ties between organizations concerned with heart
health promotion and CVD prevention; gathering and disseminat-
ing information relevant to heart health promotion; and strength-
ening membership capacity.
The EHN works through expert groups, focusing on: nutrition
for a healthy heart; tobacco policy and discouraging smoking; occu-
pational health and psychosocial factors; and physical activity as a
natural part of daily life.
The EHN facilitates networking amongst its member organiza-
tions that work actively to support heart and stroke patients.
Approximately half of the organizations’ members fall within this
category. Cardiovascular patient organizations provide their
patient members with the opportunity to obtain support from
their peers. They produce patient information in the form of book-
lets and web-based materials and they promote cardiac
rehabilitation.
5.8 Action at the European political level
Key message
† The European Heart Health Charter marks the start of a new
era of political engagement in preventive cardiology.
In 2002, the Board of the ESC marked its future involvement in
health policy by declaring a strategy for member states to
reduce deaths from CVD by 40%. It was clear that for medical pro-
fessionals to impact political decision-making on EU and national
levels, it would be necessary to build strong alliances with other
non-governmental health organizations, primarily the EHN, but
also local health authorities and the EU. The work was initiated
by providing accurate expertise and alarming statistics on the
huge burden and inequity of CVD across Europe, and resulted in
a call to action from member states and the European Commission
to tackle CVD.
This initiative was followed by partnership with the Irish presi-
dency in 2004. It was concluded that most cases of CVD are pre-
ventable through lifestyle changes and appropriate use of
medications already in existence. The following EU Council Con-
clusions on CVD was the first political statement on the EU
level acknowledging the need to improve CVD health in Europe.
Successful collaborations with the Luxemburg, Austrian, and Por-
tuguese presidencies paved the way, together with the EHN, to
create a European Heart Health Charter. This charter was
launched in June 2007 at the European Parliament, and was
endorsed by the European Commission and WHO Region
Europe. This development paved the way for a European Parlia-
ment Resolution on Action to Tackle Cardiovascular Disease,
the strongest political agreement so far on the need for CVD pre-
vention in Europe.568 The charter outlines universal targets and
goals for CVD prevention and provides the actions to be taken
in order to reach these goals. It has been translated into 26 lan-
guages and officially adopted by 30 EU member nations and
other European countries.6
In the following period, the ESC perceived the prospect from
policy-makers that combining efforts with other diseases could
make a voice stronger and more influential. In order to succeed,
the political challenge of bringing together science from different
horizons to convey a single message benefiting all of the diseases
represented in the group had to be overcome. In June 2009, the
ESC invited medical organizations representing diabetes, respira-
tory diseases, and cancer to reflect on common health determi-
nants, identify areas with sufficient evidence to support
recommendations, and discuss future collaboration. Four risk
factors were identified as presenting enough commonalities to
justify joint actions: tobacco, nutrition, alcohol consumption, and
physical inactivity. Thus the European Chronic Disease Alliance
was established. This alliance currently comprises 10 not-for-
profit European organizations representing .100 000 health
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professionals. It addresses all major non-communicable chronic
diseases, including heart disease, stroke, hypertension, diabetes,
kidney disease, cancer, respiratory disease, and liver disease.172
The alliance, which will facilitate a population-wide risk factor
control, has the potential of a large impact on public health and
healthcare savings.
In conclusion, the authors of the guidelines hope that this docu-
ment will advocate a real partnership among politicians, physicians,
allied health personnel, scientific associations, heart foundations,
voluntary organizations, and consumers’ associations to foster
both health promotion at the population level and primary and
cardiovascular prevention at the clinical level, using the complete
spectrum of evidence in medicine from experimental trials to
observations in populations.
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